GRUSF 6-K
Grown Rogue International Inc. (GRUSF)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
THE SECURITIES EXCHANGE ACT OF 1934
Date: November 15, 2024
Commission File No. 0-53646
Grown Rogue International Inc. (formerly Novicius Corp.)
(Translation of Registrant’s name into English)
550 Airport Road
Medford, Oregon, United States 97504
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ☐ No ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes ☐ No ☒
TABLE OF CONTENTS
1
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Dated November 15, 2024 | GROWN ROGUE INTERNATIONAL INC. | |
|---|---|---|
| (FORMERLY: NOVICIUS CORP.) | ||
| By: | /s/ Obie Strickler | |
| Name: | Obie Strickler | |
| Title: | President & Chief Executive Officer |
2
Exhibit 1
Grown Rogue Announces Termination of Advisory Agreement with Vireo Growth Inc.
Medford, Oregon, October 10, 2024 – Grown Rogue International Inc. (“Grown Rogue” or the “Company”) (CSE: GRIN) (OTC: GRUSF), a craft cannabis company born from the amazing terroir of Oregon’s Rogue Valley, has announced the termination of the advisory agreement with Vireo Growth Inc. (“Vireo”) (formerly Goodness Growth Holdings, Inc.).
“While we are disappointed to no longer be working with Vireo, we are pleased with the benefits this collaboration generated for both sides. This agreement allowed Grown Rogue to hone and elevate our team’s ability to support a much larger cultivation platform across multiple markets, increasing our confidence in our ability to execute a nationwide expansion strategy,” said Obie Strickler, CEO of Grown Rogue. “We are already applying what we learned in New Jersey and intend to do the same in Illinois next year. We view the agreement as a great success because it has better positioned our team to take advantage of future opportunities. We’d like to thank the Vireo team for the opportunity to work with them these last eighteen months and we wish them success in the future.”
As consideration for the early termination, Vireo will forfeit and return for cancellation 4,500,000 of the 8,500,000 share purchase warrants in Grown Rogue that are held by Vireo at a CAD$0.225 strike price and pay Grown Rogue US$800,000 in cash. Vireo has the option of deferring the cash payment by making 4 quarterly payments of US$250,000. Grown Rogue will also receive its full fee for the work performed in Q3 and retains its 10,000,000 warrants in Vireo.
About Grown Rogue
Grown Rogue International Inc. (CSE: GRIN
| OTC: GRUSF) is a craft cannabis company operating in Oregon, Michigan, New Jersey and Illinois, focused on delighting customers with premium flower and flower-derived products at fair prices. The Company’s roots are in Southern Oregon, where it has proven its capabilities in the highly competitive and discerning Oregon market. The Company’s passion for quality product and value, combined with a disciplined approach to growth, prioritizes profitability and return on capital without sacrificing quality. The Company’s strategy is to pursue capital efficient methods to expand into new markets, bringing craft-quality product at fair prices to more consumers. The Company also continues to make modest investments to improve outdoor craft cultivation capabilities in preparation for eventual interstate commerce. For more information, visit www.grownrogue.com.
FORWARD-LOOKING STATEMENTS
This press release contains statementswhich constitute “forward-looking information” within the meaning of applicable securities laws, including statementsregarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities.Forward-looking information is often identified by the words “may,” “would,” “could,”“should,” “will,” “intend,” “plan,” “anticipate,” “believe,”“estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding thefuture direction of the Company (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii)plans for expansion of the Company and securing applicable regulatory approvals, (iv) expectations for other economic, business,and/or competitive factors, and (v) statements regarding the Share Reorganization, including the record date and effective date ofthe Share Reorganization. Investors are cautioned that forward-looking information is not based on historical facts but insteadreflect the Company’s management’s expectations, estimates or projections concerning
the business of the Company’s futureresults or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements aremade. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such informationinvolves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors couldhave material adverse effects on future results, performance or achievements of the combined company. Among the key factors that couldcause actual results to differ materially from those projected in the forward-looking information are the following: changes in generaleconomic, business and political conditions, including changes in the financial markets; and in particular in the ability of the Companyto raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis;decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes inapplicable laws; or adverse changes in the application or enforcement of current laws; compliance with extensive government regulationand related costs, and other risks described in the Company’s public disclosure documents filed on Sedar.
Should one or more of these risks or uncertaintiesmaterialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially fromthose described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identifyimportant risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause resultsnot to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-lookinginformation except as otherwise required by applicable law.
The Company is indirectly involved in themanufacture, possession, use, sale and distribution of cannabis in the recreational cannabis marketplace in the United States throughits indirect operating subsidiaries. Local state laws where its subsidiaries operate permit such activities however, these activitiesare currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relatingto the Company’s business are disclosed in the Company’s Listing Statement filed on its issuer profile on SEDAR+ at www.sedarplus.ca.Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking informationor forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated,believed, estimated or expected.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
For further information on Grown Rogue, please visit www.grownrogue.com or contact:
Obie Strickler
Chief Executive Officer
Jakob Iotte
Vice President of Investor Relations
(458) 226-2662
Exhibit 2
Form 51-102F3
Material Change Report
| Item 1 | Name and Address of Company |
|---|---|
| Grown Rogue International Inc. (“Grown Rogue” or the “Company”) | |
| 550 Airport Road | |
| Medford, Oregon | |
| United States 97504 | |
| Item 2 | Date of Material Change |
| --- | --- |
October 10, 2024.
| Item 3 | News Release |
|---|
A news release was issued by the Company on October 10, 2024 through the facilities of Cision and was subsequently filed on SEDAR+.
| Item 4 | Summary of Material Change |
|---|
On October 10, 2024, the Company announced the termination of the advisory agreement with Vireo Growth Inc. (“Vireo”) (formerly Goodness Growth Holdings, Inc.).
| Item 5.1 | Full Description of Material Change |
|---|
On October 10, 2024, the Company announced the termination of the advisory agreement with Vireo.
As consideration for the early termination, Vireo will forfeit and return for cancellation 4,500,000 of the 8,500,000 share purchase warrants in Grown Rogue that are held by Vireo at a CAD$0.225 strike price and pay Grown Rogue US$800,000 in cash. Vireo has the option of deferring the cash payment by making 4 quarterly payments of US$250,000. Grown Rogue will also receive its full fee for the work performed in Q3 and retains its 10,000,000 warrants in Vireo.
| Item 6 | Reliance on Subsection 7.1(2) of National Instrument 51-102 |
|---|
Not applicable.
| Item 7 | Omitted Information |
|---|
Not applicable.
| Item 8 | Executive Officer |
|---|
J. Obie Strickler
Chief Executive Officer
Tel: +1 458 226 2100
Email: [email protected]
| Item 9 | Date of Report |
|---|
October 18, 2024.
FORWARD-LOOKING STATEMENTS
This report contains statements whichconstitute “forward-looking information” within the meaning of applicable securities laws, including statementsregarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities.Forward-looking information is often identified by the words “may,” “would,” “could,”“should,” “will,” “intend,” “plan,” “anticipate,” “believe,”“estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding thefuture direction of the Company (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii)plans for expansion of the Company and securing applicable regulatory approvals, and (iv) expectations for other economic, business,and/or competitive factors. Investors are cautioned that forward-looking information is not based on historical facts but insteadreflect the Company’s management’s expectations, estimates or projections concerning the business of the Company’sfuture results or events based on the opinions, assumptions and estimates of management considered reasonable at the date thestatements are made. Although the Company believes that the expectations reflected in such forward-looking information arereasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, asunknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combinedcompany. Among the key factors that could cause actual results to differ materially from those projected in the forward-lookinginformation are the following: changes in general economic, business and political conditions, including changes in the financialmarkets; and in particular in the ability of the Company to raise debt and equity capital in the amounts and at the costs that itexpects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis productsin the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application orenforcement of current laws; compliance with extensive government regulation and related costs, and other risks described in theCompany’s public disclosure documents filed on www.Sedar.com.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Exhibit 3
GROWN ROGUE INTERNATIONAL INC.
Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024 and October 31, 2023
Expressed in United States Dollars
Table of Content
| Condensed Consolidated Statements of Financial Position | 3 |
|---|---|
| Condensed Consolidated Statements of Comprehensive Income (Loss) | 4 |
| Condensed Consolidated Statements of Changes in Equity | 5 |
| Condensed Consolidated Statements of Cash Flows | 7 |
Notes to the Condensed Consolidated Financial Statements
| 1. | Corporate Information | 8 |
|---|---|---|
| 2. | Significant Accounting Policies and Judgments and Defined Terms | 8 |
| 3. | Biological Assets | 11 |
| 4. | Inventory | 12 |
| 5. | Business Combinations | 12 |
| 6. | Other Investments, Purchase Deposits and Notes Receivable | 13 |
| 7. | Leases | 16 |
| 8. | Property and Equipment | 17 |
| 9. | Intangible Assets and Goodwill | 17 |
| 10. | Long-Term Debt | 18 |
| 11. | Convertible Debentures | 21 |
| 12. | Share Capital and Shares Issuable | 23 |
| 13. | Warrants | 25 |
| 14. | Stock Options | 26 |
| 15. | Changes in Non-Cash Working Capital | 28 |
| 16 | Supplemental Cash Flow Disclosure | 28 |
| 17. | Related Party Transactions | 28 |
| 18. | Financial Instruments | 31 |
| 19. | General and Administrative Expenses | 36 |
| 20. | Income Taxes | 36 |
| 21. | Capital Disclosures | 39 |
| 22. | Segment Reporting | 40 |
| 23. | Non-Controlling Interests | 40 |
| 24. | Commitments and Contingencies | 41 |
| 25. | Subsequent Events | 42 |
Grown Rogue International Inc.
Condensed Consolidated Statements of Financial Position
Expressed in United States Dollars
| September 30, 2024 | December 31, 2023 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current assets | ||||
| Cash and cash equivalents | ||||
| Accounts receivable (Note 18) | ||||
| Biological assets (Note 3) | ||||
| Inventory (Note 4) | ||||
| Prepaid expenses and other assets | ||||
| Current portion of notes receivable (Note 6.3) | ||||
| Total current assets | ||||
| Property and equipment (Note 8) | ||||
| Notes receivable (Note 6.3) | ||||
| Warrants asset (Note 13) | ||||
| Intangible assets and goodwill (Note 9) | ||||
| Deferred tax assets (Note 20) | ||||
| Other investments (Note 6.2) | ||||
| TOTAL ASSETS | ||||
| LIABILITIES | ||||
| Current liabilities | ||||
| Accounts payable and accrued liabilities | ||||
| Current portion of lease liabilities (Note 7) | ||||
| Current portion of long-term debt (Note 10) | ||||
| Current portion of business acquisition consideration payable (Note 5) | ||||
| Derivative liability (Note 11) | ||||
| Income tax payable | ||||
| Convertible debentures (Note 11) | ||||
| Total current liabilities | ||||
| Lease liabilities (Note 7) | ||||
| Long-term debt (Note 10) | ||||
| Convertible debentures (Note 11) | ||||
| Business acquisition consideration payable (Note 5) | ||||
| TOTAL LIABILITIES | ||||
| EQUITY | ||||
| Share capital (Note 12) | ||||
| Contributed surplus (Notes 13 and 14) | ||||
| Accumulated other comprehensive loss | ) | ) | ||
| Accumulated deficit | ) | ) | ||
| Equity attributable to shareholders | ||||
| Non-controlling interests (Note 23) | ||||
| TOTAL EQUITY | ||||
| TOTAL LIABILITIES AND EQUITY |
All values are in US Dollars.
Commitments and contingencies (Note 24)
Subsequent events (Note 25)
| Approved on behalf of the Board of Directors: | |
|---|---|
| Signed “J. Obie Strickler”, Director | Signed “Stephen Gledhill”, Director |
The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.
Page 3 of 42
Grown Rogue International Inc.
Condensed Consolidated Statements of Loss
Expressed in United States Dollars
| Three months ended September 30, 2024 | Three months ended October 31, 2023 | Nine months ended September 30, 2024 | Nine months ended October 31, 2023 | |||||
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| Product sales | ||||||||
| Service revenue | ||||||||
| Total revenue | ||||||||
| Cost of goods sold | ||||||||
| Cost of finished cannabis inventory sold | ) | ) | ) | ) | ||||
| Costs of service revenue | ) | ) | ) | ) | ||||
| Gross profit, excluding fair value items | ||||||||
| Realized fair value loss amounts in inventory sold | ) | ) | ) | ) | ||||
| Unrealized fair value gain on growth of biological assets | ||||||||
| Gross profit | ||||||||
| Expenses | ||||||||
| Amortization of property and equipment (Note 8) | ||||||||
| General and administrative (Note 19) | ||||||||
| Share option expense | ||||||||
| Total expenses | ||||||||
| Income from operations | ||||||||
| Other income and (expense) | ||||||||
| Interest expense | ) | ) | ) | ) | ||||
| Accretion expense | ) | ) | ) | ) | ||||
| Other (expense) income | ) | |||||||
| Unrealized loss on derivative liability | ) | ) | ) | ) | ||||
| Unrealized gain on warrants asset | ||||||||
| Gain (loss) on disposal of property and equipment | ) | ) | ||||||
| Total expense, net | ) | ) | ) | ) | ||||
| Loss from operations before taxes | ) | ) | ) | ) | ||||
| Income tax (Note 20) | ) | ) | ) | |||||
| Net loss | ) | ) | ) | ) | ||||
| Other comprehensive income (loss) (items that may be subsequently reclassified to profit & loss) | ||||||||
| Currency translation gain (loss) | ) | ) | ) | ) | ||||
| Total comprehensive loss | ) | ) | ) | ) | ||||
| Loss per share attributable to owners of the parent – basic | ) | ) | ) | ) | ||||
| Weighted average shares outstanding – basic | ||||||||
| Gain (loss) per share attributable to owners of the parent – diluted | ) | ) | ) | |||||
| Weighted average shares outstanding – diluted | ||||||||
| Net income (loss) for the period attributable to: | ||||||||
| Non-controlling interest | ||||||||
| Shareholders | ) | ) | ) | ) | ||||
| Net loss | ) | ) | ) | ) | ||||
| Comprehensive income (loss) for the period attributable to: | ||||||||
| Non-controlling interest | ||||||||
| Shareholders | ) | ) | ) | ) | ||||
| Total comprehensive loss | ) | ) | ) | ) |
All values are in US Dollars.
The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.
In these unaudited interim consolidated financial statements, other income and (expense) includes accretion expense and comparative periods have been conformed to current period.
Page 4 of 42
Grown Rogue International Inc.
Condensed Consolidated Statements of Changes in Equity
Expressed in United States Dollars
| Number of common shares* | Number of subordinate<br><br> <br>voting shares* | Number of multiple<br><br> <br>voting shares** | Number of total shares** | Share capital | Contributed<br> surplus | Accumulated<br> other comprehensive loss | Accumulated<br> deficit | Non-controlling<br> interests | Total equity | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # | # | # | # | ||||||||||||||||||||
| Balance – December 31, 2023 | 182,005,886 | - | - | 182,005,886 | ) | ) | |||||||||||||||||
| Conversion of options to common shares (Note 12.1) | 1,933,750 | 1,582,558 | - | 3,516,308 | ) | ||||||||||||||||||
| Partial settlement of July Convertible Debentures for common shares (Note 12.3) | 5,388,062 | - | - | 5,388,062 | |||||||||||||||||||
| Full settlement of December Convertible Debentures for common shares (Note 12.2) | 336,775 | 2,076,750 | - | 2,413,525 | |||||||||||||||||||
| Full settlement of August Convertible Debentures for common shares (Note 12.4) | 5,682,083 | - | - | 5,682,083 | |||||||||||||||||||
| Exercise of warrants relating to December Convertible Debentures (Note 12.5) | 6,716,499 | - | - | 6,716,499 | |||||||||||||||||||
| Exercise of warrants relating to July Convertible Debentures<br> (Note 12.5) | 13,737,500 | - | - | 13,737,500 | |||||||||||||||||||
| Exercise of warrants relating to August Convertible Debentures<br> (Note 12.5) | 2,816,250 | - | - | 2,816,250 | |||||||||||||||||||
| Issuance costs on proceeds received from warrants exercises<br> (Note 12.5) | - | - | - | - | ) | ) | |||||||||||||||||
| Investment in Grown Rogue West New York, LLC (Note 23.2) | - | - | - | - | |||||||||||||||||||
| Dividend issued from Golden Harvests, LLC to minority owner | - | - | - | - | ) | ) | |||||||||||||||||
| Grown Rogue Unlimited, LLC buyout of Canopy Management, LLC and Canopy Management, LLC’s acquisition of 20% of Golden Harvests, LLC (Note 23.1) | - | - | - | - | ) | ) | |||||||||||||||||
| Grown Rogue Unlimited, LLC buyout of Canopy Management, LLC and acquisition of 20% of Golden Harvests, LLC (Note 23.1) | - | - | - | - | ) | ||||||||||||||||||
| Stock options vesting expense | - | - | - | - | |||||||||||||||||||
| Share Reorganization (Note 12.6) | (218,616,805 | ) | 143,421,865 | 75,195 | (75,119,745 | ) | |||||||||||||||||
| Share Reorganization (Note 12.6) | - | 75,194,940 | (75,195 | ) | 75,119,745 | ||||||||||||||||||
| Currency translation loss | - | - | - | - | ) | ) | |||||||||||||||||
| Net income (loss) | - | - | - | - | ) | ) | |||||||||||||||||
| Balance – September 30, 2024 | - | 222,276,113 | - | 222,276,113 | ) | ) |
All values are in US Dollars.
| * | As of June 24, 2024, the Company completed a reorganization of the Company’s share capital (the “Share Reorganization”), in which the common shares of the Company were replaced with subordinate voting shares (“SV Shares”) and a new class of unlisted multiple voting shares (“MV Shares”) was created. Thus, additional shares issued after the Share Reorganization are reflected in the issuance of SV Shares. |
|---|---|
| ** | As of the consolidated statements of financial position dated September 30, 2024, total common shares outstanding were 222,276,113, in which all MV Shares have been converted into SV Shares. |
Page 5 of 42
Grown Rogue International Inc.
Condensed Consolidated Statements of Changes in Equity
Expressed in United States Dollars
| Number of<br> common shares | Share capital | Contributed surplus | Accumulated other comprehensive loss | Accumulated deficit | Non- controlling interests | Total equity | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| # | |||||||||||
| Balance – January 31, 2023 | 170,832,611 | ) | ) | ||||||||
| Stock options vesting expense | - | ||||||||||
| Vireo Growth warrants swap | - | ||||||||||
| Settlement of convertible debentures for common shares (Note 12.2) | 11,173,275 | ||||||||||
| Currency translation loss | - | ) | ) | ||||||||
| Net income (loss) | - | ) | ) | ||||||||
| Balance – October 31, 2023 | 182,005,886 | ) | ) |
All values are in US Dollars.
The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.
Page 6 of 42
Grown Rogue International Inc.
Condensed Consolidated Statements of Cash Flow
Expressed in United States Dollars
| Nine months ended September 30, 2024 | Nine months ended October 31, 2023 | |||
|---|---|---|---|---|
| Operating activities | ||||
| Net loss | ) | ) | ||
| Adjustments for non-cash items in net income (loss): | ||||
| Amortization of property and equipment | ||||
| Amortization of property and equipment included in costs of inventory sold | ||||
| Unrealized fair value gain amounts on growth of biological assets | ) | ) | ||
| Realized fair value loss amounts in inventory sold | ||||
| Deferred income taxes | ) | ) | ||
| Share option expense | ||||
| Accretion expense | ||||
| Loss on equity method investment | ||||
| Loss on disposal of property and equipment | ) | |||
| Unrealized loss on fair value of derivative liability | ||||
| Unrealized gain on warrants asset | ) | ) | ||
| Currency translation loss | ) | ) | ||
| Loss on acquisition of non-controlling interest paid in shares | ||||
| Changes in non-cash working capital (Note 15) | ) | |||
| Net cash provided by operating activities | ||||
| Investing activities | ||||
| Purchase of property and equipment and intangibles | ) | ) | ||
| Cash advances and loans made to other parties | ) | ) | ||
| Repayment of NJ Retail promissory note | ||||
| Acquisition of Canopy Management, LLC and Golden Harvests, LLC | ) | |||
| Equity investment in ABCO Garden State LLC | ) | |||
| Net cash used in investing activities | ) | ) | ||
| Financing activities | ||||
| Proceeds from convertible debentures | ||||
| Proceeds from warrants exercises | ||||
| Proceeds from options exercises | ||||
| Proceeds from sale of membership units of subsidiary | ||||
| Payment of equity and debt issuance costs | ) | |||
| Repayment of long-term debt | ) | ) | ||
| Repayment of convertible debentures | ) | ) | ||
| Payments of lease principal | ) | ) | ||
| Net cash provided by financing activities | ||||
| Change in cash and cash equivalents | ) | |||
| Cash and cash equivalents, beginning | ||||
| Cash and cash equivalents, ending |
All values are in US Dollars.
Supplemental cash flow disclosures (Note 16)
The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.
Page 7 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 1. | CORPORATE INFORMATION |
|---|
These unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2024, and October 31, 2023, include the accounts of Grown Rogue International Inc. and its subsidiaries. The registered office is located at 40 King St W Suite 5800, Toronto, ON M5H 3S1.
Grown Rogue International Inc.’s subsidiaries and ownership thereof are summarized in the table below.
| Company | Ownership | Defined Term |
|---|---|---|
| Grown Rogue International Inc. | 100% owner of GR Unlimited | The “Company” |
| Grown Rogue Unlimited, LLC | 100% by the Company | “GR Unlimited” |
| Grown Rogue Gardens, LLC | 100% by Grown Rogue Unlimited, LLC | “GR Gardens” |
| GRU Properties, LLC | 100% by Grown Rogue Unlimited, LLC | “GRU Properties” |
| GRIP, LLC | 100% by Grown Rogue Unlimited, LLC | “GRIP” |
| Grown Rogue Distribution, LLC | 100% by Grown Rogue Unlimited, LLC | “GR Distribution” |
| Rogue EBC, LLC | 70% by Grown Rogue Unlimited, LLC* | “Rogue EBC” |
| Cannequality, LLC | 100% by Rogue EBC* | “Cannequality” |
| GR Michigan, LLC | 87% by Grown Rogue Unlimited, LLC | “GR Michigan” |
| Canopy Management, LLC | 100% by Grown Rogue Unlimited, LLC | “Canopy” |
| Golden Harvests LLC | 80% by Canopy Management, LLC | “Golden Harvests” |
| Grown Rogue Retail Ventures, LLC | 100% by Grown Rogue Unlimited, LLC | “GR Retail” |
| Grown Rogue West New York, LLC | 43.48% by Grown Rogue Retail Ventures, LLC** | “West NY” |
| * | The Company consolidated 70% of Rogue EBC’s business activity under International Financial Reporting Standards (“IFRS”) 11 – Joint Arrangements. Cannequality is wholly owned by Rogue EBC, in which Cannequality is the legal entity that holds the acquired cannabis license for Rogue EBC’s joint arrangement operations. When regulatory milestones are achieved, the Company plans to dissolve Cannequality. | |
| --- | --- | |
| ** | The Company, through its subsidiary GR Retail invested $500,000 in the equity of West NY. West NY is a lender to a retail business in New Jersey. |
The Company is primarily engaged in the business of growing and selling cannabis products. The primary cannabis product produced and sold is cannabis flower.
| 2. | SIGNIFICANT ACCOUNTING POLICIES AND JUDGMENTS AND DEFINED TERMS |
|---|---|
| 2.1 | Statement of Compliance |
| --- | --- |
These unaudited condensed interim consolidated financial statements, including comparatives, have been prepared in accordance with International Accounting Standard (“IAS”) 34 - Interim Financial Reporting, using accounting policies consistent with IFRS issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”). The Company has prepared these unaudited condensed interim consolidated financial statements on the basis that it will continue to operate as a going concern. These unaudited condensed interim consolidated financials are filed on the system for electronic document analysis and retrieval (SEDAR+).
These unaudited condensed interim financial statements do not include all disclosures required by IFRS for annual audited consolidated financial statements and accordingly should be read in conjunction with our audited consolidated financial statements for the two months ended December 31, 2023, and our audited consolidated financial statements for the year ended October 31, 2023.
Page 8 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
The Board of Directors authorized the issuance of these unaudited condensed interim consolidated financial statements on November 13^th^, 2024.
The principal accounting policies adopted in the preparation of these unaudited condensed interim consolidated financial statements are set forth below.
| 2.2 | Basis of Consolidation |
|---|
The subsidiaries are those companies controlled by the Company, as the Company is exposed, or has rights, to variable returns from its involvement with the subsidiaries and has the ability to affect those returns through its power over the subsidiaries by way of its ownership and rights pertaining to the subsidiaries. The financial statements of subsidiaries are included in these unaudited condensed interim consolidated financial statements from the date that control commences until the date control ceases. All intercompany balances and transactions have been eliminated upon consolidation.
| 2.3 | Basis of Measurement |
|---|
These unaudited condensed interim consolidated financial statements have been prepared on a historical cost basis except for certain financial instruments and biological assets, which are measured at fair value, as described herein.
| 2.4 | Change in Fiscal Year End |
|---|
Effective December 31, 2023, the Company changed its financial year-end to December 31 from October 31. Comparative figures in preparing these unaudited condensed interim consolidated financial statements have been reclassified to conform to the current period presentation, and to reflect the results for the three months and nine months ended October 31, 2023, in the unaudited condensed interim consolidated statements of comprehensive loss, cash flows and changes in equity.
| 2.5 | Functional and Presentation Currency |
|---|
The Company’s functional currency is the Canadian dollar, and the functional currency of its subsidiaries is the United States (“U.S.”) dollar. These unaudited condensed interim consolidated financial statements are presented in U.S. dollars.
Transactions denominated in foreign currencies are initially recorded in the functional currency using exchange rates in effect at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency using exchange rates prevailing at the end of the reporting period. All exchange gains and losses are included in the consolidated statements of comprehensive income (loss).
For the purpose of presenting consolidated financial statements, the assets and liabilities of the Company are expressed in U.S. dollars using exchange rates prevailing at the end of the reporting period. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuated significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized in other comprehensive income (loss) and reported as currency translation reserve in shareholders’ equity.
Page 9 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
Foreign exchange gains or losses arising from a monetary item receivable from or payable to a foreign operation, the settlement of which is neither planned nor likely to occur in the foreseeable future and which, in substance, is considered to form part of the net investment in the foreign operation, are recognized in other comprehensive income (loss).
The preparation of these financial statements requires management to make judgments, estimates, and assumptions that affect the application of policies and reported amounts of assets, liabilities, and expenses. Areas that have the most significant effect on the amounts recognized in the financial statements are disclosed in Note 3 of the Company’s consolidated financial statements for the two months ended December 31, 2023. The accounting policies applied in these unaudited condensed interim financial statements are consistent with those used in the Company’s consolidated financial statements for the two months ended December 31, 2023.
| 2.6 | Adoption of New Accounting Pronouncements |
|---|
Amendments to IAS 1 – Presentation of Financial Statements
The amendment to IAS 1 – Presentation of Financial Statements specifies that the classification of current versus non-current liabilities may change (e.g. convertible debt). Prior to this amendment, the classification of liabilities was considered current when there was no unconditional right to defer settlement for at least twelve months after the reporting date. Under the amendment to IAS 1, the IASB removed the requirement for a right to be unconditional and instead requires that a right to defer settlement must exist at the reporting date and have substance. The amendment is effective for annual periods beginning on or after January 1, 2024. The Company adopted the amendments to IAS 1 effective January 1, 2024, which impacts the classification of the Company’s Financial Statements by recording its convertible debt as a current liability in its condensed consolidated statements of financial position dated September 30, 2024.
| 2.7 | New Accounting Pronouncements |
|---|
IFRS 18 – Presentation and Disclosures
IFRS 18 – Presentation and Disclosures in Financial Statements will replace IAS 1 – Presentation of Financial Statements. The new standard aims at improving how entities communicate in their financial statements and will be effective for annual periods beginning on or after January 1, 2027. The standard is applied retrospectively, with specific transition provisions, and early adoption is permitted. The Company is evaluating the impact of this standard on the Company’s consolidated financial statements.
Page 10 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 3. | BIOLOGICAL ASSETS |
|---|
Biological assets consist of cannabis plants, which reflect measurement at fair value less costs to sell (“FVLCTS”). Changes in the carrying amounts of biological assets for the nine months ended September 30, 2024, and the two months ended December 31, 2023, are as follows:
| Nine months ended | Two months ended | |||
|---|---|---|---|---|
| September 30, 2024 | December 31,<br> 2023 | |||
| **** | **** | **** | ||
| Beginning balance | ||||
| Increase in biological assets due to capitalized costs | ||||
| Change in FVLCTS due to biological transformation | ||||
| Transferred to inventory upon harvest | ) | ) | ||
| Ending balance |
All values are in US Dollars.
FVLCTS is determined using a model which estimates the expected harvest yield for plants currently being cultivated, and then adjusts that amount for the expected selling price and also for any additional costs to be incurred, such as post-harvest costs.
The following significant unobservable inputs, all of which are classified as level 3 on the fair value hierarchy, were used by management as part of this model:
- Expected costs required to grow the cannabis up to the point of harvest
- Estimated selling price per pound
- Expected yield from the cannabis plants
- Estimated stage of growth – the Company applied a weighted average number of days out of the approximately 62-day growing cycle that biological assets have reached as of the measurement date based on historical evidence. The Company assigns fair value according to the stage of growth and estimated costs to complete cultivation.
| Impact of 20% change | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| September 30,<br> 2024 | December 31,<br> 2023 | September 30,<br> 2024 | December 31,<br> 2023 | |||||||
| Estimated selling price per (pound) | $ | 459 | $ | 938 | $ | 764,431 | $ | 335,193 | ||
| Estimated stage of growth | 72 | % | 55 | % | $ | 541,596 | $ | 285,243 | ||
| Estimated flower yield per harvest (pound) | 3,858 | 2,972 | $ | 541,596 | $ | 285,243 |
Page 11 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 4. | INVENTORY |
|---|
The Company’s inventory composition is as follows:
| September 30, 2024 | December 31,<br> 2023 | |
|---|---|---|
| Raw materials | ||
| Work in process | ||
| Finished goods | ||
| Ending balance |
All values are in US Dollars.
The cost of inventories, excluding changes in fair value, included as an expense and included in cost of goods sold for the nine months ended September 30, 2024, was $9,894,320 (for the nine months ended October 31, 2023 - $9,118,395). The cost of inventories, excluding changes in fair value, included as an expense and included in cost of goods sold for the three months ended September 30, 2024, was $3,554,113 (for the three months ended October 31, 2023 - $3,005,867).
| 5. | BUSINESS COMBINATIONS |
|---|
The following table summarizes the movement in business acquisition consideration payable.
| Business acquisition consideration payable | **** | |
|---|---|---|
| Acquisition date fair value (Note 5.2) | ||
| Payments (Note 5.2) | ) | |
| Application of prepayments (Note 5.2) | ) | |
| Accretion (Note 5.2) | ||
| Balance – December 31, 2023 | ||
| Buyout of Canopy minority interest (Note 5.1) | ||
| Acquisition of an additional 20% membership units in Golden Harvest (Note 5.2) | ||
| Canopy buyout payments (Note 5.1) | ) | |
| Golden Harvests 20% acquisition payments (Note 5.2) | ) | |
| Accretion | ||
| Balance – September 30, 2024 |
All values are in US Dollars.
| 5.1 | Canopy Buyout |
|---|
On April 24, 2024, the Company acquired the 13% non-controlling interest in Canopy, after which the Company owned a 100% interest in Canopy, for aggregate consideration of $780,000 comprised of upfront cash payments of $156,000 and deferred cash payments of $624,000. The deferred cash payments are to be paid in 48 equal installments with a 5.21% interest rate applied. Consideration remaining to be paid at the date of these unaudited condensed interim consolidated financial statements included cash payments of $620,478.
Page 12 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 5.2 | Golden Harvests |
|---|
On May 1, 2021, the Company acquired a controlling 60% interest in Golden Harvests for aggregate consideration of $1,007,719 comprised of 1,025,000 common shares of the Company with a fair value of $158,181 and cash payments of $849,536. Consideration remaining to be paid at the date of these unaudited condensed interim consolidated financial statements included cash payments of $360,000. During the year ended October 31, 2023, 200,000 common shares issuable since May 1, 2021, with an aggregate fair value of $35,806, were issued.
On December 1, 2021, the Company and the seller of the 60% controlling interest in Golden Harvests agreed to extend the due date of the cash portion of business acquisition consideration payable until December 31, 2024, in exchange for monthly payments at a rate of 18% per annum. The Company may pay all or part of the cash portion of the business acquisition consideration payable prior to December 31, 2024.
On April 24, 2024, the Company acquired an additional 20% interest in Golden Harvests for aggregate consideration of $2,342,207 comprised of deferred cash payments of $2,000,0000 (the Initial Purchase Price or “IPP”) plus true-up amounts (the Additional Purchase Price or “APP”). The IPP is to be paid for in thirteen quarterly installments beginning on January 1, 2025. The Company may pay all or part of the cash portion of the business acquisition consideration payable after January 1, 2025. IPP remaining to be paid at the date of these unaudited condensed interim consolidated financial statements included cash payments of $2,000,000. The IPP was recorded at its fair value at the date of inception of $1,644,695.
The APP is calculated on a distribution equivalent basis whereby the seller receives a true-up payment pro-rata based on the proportion of remaining IPP balance at the time of the distribution payment made to the Company. If distribution equivalent amounts in any quarter are in excess of the minimum interest amounts, then no minimum interest amount is due. The distribution equivalent is reduced pro-rata in accordance with amounts paid down against sellers IPP.
| 6. | OTHER INVESTMENTS, PURCHASE DEPOSITS AND NOTES RECEIVABLE |
|---|---|
| 6.1 | Investment in Assets Sold by High Street Capital Partners, LLC (“HSCP”) |
| --- | --- |
On February 5, 2021, the Company agreed to acquire substantially all of the assets of the growing and retail operations pursuant to the HSCP Transaction, for an aggregate total of $3,000,000 in consideration, payable in a series of tranches, subject to receipt of all necessary regulatory and other approvals. A payment of $250,000 was to be due at closing and the payment of the remaining purchase price was to depend on the timing of the closing. The Company also executed the HSCP Management Services Agreement (“MSA”), pursuant to which the Company agreed to pay $21,500 per month as consideration for services rendered thereunder, until the completion of the HSCP Transaction. In accordance with the MSA, the Company owned all production from the growing assets derived from the growing operations of HSCP, and the Company operated the growing facility of HSCP under the MSA until receipt of the necessary regulatory approvals relating to the acquisition by the Company of HSCP’s growing assets. The Company had no involvement with the retail operations contemplated in the agreement until the HSCP Transaction was completed.
On April 14, 2022, the HSCP Transaction closed with modifications to the original terms: the retail purchase was mutually terminated, and total consideration for the acquisition was reduced to $2,000,000. Upon closing, the Company had paid $750,000 towards the acquisition, and owed a principal sum of $1,250,000 as a Secured Promissory Note, which was fully paid during the two months ended December 31, 2023.
Page 13 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 6.2 | Investment in ABCO Garden State, LLC (“ABCO”) |
|---|
On October 4, 2023, the Company announced that it signed a definitive agreement with an option to acquire 70% of ABCO, pending regulatory approval from the New Jersey Cannabis Regulatory Commission (“CRC”). As of May 31, 2024, the Company executed the first option to acquire a 44% membership interest in ABCO. ABCO received licensing approval from the CRC and has an annual NJ cultivation license with local zoning, planning approvals and sufficient power supply. The Company purchased the first option to acquire 44% of ABCO for total consideration of $1,257,142, which has been paid via conversion of previously advanced amounts. The Company may exercise the second option to purchase an additional 26% membership interest in ABCO, pending regulatory approval, two years after operations commence. The purchase price for the second option is $722,858, which remains classified as Other Investments.
| 6.3 | Notes Receivable |
|---|
Transactions related to the Company’s notes receivable for the nine months ended September 30, 2024, and the two months ended December 31, 2023, include the following:
| **** | Notes | **** | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Movement in notes receivable | 6.3.1 | 6.3.2 | 6.3.3 | 6.3.4 | 6.3.5 | Total | ||||||||
| Balance – October 31, 2023 | 1,178,860 | 251,667 | - | - | - | |||||||||
| Advances | 982,757 | - | - | - | - | |||||||||
| Accrued interest | 30,755 | 5,083 | - | - | - | |||||||||
| Balance – December 31, 2023 | 2,192,372 | 256,750 | - | - | - | |||||||||
| Advances | 1,847,141 | - | 1,150,000 | 400,000 | 2,500,000 | |||||||||
| Accrued interest | 337,548 | 9,667 | 66,250 | 23,410 | 39,521 | |||||||||
| Repayments | (161,959 | ) | (266,417 | ) | - | - | - | ) | ||||||
| Balance – September 30, 2024 | 4,215,102 | - | 1,216,250 | 423,410 | 2,539,521 | |||||||||
| Current portion | 1,333,333 | - | - | 423,410 | 2,539,521 | |||||||||
| Non-current portion | 2,881,769 | - | 1,216,250 | - | - |
All values are in US Dollars.
| 6.3.1 | ABCO Promissory Note (Formerly Iron Flag Promissory Note) |
|---|
On October 3, 2023, GR Unlimited executed the ABCO Promissory Note with ABCO’s affiliate, Iron Flag LLC, to fund tenant improvements and for general working capital at the 50,000 square foot facility leased by ABCO for use in ABCO’s cannabis cultivation operations under construction and estimated to be completed in the third quarter of 2024.
Pursuant to the ABCO Promissory Note, GR Unlimited shall make the maximum amount available in one or more advances in an aggregate amount not to exceed $4,000,000. Interest on the outstanding principal borrowed shall accrue at a rate of 12.5% per annum commencing with respect to each advance and accruing until the date the standing advances and all accrued interest is paid in full. As of the unaudited condensed interim consolidated statements of financial position dated September 30, 2024, the Company has advanced the full $4M agreed to under the ABCO Promissory Note. An additional $2,054,782 has been funded, of which $1,257,142 has been converted to equity in ABCO, and $797,640 remains outstanding which will inure to the payment of the option for the remaining 26% equity that can be exercised two years from the commencement of operations.
As at September 30, 2024, the outstanding balance of the ABCO Promissory Note was $3,888,889 (December 31, 2023 - $2,152,859) and the accrued interest was $326,213 (December 31, 2023 - $30,755).
Page 14 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 6.3.2 | New Jersey Retail Promissory Note |
|---|
On October 3, 2023, GR Unlimited executed a promissory note and advanced $250,000 to an individual representing the principal amount of the note. Pursuant to the promissory note agreement, interest on the outstanding principal borrowed shall accrue at a rate of 12% per annum provided that, if the extended maturity date of the note is triggered, interest shall accrue on the outstanding balance commencing on the maturity date and ending on the extended maturity date of the promissory note.
As at September 30, 2024, the outstanding balance of the promissory note was $nil (December 31, 2023 - $250,000) and accrued interest was $nil (December 31, 2023 - $5,083) as the total balance was fully paid.
| 6.3.3 | Convertible Note |
|---|
On January 16, 2024, the Company signed a definitive agreement to invest in the development of an adult-use dispensary in West New York, New Jersey. As part of this agreement, GR Unlimited executed a secured convertible promissory note and initially advanced $500,000 to Nile of NJ LLC, a New Jersey limited liability company. The Company advanced an additional $650,000 to Nile of NJ LLC. Pursuant to the secured convertible promissory note agreement, interest on the outstanding principal borrowed shall accrue at a rate of 10%. The Company received equity investments of $600,000 into Retail Ventures from various parties including $500k from related parties to fund this investment.
As at September 30, 2024, the outstanding balance of the convertible promissory note was $1,150,000 (December 31, 2023 - nil), and the accrued interest was $66,250 (December 31, 2023 - nil).
| 6.3.4 | ABCO Bridge Note |
|---|
On June 3, 2024, GR Unlimited executed a promissory note and advanced $400,000 to ABCO representing the principal amount of the note. Pursuant to this promissory note, interest on the outstanding principal borrowed shall accrue at a rate of 18% per annum provided that the extended maturity date is not triggered, in which interest shall accrue at a rate of 22% on the outstanding balance commencing on the maturity date and ending on the extended maturity date.
As at September 30, 2024, the outstanding balance of the promissory note was $400,000 (December 31, 2023 - nil), and the accrued interest was $23,410 (December 31, 2023 - nil).
| 6.3.5 | ABCO Drawdown Promissory Note |
|---|
On June 24, 2024, GR Unlimited executed a promissory note and advanced $500,000 to ABCO. Pursuant to this note, GR Unlimited shall make the maximum amount available to ABCO in one or more advances in an aggregate amount not to exceed $3,000,000. Interest on the outstanding principal borrowed shall accrue at a rate of 10.5% per annum.
As at September 30, 2024, the outstanding balance of the promissory note was $2,500,000 (December 31, 2023 - nil), and the accrued interest was $39,521 (December 31, 2023 - nil).
Page 15 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 7. | LEASES |
|---|
The following is a continuity schedule of lease liabilities.
| September 30, 2024 | December 31, 2023 | |||
|---|---|---|---|---|
| Balance - beginning | ||||
| Additions | ||||
| Disposals | ) | |||
| Interest expense on lease liabilities | ||||
| Payments | ) | ) | ||
| Balance - ending | ||||
| Current portion | ||||
| Non-current portion |
All values are in US Dollars.
Set out below are undiscounted minimum future lease payments after September 30, 2024:
| Total future minimum lease payments () | ||
|---|---|---|
| Less than one year | ||
| Between one and five years | ||
| Total minimum lease payments | ||
| Less amount representing interest | ) | |
| Present value of minimum lease payments |
All values are in US Dollars.
Page 16 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 8. | PROPERTY AND EQUIPMENT | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| **** | Computer and Office Equipment | Production Equipment and Other | **** | Land | Leasehold Improvements | **** | Right-of- use Assets | **** | Total | **** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| COST | ||||||||||
| Balance – October 31, 2023 | ||||||||||
| Additions | ||||||||||
| Disposals | ) | ) | ) | ) | ||||||
| Balance – December 31, 2023 | ||||||||||
| Additions | ||||||||||
| Disposals | ) | ) | ||||||||
| Balance – September 30, 2024 | ||||||||||
| ACCUMULATED AMORTIZATION | ||||||||||
| Balance – October 31, 2023 | ||||||||||
| Amortization for the period | ||||||||||
| Disposals | ) | ) | ) | ) | ||||||
| Balance – December 31, 2023 | ||||||||||
| Amortization for the period | ||||||||||
| Disposals | ) | ) | ||||||||
| Balance – September 30, 2024 | ||||||||||
| NET BOOK VALUE | ||||||||||
| Balance – December 31, 2023 | ||||||||||
| Balance – September 30, 2024 |
All values are in US Dollars.
For the nine months ended September 30, 2024, amortization capitalized into inventory was $1,426,186 (December 31, 2023 - $323,007) and expensed amortization was $728,095 (December 31, 2023 - $185,415).
| 9. | INTANGIBLE ASSETS AND GOODWILL | |
|---|---|---|
| Indefinite lived intangible assets and goodwill | September 30, 2024 | December 31, 2023 |
| --- | --- | --- |
| Balance – beginning | ||
| Additions – grower licenses | ||
| Balance – ending |
All values are in US Dollars.
Page 17 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 10. | LONG-TERM DEBT |
|---|
Transactions related to the Company’s long-term debt for the nine months ended September 30, 2024, and the two months ended December 31, 2023, include the following:
| **** | Note | **** | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Movement in long-term debt | 10.1 | 10.2 | 10.3 | 10.4 | 10.5 | 10.6 | 10.7 | Total | |||||||||||||||
| Balance – October 31, 2023 | 350,000 | 375,095 | 385,762 | 197,596 | 80,063 | - | - | ||||||||||||||||
| Interest accretion | - | 18,355 | 15,418 | 3,811 | 4,769 | - | - | ||||||||||||||||
| Debt and interest payments | (350,000 | ) | (4,167 | ) | (4,167 | ) | (125,000 | ) | (84,832 | ) | - | - | ) | ||||||||||
| Balance – December 31, 2023 | - | 389,283 | 397,013 | 76,407 | - | - | - | ||||||||||||||||
| Additions to debt | - | - | - | - | - | 1,285,000 | 662,251 | ||||||||||||||||
| Interest accretion | - | 28,867 | 37,300 | 10,644 | - | 63,289 | 61,150 | ||||||||||||||||
| Debt and interest payments | - | (339,584 | ) | (352,952 | ) | (66,484 | ) | - | (94,229 | ) | (57,352 | ) | ) | ||||||||||
| Balance – September 30, 2024 | - | 78,566 | 81,361 | 20,567 | - | 1,254,060 | 666,049 | ||||||||||||||||
| Current portion | - | 78,566 | 81,361 | 20,567 | - | 144,426 | 233,595 | ||||||||||||||||
| Non-current portion | - | - | - | - | - | 1,109,634 | 432,454 |
All values are in US Dollars.
| **** | Note | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Undiscounted future payments at: | 10.1 | 10.2 | 10.3 | 10.4 | 10.5 | 10.6 | 10.7 | Total | |||||||
| December 31, 2023 | - | 427,083 | 428,824 | 88,298 | - | - | - | ||||||||
| September 30, 2024 | - | 87,500 | 86,287 | 65,442 | - | 1,421,542 | 820,638 | ||||||||
| Current portion | - | 87,500 | 86,287 | 65,442 | - | 224,782 | 328,255 | ||||||||
| Non-current portion | - | - | - | - | - | 1,196,760 | 492,383 |
All values are in US Dollars.
| 10.1 | 12.5% Note Payable Owed by GR Distribution to HSCP with Original Principal Amount of $1,250,000 |
|---|
On April 14, 2022, the Company purchased indoor growing assets from HSCP (Note 6.1). Purchase consideration included a secured promissory note payable with a principal sum of $1,250,000, of which $500,000 was due on August 1, 2022 and $750,000 was due on May 1, 2023, before amendment of the agreement, which is described below. Collateral for the secured promissory note payable is comprised of the assets purchased.
On August 1, 2022, the terms of the secured promissory note between GR Distribution and HSCP, were amended. As amended, the secured promissory note will be fully settled by two principal amounts of $500,000 and $750,000 due on May 1, 2023. Beginning on August 1, 2022, and continuing until repaid in full, the unpaid portion of the first principal amount will accrue simple interest at a rate per annum of 12.5%, payable monthly. In the event the Company raises capital, principal payments shall be made as follows. If the capital raise is less than or equal to $2 million, then 25% of the capital raise shall be paid against the principal payment of $500,000 due to HSCP on May 1, 2023 (“First Principal Payment”); if the capital raise is greater than $2 million and less than or equal to $3 million, then $250,000 shall be paid against the First Principal Payment; and if the capital raise is greater than $3 million, then $500,000 shall be paid against the First Principal Payment.
Page 18 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
On May 1, 2023, the terms of the secured promissory note were amended for a second. Under the second amendment, the secured promissory note will be fully settled in two principal amounts. On May 1, 2023, the $500,000 principal payment plus all accrued but unpaid interest under the first amendment was due and payable. The remaining principal balance of $500,000, which bore no interest, was due and payable as follows: $150,000 due and payable on August 1, 2023; $150,000 due and payable on November 1, 2023; and $200,000 due and payable on December 31, 2023. The balance was fully paid during the two months ended December 31, 2023.
| 10.2 | 10% Note Payable Owed by Golden Harvests with Original Principal Amount of $250,000 |
|---|
On May 1, 2021, the Company assumed a note payable owed by Golden Harvests (Note 5.2) with a carrying value of $227,056. The note is for a principal amount of $250,000, interest paid monthly at 10% per annum, and a maturity date of January 14, 2024. After the maturity date, additional interest payments are due quarterly, at amounts that cause total interest paid over the life of the debt to equal $250,000. The note is reported at amortized cost using an effective interest rate of approximately 33%. During the nine months ended September 30, 2024, and the two months ended December 31, 2023, the Company made principal and interest payments of $339,584 and $4,167 respectively.
| 10.3 | 10% Note Payable Owed by GR Distribution with Original Principal Amount of $250,000 |
|---|
On January 27, 2021, debt was issued by GR Distribution with a principal amount of $250,000, interest paid monthly at 10% per annum, and a maturity date of January 27, 2024. After the maturity date, additional interest payments are due quarterly, at amounts that cause total interest paid over the life of the debt to equal $250,000. The note is reported at amortized cost using an effective interest rate of approximately 27%. During the nine months ended September 30, 2024, and the two months ended December 31, 2023, the Company made principal and interest payments of $352,953 and $4,167 respectively.
| 10.4 | 10% Note Payable Owed by GR Distribution with Original Principal Amount of $125,000 |
|---|
On November 23, 2020, debt was issued by GR Distribution with a principal amount of $125,000, interest paid monthly at 10% per annum, and a maturity date of November 23, 2023. After the maturity date, additional interest payments are due quarterly, at amounts that cause total interest paid over the life of the debt to equal $125,000. The note is reported at amortized cost using an effective interest rate of approximately 27%. During the nine months ended September 30, 2024, and the two months ended December 31, 2023, the Company made principal and interest payments of $66,484 and $125,000, respectively.
Page 19 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 10.5 | 0% Stated Rate Note Payable Owed by Canopy with Original Principal Amount of $600,000 and Royalty Payments to Lenders |
|---|
On March 20, 2020, debt with a principal amount of $600,000 was received under a secured debt investment of $600,000. It carries a two-year term, with monthly payments of principal commencing June 15, 2020, and with payments calculated at 1% of cash sales receipts of Golden Harvests. Once the principal is repaid, each investor receives a monthly royalty of 1% per $100,000 invested of cash receipts for sales by Golden Harvests. The royalty commenced in December 2021, at which time principal was repaid, and is payable monthly for a period of two years. The royalty maximum is two times the amount of principal invested, and the royalty minimum is equal to the principal loaned. The Company has the right, but not the obligation, to terminate royalty payments from any lender by paying an amount equal to the original principal invested by such a lender. The debt is reported at the carrying value of the probability-weighted estimated future cash flows of all payments under the agreement at amortized cost using the effective interest method, at an effective interest rate of approximately 73%. A portion of this debt is due to related parties (Note 17.5). During the two months ended December 31, 2023, the balance was fully paid.
| 10.6 | Note Payable Owed by GRU Properties, LLC with Original Principal Amount of $1,285,000 |
|---|
On January 12, 2024, debt with a principal amount of $1,285,000 was received, secured by deed of trust of $1,285,000. Interest is paid at the higher of 5% or the London Interbank Offered Rate (‘LIBOR”) for the first twelve months. For the thirteenth month to the twenty-fourth month, interest is paid at the higher of 6% or the LIBOR and for twenty-fifth month to the thirty-sixth month, interest is paid at the higher of 7% or the LIBOR. Interest is paid at the end of the month in arrears and is computed based on a 30-day month and has a maturity date of December 1, 2027. The note is reported at amortized cost using an effective rate of approximately 7.2%. During the nine months ended September 30, 2024, the Company made principal and interest payments of $94,229.
| 10.7 | Note Payable Owed by ABCO Gardens State, LLC, with Original Principal Limit Amount of $1,100,000 |
|---|
On March 15, 2024, GR Unlimited guaranteed a note payable owed by ABCO Gardens State, LLC, with an original principal limit amount of $1,100,000. The note allows the Company to borrow any amount which is more than $150,000 but less than the loan limit of $1,100,000. All advances in aggregate should not exceed the loan limit of $1,100,000. Each advance will be subjected to a 1.55% origination fee payable to the lender at the time of the advance, which can be deducted from the advance. Interest is paid at 17.32% per annum and each advance has a maturity date of 3 years after the effective date of the advance. Interest only will be payable on the 15^th^ of the next month following the effective date of the advance and continuing for six months. At any time after the Company has paid twelve months’ worth of interest, the Company may repay the note in full following written notice to the lender. The principal and interest payments for the note payable are to be made by GR Unlimited, in which the principal loan balance has been added to the ABCO Promissory Note and is considered an advance issued by GR Unlimited. During the nine months ended September 30, 2024, the Company made principal and interest payments of $57,352.
| 10.8 | Accrued Interest Payable |
|---|
Accrued interest payable on long-term debt at September 30, 2024, was $nil (December 31, 2023 - $nil).
Page 20 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 11. | CONVERTIBLE DEBENTURES |
|---|
Transactions relating to the Company’s convertible debentures for the nine months ended September 30, 2024, and the two months ended December 31, 2023, include the following:
| **** | Note | **** | **** | **** | |||||
|---|---|---|---|---|---|---|---|---|---|
| Movement in convertible debt | 11.1 | 11.2 | Total | ||||||
| Balance – October 31, 2023 | $ | 247,316 | 2,165,446 | $ | 2,412,762 | ||||
| Interest accretion | 11,672 | 162,468 | 174,140 | ||||||
| Debt and interest payments | (7,875 | ) | (119,103 | ) | (126,978 | ) | |||
| Balance – December 31, 2023 | $ | 251,113 | $ | 2,208,811 | $ | 2,459,924 | |||
| Debt settlement through conversion of shares | (277,092 | ) | (751,514 | ) | (1,028,606 | ) | |||
| Interest accretion | 42,844 | 789,177 | 832,021 | ||||||
| Debt and interest payments | (16,865 | ) | (413,963 | ) | (430,828 | ) | |||
| Balance – September 30, 2024 | - | $ | 1,832,511 | $ | 1,832,511 | ||||
| Current portion | - | $ | 1,832,511 | $ | 1,832,511 | ||||
| Non-current portion | - | - | - | ||||||
| 11.1 | 9% Convertible Debentures with Original Principal Amount of $2,000,000 | ||||||||
| --- | --- |
On December 5, 2022, the Company announced the closing of a non-brokered private placement of the Convertible debentures with aggregate principal amount of $2,000,000 issued in December 2022. (“December Convertible Debentures”). The December Convertible Debentures accrue interest at 9% per year, paid quarterly, and mature 36 months from the date of issue. The December Convertible Debentures are convertible into common shares of the Company at a conversion price of CAD$0.20 per common share. Additionally, on closing, the Company issued to the purchasers of the December Convertible Debentures an aggregate of 6,716,499 warrants, that represents 50% coverage of each purchaser’s Convertible Debenture investment (“December Warrants”). The December Warrants are exercisable for a period of three years from issuance into common shares at an exercise price of $0.25 CAD per common share. The Company has the right to accelerate the warrants if the closing share price of the common shares on the Canadian Securities Exchange is CAD$0.40 or higher for a period of 10 consecutive trading days.
During the nine months ended September 30, 2024, the Company issued the notice of acceleration dated March 1, 2024, required by the warrant certificates governing the December Warrants, which accelerated the expiry date to 90 days from the date of notice. During the nine months ended September 30, 2024, a total of 6,716,499 common share purchase warrants were issued for 6,716,499 common shares (Note 12.5).
| 11.1.1 | Debt Settlement Through Conversion of Shares |
|---|
During the nine months ended September 30, 2024, the Purchasers of the December Convertible Debentures fully converted an aggregate total of convertible debenture principal of $277,092 at CAD$0.20 per share into 2,413,525 common shares.
The derivative liability was not remeasured at September 30, 2024, given that the December Convertible Debentures were fully settled.
Page 21 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 11.2 | 9% Convertible Debentures with Original Principal Amount of $5,000,000 |
|---|
On July 13, 2023, the Company announced the closing of a non-brokered private placement of unsecured the convertible debentures with an aggregate principal amount of $5,000,000 (“July Convertible Debentures”). The July Convertible Debentures accrue interest at 9% per year, paid quarterly, and mature 48 months from the date of issue. The July Convertible Debentures are convertible into common shares of the Company at a conversion price of CAD$0.24 per common share, at any time on or prior to the maturity date. Additionally, on closing, the Company issued to the Subscribers of the July Convertible Debentures an aggregate of 13,737,500 warrants, that represents one-half of one warrant for each CAD$0.24 of Principal amount subscribed (“July Warrants”). The July Warrants are exercisable for a period of three years from issuance into common shares at an exercise price of CAD$0.28 per common share. The Company has the right to accelerate the warrants if the closing share price of the common shares on the Canadian Securities Exchange is CAD$0.40 or higher for a period of 10 consecutive trading days.
During the nine months ended September 30, 2024, the Company issued the notice of acceleration dated March 1, 2024, required by the warrant certificates governing the July Warrants, which accelerated the expiry date to 90 days from the date of notice. During the nine months ended September 30, 2024, 13,737,500 common share purchase warrants were issued for 13,737,500 common shares (Note 12.5).
| 11.2.1 | Debt Settlement Through Conversion of Shares |
|---|
During the nine months ended September 30, 2024, Purchasers of the July Convertible Debentures converted an aggregate total of convertible debenture principal of $423,515 at CAD$0.28 per share into 5,388,062 common shares.
The conversion feature of the July Convertible Debentures gives rise to the derivative liability reported on the unaudited condensed interim consolidated statements of financial position at September 30, 2024. The derivative liability is remeasured at fair value through profit and loss at each reporting period using the Black-Scholes option pricing model. The fair value of the derivative liability at September 30, 2024, was estimated to be $13,222,934 (December 31, 2023 - $5,824,496) using the following assumptions:
| Expected dividend yield | Nil | |
|---|---|---|
| Risk-free interest rate | 2.70 | % |
| Expected life | 2.78 years | |
| Expected volatility | 93.24 | % |
| 11.2.2 | 9% Convertible Debentures with Original Principal Amount of $1,000,000 | |
| --- | --- |
On August 17, 2023, the Company announced that it had closed the second and final tranche of a non-brokered private placement of unsecured convertible debentures for gross proceeds of $1,000,000 (“August Convertible Debentures”), for a total aggregate principal amount under both tranches of $6,000,000 with the July Convertible Debentures. Additionally, on closing, the Company issued to Subscribers under the second tranche an aggregate of 2,816,250 common share purchase warrants (“August Warrants”). The terms of the August Convertible Debentures and August Warrants issued as part of this second tranche are the same as those issued in the July Convertible Debentures and July Warrants.
During the nine months ended September 30, 2024, the Company issued the notice of acceleration dated March 1, 2024, required by the warrant certificates governing the August Warrants, which accelerated the expiry date to 90 days from the date of notice. During the nine months ended September 30, 2024, 2,816,250 purchase warrants were issued for 2,816,250 common shares (Note 12.5).
Page 22 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 11.2.3 | Debt Settlement Through Conversion of Shares |
|---|
During the nine months ended September 30, 2024, Purchasers of the August Convertible Debentures converted an aggregate total of convertible debenture principal of $328,000 at CAD$0.28 per share into 5,682,083 common shares to fully settle the convertible debenture.
The derivative liability was not remeasured at September 30, 2024, given that the August Convertible Debentures were fully settled.
| 12. | SHARE CAPITAL AND SHARES ISSUABLE |
|---|
The Company was previously authorized to issue an unlimited number of common shares at no par value and an unlimited number of preferred shares issuable in series.
Effective June 24, 2024, the Company completed the Share Reorganization to redesignate its existing class of common shares without par value in the Company’s capital as SV Shares and create a new class of unlisted MV Shares. As of the unaudited condensed interim consolidated statements of financial position dated September 30, 2024, total common shares outstanding were 222,276,113, in which all MV Shares have been converted into SV Shares.
During the nine months ended September 30, 2024, the following share transactions occurred:
| 12.1 | 3,516,308 Common Shares Issued for Option Exercise |
|---|
The Company 3,516,308 common shares with an aggregate fair value of $624,360, as holders opted to convert their options.
| 12.2 | 2,413,525 Common Shares Issued to Fully Settle the December Convertible Debentures |
|---|
The Company issued 2,413,525 common shares with an aggregate fair value of $1,413,901, as all holders opted to convert their convertible debentures.
| 12.3 | 5,388,062 Common Shares Issued to Partially Settle July Convertible Debentures |
|---|
The Company issued 5,388,062 common shares with an aggregate fair value of $3,626,489, as few holders opted to convert their convertible debentures.
| 12.4 | 5,682,083 Common Shares Issued to Fully Settle August Convertible Debentures |
|---|
The Company issued 5,682,083 common shares with an aggregate fair value of $3,821,599, as all holders opted to convert their convertible debentures.
Page 23 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 12.5 | 23,270,249 Common Shares Issued for Warrant Exercise |
|---|
During the nine months ended June 30, 2024, the Company issued 23,270,249 common shares for total proceeds of $4,657,460 gross of issuance costs of $126,914.
The Company issued 6,716,499 common shares for total proceeds of $1,239,446 relating to the December Convertible Debentures which had a warrant strike price of CAD$0.25 per share.
The Company issued 13,737,500 common shares for total proceeds of $2,836,445 relating to the July Convertible Debentures which had a warrant strike price of CAD$0.28 per share.
The Company also issued 2,816,250 common shares for total proceeds of $581,569 relating to the August Convertible Debentures which had a warrant strike price of CAD$0.28 per share.
| 12.6 | Share Reorganization |
|---|
On June 24, 2024, the Company completed the Share Reorganization as approved by the Company’s shareholders at its annual and special meeting. Pursuant to the Share Reorganization, the Company amended its articles to redesignate its existing class of common shares without par value in the capital of the Company as SV Shares and created a new class of unlisted MV Shares. The SV Shares can be converted into MV Shares at a conversion ratio of 1,000:1, and the MV Shares carry 1,000 votes per share.
During the two months ended December 31, 2023, no share transactions occurred.
Page 24 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 13. | WARRANTS |
|---|
The following table summarizes the warrant activities for the nine months ended September 30, 2024, and the two months ended December 31, 2023:
| Number | Weighted Average Exercise Price (CAD) | |||
|---|---|---|---|---|
| Balance – October 31, 2022 | 33,510,696 | |||
| Issuance pursuant to the December Convertible Debentures (Note 11.1) | 6,716,499 | |||
| Issuance pursuant to the July Convertible Debentures (Note 11.2) | 13,737,500 | |||
| Issuance pursuant to the August Convertible Debentures (Note 11.2) | 2,816,250 | |||
| Issued pursuant to the Consulting Agreement with Vireo Growth Inc. (Note 13.1) | 8,500,000 | |||
| Expiration of warrants pursuant to Feb 2021 subscriptions | (8,200,000 | ) | ||
| Expiration of warrants pursuant to the Offering (Special warrant issue) | (23,162,579 | ) | ||
| Expiration of warrants to terminate purchase agreement | (2,148,117 | ) | ||
| Balance – December 31, 2023 | 31,770,249 | |||
| Conversion to common shares pursuant to the December Convertible Debentures | (6,716,499 | ) | ||
| Conversion to common shares pursuant to the July Convertible Debentures | (13,737,500 | ) | ||
| Conversion to common shares pursuant to the August Convertible Debentures | (2,816,250 | ) | ||
| Balance – September 30, 2024 | 8,500,000 |
All values are in US Dollars.
As at September 30, 2024, the following warrants were issued and outstanding:
| Exercise price (CAD$) | Warrants outstanding | Life (years) | Expiry date |
|---|---|---|---|
| 0.225 | 8,500,000 | 4.02 | October 05, 2028 |
| 0.225 | 8,500,000 | 4.02 | |
| 13.1 | Vireo Growth Consulting Agreement (formerly Goodness Growth) | ||
| --- | --- |
The Consulting Agreement with Vireo Growth Inc. (“Vireo Growth”) was executed as of May 24, 2023, whereby GR Unlimited will support Vireo Growth in the optimization of its cannabis flower products, with a particular focus on improving the quality and yield of top-grade “A” cannabis flower across its various operating markets, starting with Maryland and Minnesota.
As part of this strategic agreement, Vireo Growth is obligated to issue 10,000,000 warrants to purchase 10,000,000 subordinate voting shares of Vireo Growth to the Company, with a strike price equal to CAD$0.317 (US$0.233), being a 25.0 percent premium to the 10-day volume weighted average price (“VWAP”) of Vireo Growth’s subordinate voting shares prior to the effective date of the Consulting Agreement. Similarly, the Company issued 8,500,000 warrants to purchase 8,500,000 common shares of the Company to Vireo Growth, with a strike price equal to CAD$0.225 (US$0.166), being a 25.0 percent premium to the 10-day VWAP of the Company’s common shares prior to the effective date of the Consulting Agreement. Also see Subsequent Events.
Page 25 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
The Company first measured and recognized the fair value ($1,232,253) of the warrants using a Black-Scholes option pricing model as of the warrants’ deemed issuance date, which was the effective date of the Consulting Agreement (May 24, 2023). The Company and Vireo Growth issued and exchanged the warrants on October 5, 2023, at which time the carrying value ($1,232,253) of the warrants issued and received was recorded to equity and Warrants Asset, respectively.
The Warrants Asset is remeasured at fair value through profit and loss at each reporting period using the Black-Scholes option pricing model. The fair value of the Warrants Asset at September 30, 2024, was estimated to be $3,832,792 (December 31, 2023 - $1,761,382) using the following assumptions:
| Expected (strike) price | 0.317 | |
|---|---|---|
| Risk-free interest rate | 2.70 | % |
| Expected life | 4.02 years | |
| Expected volatility | 99 | % |
| 14. | STOCK OPTIONS | |
| --- | --- |
The following table summarizes the stock option movements for the nine months ended September 30, 2024, and the two months ended December 31, 2023:
| Number | Exercise price (CAD) | |||
|---|---|---|---|---|
| Balance – October 31, 2023 | 11,205,000 | |||
| Granted to employees | 100,000 | |||
| Granted to service providers | 500,000 | |||
| Expiration of options to employees | (5,000 | ) | ||
| Balance – December 31, 2023 | 11,800,000 | |||
| Granted to employees | 4,845,000 | |||
| Granted to service providers | 1,910,000 | |||
| Options exercised into common shares | (3,565,000 | ) | ||
| Expiration of options employees | (25,000 | ) | ||
| Balance – September 30, 2024 | 14,965,000 |
All values are in US Dollars.
| 14.1 | Stock Options Granted |
|---|
During the nine months ended September 30, 2024, 6,755,000 options were granted to employees and service providers (for the two months ended December 31, 2023 – 600,000).
The fair value of the options granted during the nine months ended September 30, 2024 was approximately $2,411,071 (CAD$3,258,515) and the two months ended December 31, 2023, was approximately $112,078 (CAD$148,466), which was estimated at the grant dates based on the Black-Scholes option pricing model, using the following assumptions:
| Expected dividend yield | Nil | % |
|---|---|---|
| Risk-free interest rate | 3.78 | % |
| Expected life | 3.02 years | |
| Expected volatility | 86 | % |
Page 26 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
The vesting terms of options granted during the nine months ended September 30, 2024, are set out in the table below:
| Number granted | Vesting terms |
|---|---|
| 50,000 | 100% of the options vest on August 31, 2025 |
| 6,705,000 | 1/3 of the Options vest on each of December 31, 2024, 2025 and 2026 |
| 6,755,000 |
The vesting terms of options granted during the two months ended December 31, 2023, are set out in the table below:
| Number granted | Vesting terms |
|---|---|
| 100,000 | 50% on one year anniversary of grant date, 50% on second anniversary of grant date |
| 500,000 | Monthly over a year |
| 600,000 | |
| 14.2 | Stock Options Issued and Outstanding |
| --- | --- |
As at September 30, 2024, the following stock options were issued and outstanding:
| Exercise price (CAD) | Options<br> outstanding | Number<br> exercisable | Remaining<br> Contractual Life<br> (years) | Expiry period | |||
|---|---|---|---|---|---|---|---|
| 200,000 | 200,000 | 0.13 | November 2024 | ||||
| 1,000,000 | 1,000,000 | 0.58 | April 2025 | ||||
| 1,150,000 | 1,150,000 | 0.65 | May 2025 | ||||
| 85,000 | 85,000 | 1.10 | November 2025 | ||||
| 300,000 | 300,000 | 1.55 | April 2026 | ||||
| 4,475,000 | 4,475,000 | 2.28 | January 2027 | ||||
| 400,000 | 116,666 | 2.96 | September 2027 | ||||
| 600,000 | 416,666 | 3.13 | November 2027 | ||||
| 5,355,000 | - | 2.92 | August 2027 | ||||
| 1,400,000 | - | 4.92 | August 2029 | ||||
| 14,965,000 | 7,743,332 | 2.52 |
All values are in US Dollars.
Page 27 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 15. | CHANGES IN NON-CASH WORKING CAPITAL |
|---|
The changes to the Company’s non-cash working capital for the nine months ended September 30, 2024, and the nine months ended October 31, 2023, are as follows:
| Nine months ended September 30, 2024 | Nine months ended October 31,<br> 2023 | |||
|---|---|---|---|---|
| Accounts receivable | ) | ) | ||
| Inventory and biological assets | ) | |||
| Prepaid expenses | ) | ) | ||
| Accounts payable and accrued liabilities | ||||
| Income tax payable | ||||
| Unearned revenue | ) | |||
| Total | ) |
All values are in US Dollars.
| 16. | SUPPLEMENTAL CASH FLOW DISCLOSURE | |
|---|---|---|
| Nine months ended September 30, 2024 | Nine months ended October 31,<br> 2023 | |
| --- | --- | --- |
| Interest paid | ||
| Fair value of common shares issued to settle convertible debentures (Note 12.2, 12.3 and 12.4) | ||
| Right-of-use assets acquired through leases (Note 7) | ||
| Note payable to HSCP used to acquire assets (Note 10.1) | ||
| Note payable to PMW LLC to acquire assets (Note 10.7) | ||
| Note payable to Lender Capital, LLC to acquire Ross Lane Property (Note 10.6) |
All values are in US Dollars.
| 17. | RELATED PARTY TRANSACTIONS |
|---|
During the nine months ended September 30, 2024, the Company incurred the following related party transactions.
| 17.1 | Transactions with the President & Chief Executive Officer (“CEO”) |
|---|
Through its wholly owned subsidiary, GRU Properties, the Company leases an outdoor grow property located in Trail, Oregon, owned by the Company’s President and CEO (“Trail”). The lease was extended during the year ended October 31, 2021, with a term through December 31, 2025. Lease charges of $54,000 (nine months ended October 31, 2023 – $54,000) were incurred for nine months ended September 30, 2024. The lease liability for Trail at September 30, 2024, was $84,011 (December 31, 2023 - $129,401).
During the year ended October 31, 2021, the Company leased an outdoor post-harvest facility located in Medford, Oregon (“Lars”), a facility which is beneficially owned by the CEO, with a term through June 30, 2026. Lease charges for Lars of $147,518 (nine months ended October 31, 2023 - $159,135) were incurred for the nine months ended September 30, 2024. The lease liability for Lars at September 30, 2024, was $326,423 (December 31, 2023 - $445,708).
Page 28 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
Leases liabilities payable to the CEO were $410,434 in aggregate at September 30, 2024 (December 31, 2023 - $575,109).
During the year ended October 31, 2023, the Company, through GR Unlimited, acquired 87% of the membership units of Canopy from the CEO. All payments necessary for GR Unlimited to exercise its option to acquire 87% of Canopy were equal to payments made by Canopy to purchase a controlling 60% interest of Golden Harvests for aggregate consideration of $1,007,719 comprised of 1,025,000 common shares of the Company with a fair value of $158,181 and cash payments of $849,536. Following GR Unlimited’s acquisition of 87% of the membership units of Canopy in January of 2023, Canopy became owned 87% by GR Unlimited; 7.5% by officers and directors; and 5.5% by the CEO. (Also see Note 23.1).
During April 2024, the Company, through GR Unlimited, acquired the remaining 13% of the membership units in Canopy. As part of this transaction, the Company purchased the CEO’s 5.5% membership interest in Canopy. The consideration due to the CEO is comprised of an upfront cash payment of $66,000 and deferred cash payments of $264,000. (Also see Note 5.1).
| 17.2 | Transactions with Spouse of CEO |
|---|
During the nine months ended September 30, 2024, the Company incurred expenses of $75,384 (nine months ended October 31, 2023 - $75,769) for salary paid to the spouse of the CEO. At September 30, 2024, accounts and accrued liabilities payable to this individual were $2,308 (December 31, 2023 - $3,846).
During the nine months ended September 30, 2024, the spouse of the CEO exercised 500,000 stock options into common share. The Company also issued 300,000 stock options during the nine months ended September 30, 2024.
| 17.3 | Transactions with Michigan General Manager (“GM”) |
|---|
Through its subsidiary, Golden Harvests, the Company leased Morton, owned by the Company’s GM, that is located in Michigan, with a lease term through January 2026. Lease charges of $162,000 (nine months ended October 31, 2023 - $154,000) were incurred during the nine months ended September 30, 2024. The lease liability of Morton at September 30, 2024, was $255,170 (December 31, 2023 - $350,668).
Through its subsidiary, Golden Harvests, the Company also leased Morton Annex located in Michigan, which is owned by the Company’s GM. The lease term was extended during the two months ended December 31, 2023, through November 2024. Lease charges of $250,000 (nine months ended October 31, 2023 - $580,000) were incurred during the nine months ended September 30, 2024. The lease liability of Morton Annex at September 30, 2024, was $nil (December 31, 2023 - $239,871).
During April 2024, the Company, through Canopy, acquired an additional 20% of the membership units in Golden Harvest from the GM for aggregate consideration of $1,644,695, comprised of deferred cash payments of $2,000,0000 plus true-up amounts. A distribution of $360,000 was paid to the GM during the nine months ended September 30, 2024 and true-up amounts of $360,000 were paid to the GM.
Page 29 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 17.4 | Transactions with Key Management Personnel |
|---|
Key management personnel consist of the President and CEO, the Chief Financial Officer (“CFO”), GM and the Senior Vice President (“SVP”)* of the Company. The compensation to key management is presented in the following table:
| Three months ended | Three months ended | Nine months ended | Nine months ended | |
|---|---|---|---|---|
| September 30, 2024 | October 31, 2023 | September 30, 2024 | October 31, 2023 | |
| Salaries and consulting fees | ||||
| Royalty fees paid to GM | ||||
| Stock option expense | ||||
| Total |
All values are in US Dollars.
| * | SVP ’s effective last day was December 31, 2023. |
|---|
Stock options granted to key management personnel and close family members of key management personnel include the following. During the nine months ended September 30, 2024, 1,400,000 options were granted to the CEO; 170,000 options granted to the CFO, and 300,000 options granted to the GM. During the nine months ended September 30, 2024, the CFO exercised 1,000,000 stock options into common shares. During the two months ended December 31, 2023, no options were granted to key management personnel.
During the nine months ended September 30, 2024, options of 250,000 were exercised into common shares by a Director. Options of 510,000 were also granted to Directors during the nine months ended September 30, 2024.
Accounts payable, accrued liabilities, and lease liabilities due to key management at September 30, 2024, totaled $3,122,109 (December 31, 2023 - $1,230,808).
| 17.5 | Debt Balances and Movements with Related Parties |
|---|
The following table sets out portions of debt pertaining to related parties:
| CEO | SVP | Director | GM | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Balance – October 31, 2023 | ||||||||||
| Interest | ||||||||||
| Payments | ) | ) | ) | ) | ) | |||||
| Balance – December 31, 2023 | ||||||||||
| Borrowed | ||||||||||
| Interest | ||||||||||
| Payments | ) | ) | ) | |||||||
| Balance – September 30, 2024 |
All values are in US Dollars.
| * | SVP’s effective last day was December 31, 2023. |
|---|
Pursuant to the loan and related agreements transacted during the year ended October 31, 2020, the CEO, SVP, and a director obtained 5.5%; 1%; and 2.5% of GR Michigan, respectively; third parties obtained 4% as part of the agreements, such that GR Michigan has a 13% non-controlling interest (Note 23.1). These parties, except the CEO, obtained the same interests in Canopy; the CEO obtained 92.5% of Canopy Management, of which 87% was acquired by the Company in January 2023 (Note 23.2); all payments necessary for the Company to exercise its option to acquire 87% of Canopy were equal to payments made by Canopy to purchase a controlling 60% interest of Golden Harvests. Interest payments of $48,600 were made on the business acquisition consideration payable of $360,000 for the nine months ended September 30, 2024 ($10,400 for the two months ended December 31, 2023). (Alse see Note 5.2).
Page 30 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
Pursuant to the Canopy purchase agreement executed on April 24, 2024, the Company, through GR Unlimited, acquired the remaining 13% of the membership units in Canopy. As part of this transaction, the Company purchased a 5.5% membership interest in Canopy from the CEO, comprised of an upfront cash payment of $66,000 and deferred cash payments of $264,000. Additionally, the Company purchased a 2.5% membership interest in Canopy from a Director, comprised of an upfront cash payment of $66,000 and deferred cash payments of $264,000. The deferred cash payments are to be paid in 48 equal installments with a 5.21% interest rate applied. Principal payments of $25,798 and interest payments of $4,726 were made on the business acquisition consideration payable ($264,000) due to the CEO for the nine months ended September 30, 2024 ($nil for the two months ended December 31, 2023). Principal payments of $11,726 and interest payments of $2,149 were made on the business acquisition consideration payable ($120,000) due to the Director for the nine months ended September 30, 2024 ($nil for the two months ended December 31, 2023). (Also see Note 5.1).
During April 2024, the Company, through Canopy, acquired an additional 20% of the membership units in Golden Harvest from the GM for aggregate present value consideration of $1,644,695, comprised of deferred cash payments of $2,000,0000 plus true-up amounts. Pursuant to the purchase agreement executed on April 24, 2024, the deferred cash payments are to be paid in thirteen quarterly installments beginning on January 1, 2025. True-up payments of $360,000 were made on the business acquisition consideration payable of $1,644,695 for the nine months ended September 30, 2024 ($nil for the two months ended December 31, 2023). (Also see Note 5.2).
| 18. | FINANCIAL INSTRUMENTS |
|---|---|
| 18.1 | Market Risk (Including Interest Rate Risk, Currency Risk and Other Price Risk) |
| --- | --- |
Market risk is the risk that the fair value or cash flows of a financial instrument will fluctuate due to changes in market prices. Market risk reflects interest rate risk, currency risk and other price risks.
| 18.1.1 | Interest Rate Risk |
|---|
At September 30, 2024, and December 31, 2023, the Company’s exposure to interest rate risk relates to long term debt and finance lease obligations; each of these items bear interest at a fixed rate.
| 18.1.2 | Currency Risk |
|---|
As at September 30, 2024, the Company had a portion of its accounts payable and accrued liabilities denominated in Canadian dollars which amounted to CAD$203,112 (CAD $155,679 at December 31, 2023). The Company also has derivative liabilities of $13,222,933 which are based on the underlying price of the Company’s stock in Canadian Dollars. The Company is exposed to the risk of fluctuation in the rate of exchange between the Canadian Dollar and the United States Dollar.
Page 31 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 18.1.3 | Other Price Risk |
|---|
Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices, other than those arising from interest rate risk or foreign currency risk and a change in the price of cannabis. The Company is exposed to price risk related to its derivative liabilities and warrant assets which are based on the underlying value of the Company stock. The Company is not exposed to significant other price risks.
| 18.2 | Credit Risk |
|---|
Credit risk is the risk that one party to a financial instrument will cause a loss for the other party by failing to pay for its obligation.
Credit risk to the Company is derived from cash, trade accounts receivable, and notes receivable. The Company places its cash in deposit with United States financial institutions. The Company has established a policy to mitigate the risk of loss related to granting customer credit by primarily selling on a cash-on-delivery basis.
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits and notes receivable. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At September 30, 2024 and December 31, 2023, the Company had $4,841,717 and $6,054,579 in excess of the FDIC insured limit, respectively. The Company has loaned ABCO Garden State, LLC $7,697,640 under secured and unsecured notes and advances.
Accounts receivable primarily consist of trade accounts receivable and sales tax receivable. The Company provides credit to certain customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. Credit risk is assessed on a case-by-case basis and a provision is recorded where required.
The carrying amount of cash, accounts receivable, and notes receivables represent the Company’s maximum exposure to credit risk; the balances of these accounts are summarized in the following table:
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| Cash | ||
| Accounts receivable | ||
| Notes receivable | ||
| Total |
All values are in US Dollars.
The allowance for doubtful accounts at September 30, 2024, was $390,604 (December 31, 2023 - $373,393).
Page 32 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
As at September 30, 2024, and December 31, 2023, the Company’s trade accounts receivable were aged as follows:
| September 30, 2024 | December 31, 2023 | |||
|---|---|---|---|---|
| Current | ||||
| 1-30 days | ||||
| 31 days older | ||||
| Total trade accounts receivable | ||||
| GST /HST | ||||
| Provision for bad debt | ) | ) | ||
| Total accounts receivable |
All values are in US Dollars.
Major customers are defined as customers that each individually account for greater than 10% of the Company’s annual revenues. During the nine months ended September 30, 2024, there was no major customer that accounted for greater than 10% of revenues (nine months ended October 31, 2023 – no major customer that accounted for greater than 10% of revenues). There was no customer with an accounts receivable balance greater than 10% at September 30, 2024, of the total accounts receivable balance (December 31, 2023 – one major customer comprised 11% of total accounts receivable balance).
| 18.3 | Liquidity Risk |
|---|
Liquidity risk is the risk that an entity will have difficulties in paying its financial liabilities.
The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when they become due. At September 30, 2024, and December 31, 2023, the Company’s working capital accounts were as follows:
| September 30, 2024 | December 31, 2023 | |||
|---|---|---|---|---|
| Cash | ||||
| Current assets excluding cash | ||||
| Total current assets | ||||
| Current liabilities | ) | ) | ||
| Working capital |
All values are in US Dollars.
Page 33 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
The current liabilities included to derive working capital excludes the current portion of convertible debt and derivative liabilities, which has a maturity greater than one year but is classified as current liabilities based on the newly adopted amendment to IAS 1 effective January 1, 2024.
The contractual maturities of the Company’s liabilities occur over the next five years are as follows:
| Year 1 | Over 1<br> Year -<br>3 Years | Over 3<br> Years -<br>5<br> Years | |
|---|---|---|---|
| Accounts payable and accrued liabilities | |||
| Lease liabilities | |||
| Convertible debentures | |||
| Debt | |||
| Business acquisition consideration payable | |||
| Total |
All values are in US Dollars.
| 18.4 | Fair Values |
|---|
The carrying amounts for the Company’s cash, accounts receivable, prepaid and other assets, accounts payable and accrued liabilities, current portions of debt and debentures payable, unearned revenue, and interest payable approximate their fair values because of the short-term nature of these items.
| 18.5 | Fair Value Hierarchy |
|---|
A number of the Company’s accounting policies and disclosures require the measurement of fair value for both financial and nonfinancial assets and liabilities. The Company has an established framework, which includes team members who have overall responsibility for overseeing all significant fair value measurements, including Level 3 fair values. When measuring the fair value of an asset or liability, the Company uses observable market data as far as possible. The Company regularly assesses significant unobservable inputs and valuation adjustments. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:
Level 1: unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly; or
Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).
Page 34 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
The carrying values of the financial instruments at September 30, 2024, are summarized in the following table:
| Level in fair<br> value hierarchy | Amortized Cost | FVTPL1 | |
|---|---|---|---|
| Financial Assets | |||
| Cash | Level 1 | ||
| Accounts receivable | Level 2 | ||
| Warrants asset | Level 2 | ||
| Financial Liabilities | |||
| Accounts payable and accrued liabilities | Level 2 | ||
| Debt | Level 2 | ||
| Convertible debentures | Level 2 | ||
| Business acquisition consideration payable | Level 2 | ||
| Derivative liabilities | Level 2 |
All values are in US Dollars.
During the nine months ended September 30, 2024, there were no transfers of amounts between levels.
The carrying values of the financial instruments at December 31, 2023, are summarized in the following table:
| Level in fair<br> value hierarchy | Amortized Cost | FVTPL | |
|---|---|---|---|
| Financial Assets | |||
| Cash | Level 1 | ||
| Accounts receivable | Level 2 | ||
| Warrants asset | Level 2 | ||
| Financial Liabilities | |||
| Accounts payable and accrued liabilities | Level 2 | ||
| Debt | Level 2 | ||
| Convertible debentures | Level 2 | ||
| Business acquisition consideration payable | Level 2 | ||
| Derivative liabilities | Level 2 |
All values are in US Dollars.
During the two months ended December 31, 2023, there were no transfers of amounts between levels.
| ^1^ | Fair Value through Profit or Loss (“FVTPL”) |
|---|
Page 35 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 19. | GENERAL AND ADMINISTRATIVE EXPENSES |
|---|
General and administrative expenses for the three and nine months ended September 30, 2024, and the three and nine months ended October 31, 2023, are as follows:
| Three months ended September 30, 2024 | Three months ended October 31, 2023 | Nine months ended September 30, 2024 | Nine months ended October 31, 2023 | |
|---|---|---|---|---|
| Office, banking, travel, and overheads | ||||
| Professional services | ||||
| Salaries and benefits | ||||
| General and administrative expenses |
All values are in US Dollars.
| 20. | INCOME TAXES |
|---|
The Company is treated as a U.S. corporation for U.S. federal income tax purposes under Internal Revenue Code (“IRC”) Section 7874 and is subject to U.S. federal income tax on its worldwide income. However, for Canadian tax purposes, the Company, regardless of any application of IRC Section 7874, is treated as a Canadian resident company for Canadian income tax purposes as defined in the Income Tax Act (Canada). As a result, the Company is subject to taxation both in Canada and the United States. The Company is also subject to state income taxation in various state jurisdictions in the United States. The Company’s income tax is accounted for in accordance with IAS 12 – Income Taxes.
For the nine months and three months ended September 30, 2024 and October 31, 2023, income taxes expense consisted of:
| **** | Three months ended September 30, 2024 | **** | Three months ended October 31, 2023 | **** | Nine months ended September 30, 2024 | **** | Nine months ended October 31, 2023 | **** |
|---|---|---|---|---|---|---|---|---|
| Current expense: | ||||||||
| Federal | ||||||||
| State | ||||||||
| Adjustment to prior years provision versus statutory tax returns | ||||||||
| Total current expense: | ||||||||
| Deferred expense (benefit): | ||||||||
| Federal | ) | ) | ) | ) | ||||
| State | ) | ) | ) | ) | ||||
| Change in unrecognized deductible temporary differences | ) | |||||||
| Total deferred expense (benefit): | ) | ) | ) | ) | ||||
| Total income tax expense (benefit): | ) |
All values are in US Dollars.
Page 36 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
The difference between the income tax expense for the three and nine months ended September 30, 2024 and October 31, 2023, and the expected income taxes based on the statutory tax rate applied to gain (loss) from operations before taxes are as follows:
| Three months ended September 30, 2024 | Three months ended October 31, 2023 | Nine months ended September 30, 2024 | Nine months ended October 31, 2023 | |||||
|---|---|---|---|---|---|---|---|---|
| Gain (loss) from operations before taxes | ) | ) | ) | ) | ||||
| Statutory tax rates | % | % | % | % | ||||
| Expected income tax (recovery) | ) | ) | ) | ) | ||||
| Change in statutory tax rates and FX rates | ) | ) | ) | |||||
| Nondeductible expenses | ) | ) | ||||||
| Deferral adjustments | ) | ) | ||||||
| Change in unrecognized deductible temporary | ) | ) | ||||||
| differences | ||||||||
| Net operating loss | ) | |||||||
| Fiscal year to calendar year adjustment | ) | |||||||
| Adjustment to prior years provision<br> versus statutory tax returns | ||||||||
| Total income tax expense (benefit): | ) |
All values are in US Dollars.
The following tax assets arising from temporary differences and non-capital losses have been recognized in the consolidated financial statements for the nine months ended September 30, 2024, and the two months ended December 31, 2023:
| September 30, 2024 | December 31, 2023 | |||
|---|---|---|---|---|
| Property, plant and equipment | ||||
| Inventory | ||||
| ROU Leases | ) | ) | ||
| Net Operating Loss Carryforward (federal) | ||||
| Net Operating Loss Carryforward (state) | ||||
| Net deferred tax assets: |
All values are in US Dollars.
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred income tax liabilities result primarily from amounts not taxable until future periods. Deferred income tax assets result primarily from operating tax loss carry forwards and temporary differences related to property, plant and equipment and inventory, and have been offset against deferred income tax liabilities. As of September 30, 2024, the Company has estimated Canadian non-capital losses of CAD$9,748,296 and capital losses of CAD$5,168,246. The Canadian non-capital losses are available to be carried forward, to be applied against Grown Rogue International Inc.’s taxable income earned in Canada over the next 20 years and expire between 2030 and 2043. The Canadian capital losses can be carried forward indefinitely. The deferred tax benefit of these Canadian tax losses has not been set up as an asset as it is not probable that sufficient taxable profits will be available for Canadian tax purposes to realize the carryforward of unused tax losses. Additionally, the deferred tax benefit of capitalized transaction costs and startup costs have not been setup as a deferred tax asset since it is not probable that the Company would be able to realize these deductible temporary differences for U.S. tax purposes.
Page 37 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
The Company operates in various U.S. state tax jurisdictions and is subject to examination of its income tax returns by tax authorities in those jurisdictions who may challenge any item on these returns. Because the tax matters challenged by tax authorities are typically complex, the ultimate outcome of these challenges is uncertain. In accordance with IAS 12, the Company recognizes the benefits of uncertain tax positions in our consolidated financial statements only after determining that it is more likely than not that the uncertain tax positions will be sustained. For the nine months ended September 30, 2024 and the two months ended December 31, 2023, the Company did not record an accrual for uncertain tax positions.
The Company files income tax returns in the United States, including various state jurisdictions, and in Canada, which remain open to examination by the respective jurisdictions starting with the 2018 tax year to the present.
Upon filing of its tax return for fiscal year ending October 31, 2023, the Company has adopted a new U.S. federal income tax position as of August 15, 2024, asserting that the restrictions of IRC Section 280E do not apply to the Company’s cannabis operations. The decision to adopt this position is supported by legal interpretations that challenge the Company’s tax liability as determined pursuant to IRC Section 280E. If the Company’s interpretation is upheld, the Company’s financial position could be significantly enhanced by the ability to deduct additional ordinary and necessary business expenses that are non-deductible under IRC Section 280E.
While the Company believes its position is supported by sound legal reasoning, the cannabis industry remains in a complex regulatory environment. The U.S. federal illegality of cannabis poses unique challenges and uncertainties, including the potential for differing interpretations and enforcement actions. The Company is prepared to vigorously defend its tax position if challenged and will continue to monitor legal developments in this matter closely; however, the Company cannot be certain that it will prevail on this issue with the Internal Revenue Service (“IRS”). As a precautionary measure, if the Company were not to prevail on this issue with the IRS, it has set aside reserves to mitigate the potential financial impact of such a determination, which is recognized within the Company’s income tax payable on its condensed interim consolidated statements of financial position (unaudited).
U.S. Federal and state tax laws impose restrictions on net operating loss carryforwards in the event of a change in ownership of the Company, as defined by the IRC Section 382. The Company does not believe that a change in ownership, as defined by IRC Section 382, has occurred but a formal study has not been completed.
U.S. Congress passed the Inflation Reduction Act in August 2022. The Company does not anticipate any impact to its income tax provision as a result of the new U.S. legislation.
Page 38 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 21. | CAPITAL DISCLOSURES |
|---|
The Company includes equity, comprised of share capital, contributed surplus (including the fair value of equity instruments to be issued), equity component of convertible promissory notes and deficit, in the definition of capital.
The Company’s objectives when managing capital are as follows:
to safeguard the Company’s assets and ensure the Company’s ability to continue as a going concern.
to raise sufficient capital to finance the construction of its production facility and obtain license to produce recreational marijuana; and
to raise sufficient capital to meet its general and administrative expenditures.
The Company manages its capital structure and makes adjustments to, based on the general economic conditions, the Company’s short-term working capital requirements, and its planned capital requirements and strategic growth initiatives.
The Company’s principal source of capital is from the issuance of common shares and debt. In order to achieve its objectives, the Company expects to spend its working capital, when applicable, and raise additional funds as required.
The Company does not have any externally imposed capital requirement.
Page 39 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 22. | SEGMENT REPORTING |
|---|
Geographical information relating to the Company’s activities is as follows:
| Segments | Oregon | Michigan | Other | Services | Total |
|---|---|---|---|---|---|
| Non-current assets other than financial instruments: | |||||
| As at September 30, 2024 | |||||
| As at December 31, 2023 | |||||
| Nine months ended September 30, 2024: | |||||
| Net revenue | |||||
| Gross profit | |||||
| Gross profit before fair value adjustments | |||||
| Nine months ended October 31,<br> 2023: | |||||
| Net revenue | |||||
| Gross profit | |||||
| Gross profit before fair value adjustments | |||||
| Three months ended September 30, 2024: | |||||
| Net revenue | |||||
| Gross profit | |||||
| Gross profit before fair value adjustments | |||||
| Three months ended October 31,<br> 2023: | |||||
| Net revenue | |||||
| Gross profit | |||||
| Gross profit before fair value adjustments |
All values are in US Dollars.
| 23. | NON-CONTROLLING INTERESTS |
|---|
The changes to the non-controlling interest for the nine months ended September 30, 2024, and the two months ended December 31, 2023, are as follows:
| September 30, 2024 | December 31, 2023 | ||
|---|---|---|---|
| Balance, beginning of period | |||
| Canopy buyout of 13% minority interest | ) | ||
| and acquisition of an additional 20% of Golden Harvests | |||
| Distributions to Golden Harvest minority interest | ) | ||
| Non-controlling interest share of Golden Harvests | |||
| Acquisition of 43.48% of West New York | |||
| Non-controlling interest share of West New York | |||
| Balance, end of period |
All values are in US Dollars.
Page 40 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 23.1 | Non-controlling Interest in Canopy and Golden Harvests | |
|---|---|---|
| September 30, 2024 | December 31, 2023 | |
| --- | --- | --- |
| Current assets | ||
| Non-current assets | ||
| Current liabilities | ||
| Non-current liabilities | ||
| Net income for the period attributed to non-controlling interest |
All values are in US Dollars.
In January of 2023, GR Unlimited exercised its option to acquire 87% of the membership units of Canopy from the CEO. Prior to this, ninety-six percent (96%) of Canopy was owned by officers and directors of the Company, and four percent (4%) was owned by a third party. Ownership by officers and directors, excluding the CEO, was pursuant to agreements which caused their ownership of Canopy to be equal to their ownership in GR Michigan, which total 3.5%. The CEO owned 92.5% of Canopy, which was analogous to the CEO’s 5.5% ownership of GR Michigan, and an additional 87% of Canopy, which was and is equal to the Company’s 87% ownership of GR Michigan. Following GR Unlimited’s acquisition of 87% of the membership units of Canopy in January of 2023, Canopy became owned 87% by GR Unlimited; 7.5% by officers and directors; and 5.5% by the CEO.
In April of 2024, GR Unlimited acquired the remaining 13% membership units of Canopy. Following this acquisition of the additional 13% interest in Canopy, Canopy became wholly owned by GR Unlimited.
In April of 2024, Canopy acquired an additional 20% of the membership units of Golden Harvest. Following the acquisition of an additional 20% interest in Golden Harvest on April 24, 2024, Golden Harvest became 80% owned by Canopy.
| 23.2 | Non-controlling Interest in West New York | |
|---|---|---|
| September 30, 2024 | December 31, 2023 | |
| --- | --- | --- |
| Non-current assets | ||
| Net income for the period attributed to non-controlling interest |
All values are in US Dollars.
| 24. | COMMITMENTS AND CONTINGENCIES |
|---|
On September 22, 2022, the SEC issued an Order Instituting Proceedings pursuant to Section 12(j) of Securities Exchange Act of 1934 (“1934 Act”), against the Company alleging violations of the 1934 Act, as amended, and the rules promulgated thereunder, by failing to timely file periodic reports. Section 12(j) authorizes the SEC as it deems necessary or appropriate for the protection of investors to suspend for a period not exceeding 12 months, or to revoke, the registration of a security if the SEC finds, on the record after notice and opportunity for hearing, that the issuer of such security has failed to comply with any provision of the 1934 Act, as amended, or the rules promulgated thereunder. The Company has filed an answer to the Order Instituting Proceedings and is seeking a hearing in the matter. The Company is currently fully compliant with all of its filings, is vigorously defending itself in the matter, and is preparing to re-register its securities if necessary.
Page 41 of 42
Grown Rogue International Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2024, and October 31, 2023 (note 2.4)
Expressed in United States Dollars, unless otherwise indicated
| 25. | SUBSEQUENT EVENTS |
|---|---|
| 25.1 | Termination of Advisory Agreement with Vireo Growth Inc. |
| --- | --- |
On October 11, 2024, the Company announced the termination of the advisory agreement with Vireo Growth. As consideration for the early termination, Vireo Growth will forfeit and return for cancellation 4,500,000 of the 8,500,000 share purchase warrants in Grown Rogue International Inc. that are held by Vireo Growth at a CAD$0.225 strike price. Additionally, Vireo Growth will pay the Company US$800,000 in cash. Vireo has the option of deferring the cash payment by making 4 quarterly payments of US$250,000. Grown Rogue will also receive its full consulting fee for the work performed in Q3 2024 and retains its 10,000,000 warrants in Vireo Growth Inc. Subsequent to the unaudited interim consolidated statements of financial position dated September 30, 2024, the Company received a termination fee of $800,000 in cash in accordance with the Consulting Agreement on October 18, 2024.
| 25.2 | ABCO Convertible Note |
|---|
On October 25, 2024, the Company executed a convertible promissory note with ABCO Garden State, LLC in the amount of $1,050,000. The note is convertible into equity of ABCO at a rate of 1% per $28,571.43 of principal borrowed upon certain future regulatory milestones. The note carries an interest rate of 15% and can be drawn down in increments of $10,000. As of November 13, 2024, the Company had advanced $700k on this promissory note.
| 25.3 | Advances to Nile of NJ LLC under convertible promissory note |
|---|
On November 1, 2024, the Company through its subsidiary West New York advanced an additional $287,500 to Nile of NJ LLC under a convertible note in the amount of $287,500. West New York concurrently received equity subscriptions of $137,500 in support of this funding.
Page 42 of 42
Exhibit 4
GROWN ROGUE INTERNATIONAL INC.
FORM 51-102F1
MANAGEMENT DISCUSSION & ANALYSIS
For the Nine Months Ended September 30, 2024
Pg **1** of **48**
TABLE OF CONTENTS
| Management’s Responsibilities for Financial Reporting | 3 |
|---|---|
| Forward-Looking Statements | 4 |
| Description of Business | 4 |
| Selected Financial Information | 11 |
| Results of Operations | 11 |
| Liquidity | 19 |
| Capital Resources | 23 |
| Off-Balance Sheet Arrangements | 24 |
| Transactions with Related Parties | 25 |
| Other Selected Financial Information | 28 |
| Outstanding Share Data | 29 |
| Critical Accounting Judgments and Estimation Uncertainties | 31 |
| Newly Adopted Accounting Pronouncements | 31 |
| New Accounting Pronouncements | 31 |
| Financial Instruments and Other Risk Factors | 31 |
| Subsequent Events | 37 |
| Regulatory Disclosure | 38 |
| Internal Control over Financial Reporting and Disclosure Controls | 48 |
Pg **2** of **48**
This Management Discussion and Analysis (“MD&A”) made as of November 14, 2024, should be read in conjunction with the unaudited condensed interim consolidated financial statements of Grown Rogue International Inc. (the “Company”, “Grown Rogue”, (“we”, “our”, or “us”) for the three and nine months ended September 30, 2024 and the three and nine months ended October 31, 2023 (the “Reporting Period”), and the related notes thereto (the “Interim Financial Statements”) and the Company’s audited consolidated financial statements for the two months ended December 31, 2023 and years ended October 31, 2023 and 2022 (together, the “AuditedConsolidated Financial Statements”) and altogether, the “Financial Statements”. The Company’s Financial Statements are presented on a consolidated basis with its wholly-owned subsidiary, Grown Rogue Unlimited, LLC (“GR Unlimited”), and GR Unlimited’s wholly-owned subsidiaries: Grown Rogue Gardens, LLC (“GR Gardens”), GRU Properties, LLC (“GRUProperties”), GRIP, LLC (“GRIP”), Grown Rogue Distribution, LLC (“GR Distribution”), and Grown Rogue Retail Ventures, LLC (“GR Retail”); as well as GR Retail’s 43.48% interest in Grown Rogue West New York, LLC (“West NY”), and GR Unlimited’s 100% interest in Canopy Management, LLC (“Canopy”), which owns 80% of Golden Harvests, LLC (“Golden Harvests”). Additionally, GR Unlimited holds a 70% interest in Rogue EBC, LLC (“Rogue EBC”), in which Rogue EBC holds a 100% interest in Cannequality, LLC (“Cannequality”). Grown Rogue’s reporting currency is the United States (“U.S.”) dollar and all amounts in this MD&A are expressed in U.S. dollars unless otherwise noted. The Company’s functional currency is the Canadian dollar while all subsidiaries use U.S. dollars as the functional currency. The use of “CAD$” refers to Canadian dollars and “US$” refers to U.S. dollars.
Additional information relating to the Company is also available on the System for Electronic Document Analysis and Retrieval (SEDAR+) at www.sedarplus.ca. The common shares of GRIN are listed on the Canadian Securities Exchange under the symbol “GRIN”.
MANAGEMENT’S RESPONSIBILITIES FOR FINANCIAL REPORTING
The Interim Financial Statements including comparatives have been prepared in accordance with International Accounting Standards (“IAS”) 34 – Interim Financial Reporting using accounting policies consistent with the International Financial Reporting Standards (“ IFRS”) issued by the International Accounting Standards Board (“IASB”) and Interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”); and have been approved by the Company’s board of directors on November 13^th^, 2024. The integrity and objectivity of the Financial Statements are the responsibility of management. In addition, management is responsible for ensuring that the information contained in the MD&A is consistent where appropriate, with the information contained in the Financial Statements.
The Interim Financial Statements may contain certain amounts based on estimates and judgments. Management has determined such amounts on a reasonable basis to ensure that the Financial Statements are presented fairly in all material respects.
As the Company is a Venture Issuer (as defined under under National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings) (“NI 52-109”), the Company and Management are not required to include representations relating to the evaluation, design, establishment and/or maintenance of disclosure controls and procedures (“DC&P”) and/or Internal Controls over Financial Reporting (“ICFR”), as defined in NI 52-109, nor has it completed such an evaluation. Inherent limitations on the ability of the certifying officers to design and implement on a cost-effective basis DC&P and ICFR for the issuer may result in additional risks of quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation.
Pg **3** of **48**
FORWARD-LOOKING STATEMENTS
This MD&A contains information and projections based on current expectations. Certain statements herein may constitute “forward-looking” statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this MD&A, such statements use such words as “will”, “may”, “could”, “intends”, “potential”, “plans”, “believes”, “expects”, “projects”, “estimates”, “anticipates”, “continue”, “potential”, “predicts” or “should” and other similar terminology. These statements reflect expectations regarding future events and performance but speak only as of the date of this MD&A. Forward-looking statements include statements with respect to planned acquisitions, strategic partnerships or other transactions and expansions not yet concluded, including the timing thereof; plans to market, sell and distribute products; market competition; plans to retain and recruit personnel; the ability to secure funding; and the ability to obtain regulatory and other approvals are all forward-looking information.
The Interim Financial Statements may contain certain amounts based on estimates and judgments. Management has determined such amounts on a reasonable basis to ensure that the Interim Financial Statements are presented fairly in all material respects. These Interim Financial Statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements.
There can be no assurance that any intended or proposed activity or transaction will occur or that, if any such action or transaction is undertaken, it will be completed on terms currently intended by the Company. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.
Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. The forward-looking statements herein speak only as of the date hereof. Actual results could differ materially from those anticipated due to a number of factors and risks including those described in this MD&A under “Risk Factors” and in section 17 of the Company’s Listing Statement dated November 15, 2018, which can be found under the Company’s profile on www.sedarplus.ca.
DESCRIPTION OF BUSINESS
Grown Rogue, headquartered in Medford, Oregon, is a craft cannabis^1^ company focused on delighting customers with premium flower and flower-derived products at fair prices. Our roots are in Southern Oregon where we have demonstrated our capabilities in the highly competitive and discerning Oregon market by becoming the number one flower producer in Oregon in 2022, which we have maintained year-to-date in 2024. In 2021, we successfully expanded our platform to Michigan, where by 2022 we became a top 5 indoor flower wholesaler in the state, a distinction we have maintained year-to-date in 2024. We combine our passion for product and value with a disciplined approach to growth, prioritizing profitability and return on capital.
Grown Rogue’s strategy is built to win now, and in the future, as the Company profitably delivers craft cannabis at appropriate scale and continues building out indoor cultivation in new markets, while scaling sungrown capabilities to support eventual interstate commerce.
| ^1^ | The terms cannabis and marijuana are used interchangeably throughout this MD&A. |
|---|
Pg **4** of **48**
Grown Rogue’s competitive advantage is profitably cultivating and delivering craft cannabis at accessible prices, maintaining a healthy balance sheet with a limited leverage profile, and efficiently and swiftly deploying capital in high-return, growth opportunities.
OREGON
Grown Rogue, through its wholly owned subsidiary, GR Gardens, operates four cultivation facilities in Oregon, comprising approximately 95,000 square feet of flowering cultivation canopy, that currently service the Oregon recreational marijuana market: two outdoor, sungrown farms called “Foothill” and “Ross Lane,” and two state-of-the-art indoor facilities (“Rossanley” and “Airport”). GR Gardens currently holds five producer licenses in Oregon from the Oregon Liquor Control Commission (“OLCC”), two wholesaler licenses, and two processor licenses.
During the year ended October 31, 2023, we executed a two-year lease which included an option to purchase Ross Lane, an Oregon property which includes 35 acres, 3 tax lots and an additional OLCC producer license. The Company executed this purchase option on January 12, 2024 for total consideration of $1,525,000 comprised of a promissory note for $1,285,000 with the remaining consideration consisting of a down payment and a credit for prepaid rents.
Grown Rogue’s Oregon business is headquartered in the world-renowned Emerald Triangle, which is known world-wide for the quality of its cannabis. The Emerald Triangle includes the southern part of Oregon and northern part of California. The Company capitalizes on this ideal outdoor growing environment to produce high-quality, low-cost cannabis flower. The two sungrown farms produce one crop each year per farm, which is planted in June and harvested in October.
GR Gardens is responsible for the production of recreational marijuana using outdoor and indoor production methodologies. Foothill and Ross Lane are outdoor farms with 40,000 square feet of flowering canopy each, for a total of 80,000 square feet, sitting on a combined land package of approximately 135 acres. Our “Trail’s End” outdoor property will not be cultivated in 2023, and the Company will transfer the Trail’s End license to Ross Lane for production in 2024 to streamline operational efficiencies by centralizing production facilities.
Rossanley, an approximately 17,000 square-foot indoor facility, with approximately 5,600 square feet of flowering bench space, produces high-quality indoor flower through controlled environment agriculture (“CEA”) operations. By carefully controlling temperature, humidity, carbon dioxide levels, and other criteria, we produce a year-round supply of high-quality cannabis flower with multiple harvests per month. Rossanley has eight dedicated flower rooms, which allows for an average of nearly four harvests per month resulting in approximately 4,000 pounds annually.
Airport, acquired in 2022 is a 30,000 square-foot indoor growing facility adding 30,000 square feet of CEA indoor production space and 9,152 square feet of flowering bench space. Airport is a short distance from Rossanley, which is a benefit to operating efficiency, and it is equipped with state-of-the-art equipment which facilitates the implementation of best practices developed at Rossanley.
The total annual production capacity for Grown Rogue’s Oregon operations, based on the current constructed capacity, will range between 20,000 and 24,000 pounds, depending upon various factors including sungrown growing conditions and strain performance.
MICHIGAN
In May 2021, we acquired, through Canopy, a controlling 60% interest in our Michigan operation called Golden Harvests. In April 2024, we increased our ownership, through Canopy, to 80% for an initial consideration of $2,000,000, plus true-up amounts.
Pg **5** of **48**
The Golden Harvests facility is approximately 65% constructed, with approximately 50,000 square feet in operation, including approximately 14,550 square feet of flowering bench space, in addition to all the ancillary support space, including office and administration to support the operations. The facility produces high quality indoor flower through CEA, with fourteen individual flowering rooms in operation. Harvested pounds in Michigan in 2023 totaled approximately 10,000 pounds; while for the nine months ending September 30, 2024, harvested pounds totaled approximately 8,985 pounds. Golden Harvests produces bulk flower and packaged flower, and manufactures pre-rolls on site.
SERVICES
On May 24, 2023, GR Unlimited entered into an independent contractor consulting agreement (the “Consulting Agreement”) with Vireo Growth Inc.^2^ (CSE: VREO; OTCQX: VREOF) (“Vireo Growth”). Under the Consulting Agreement, GR Unlimited will support Vireo Growth in the optimization of its cannabis flower products, with a particular focus on improving the quality and yield of top-grade “A” cannabis flower across its various operating markets, starting with Maryland and Minnesota.
Under the initial term of the Consulting Agreement, which expires on June 30, 2025, Vireo Growth will provide compensation to GR Unlimited for sustained consulting support, including input on systems and processes, and recommendations to improve Vireo Growth’s cultivation operations. GR Unlimited will be entitled to receive additional incentive compensation if our services result in improved cash flow performance as compared to Vireo Growth’s baseline expectations over the term of the agreement. Our cooperation in the agreement will be on an exclusive basis to Vireo Growth within the markets in which Vireo Growth operates. The agreement will automatically extend for up to two additional two-year terms, unless terminated by Vireo Growth or the Company.
A termination fee of at least $5,000,000 is payable to GR Unlimited in the event that Vireo Growth is acquired, sells all or substantially all of its assets, or is merged into another entity and is not the surviving entity of such merger. A termination fee of at least $2,500,000 is payable to GR Unlimited in the event that the Consulting Agreement terminates for certain other conditions.
As part of this strategic agreement, Vireo Growth issued 10,000,000 warrants to purchase 10,000,000 subordinate voting shares of Vireo Growth to the Company, with a strike price equal to CAD$0.317 (US$0.233), representing a 25% premium to the 10-day volume weighted average price (“VWAP”) of Vireo Growth’s subordinate voting shares prior to the effective date of the Consulting Agreement. Similarly, the Company issued 8,500,000 warrants to purchase 8,500,000 common shares of the Company to Vireo Growth, with a strike price equal to CAD$0.225 (US$0.166), representing a 25% premium to the 10-day VWAP of the Company’s common shares prior to the effective date of the Consulting Agreement. These warrants were issued on October 5, 2023.
On October 11, 2024, the Company announced the termination of the advisory agreement with Vireo Growth. As consideration for the early termination, Vireo Growth will forfeit and return for cancellation 4,500,000 of the 8,500,000 share purchase warrants in Grown Rogue International Inc. that are held by Vireo Growth at a CAD$0.225 strike price and pay the Company US$800,000 in cash. Vireo has the option of deferring the cash payment by making 4 quarterly payments of US$250,000. Grown Rogue will also receive its full fee for the work performed in Q3 2024 and retains its 10,000,000 warrants in Vireo Growth Inc. Subsequent to the unaudited interim consolidated statements of financial position dated September 30, 2024, the Company received a termination fee of $800,000 in cash in accordance with the Consulting Agreement.
| ^2^ | Formerly Goodness Growth Holdings, Inc. (CSE: GDNS; OTCQX: GDNSF**).** |
|---|
Pg **6** of **48**
PRODUCT
Grown Rogue produces a range of cultivars for consumers to enjoy, which are traditionally classified as indicas, sativas, and hybrids. Grown Rogue has a mix of “core” and “limited” strains to provide consumers with consistent and unique purchasing options at their local dispensary. Grown Rogue flower has won multiple awards in Oregon, which is one of the most competitive cannabis production environments in the world, including the prestigious Growers Cup competition on two occasions. Grown Rogue won 1^st^place for highest THC content, 1^st^ place for highest terpene content, and 3^rd^ place in the grower’s choice category. In addition, we believe we achieved an outdoor production potency record, at the time, in the state of Oregon, when its Monkey Train cultivar tested at a THC potency of 35.13%. In 2023, Grown Rogue won 3^rd^ place in the Oregon Grower’s Cup Outdoor category for its Sour Grape strain. Consumers can enjoy bulk flower in both Oregon and Michigan. In the Michigan market we also offer our innovative nitrogen sealed 3.5 gram flower jars, our patented nitrogen sealed pre-rolls, 3.5 gram flower bags, and regularly packaged pre-rolls.
We recently launched a new line of strain-specific prepackaged flower, coupled with proprietary genetics, in Michigan, and launched a new branded pre-roll pack product in Oregon in 2023. In addition, Grown Rogue launched a new brand of pre-rolls, a rapidly growing category, called Yeti in 2023. According to LeafLink’s MarketScape data, Grown Rogue was the #1 flower producer in Oregon and a top 5 indoor flower wholesaler in Michigan in 2022 and in 2023.
GENETICS
We are committed to developing unique, proprietary genetics as long-term genetic diversity will be a major factor in establishing brand differentiation with consumers. We have allocated research and development space to develop new strains, while also phenotype hunting to identify new and exciting strain options that will delight consumers. Grown Rogue has developed a compelling mix of proprietary strains, along with a library of “fan favorites” to ensure that consumer and dispensary demand will remain strong for our flower and flower-derived products. All Grown Rogue genetics are rigorously tested to establish the genetic makeup of each strain in our portfolio. We continue to focus on bringing new unique genetics to ensure a steady flow of innovative flower and flower products to market. Currently we carry more than 50 unique cultivars in our genetic library, and we continue to develop our portfolio as we trial new genetics.
DISTRIBUTIONAND SALES
Grown Rogue uses a multi-channel distribution strategy that includes direct-to-retail delivery and third-party delivery (Michigan regulations mandate independent third-party delivery); wholesalers, who have their own distribution channels; and processors, who utilize Grown Rogue products (e.g., trim) to create retail-ready products.
Regarding the direct-to-retail channel, Grown Rogue’s sales team works closely with dispensary owners and intake managers to provide consistent products, competitive prices, and personalized service using sales techniques from other industries such as pharmaceutical and liquor. Grown Rogue’s goal is to establish and maintain the client relationship as we continue to expand our footprint in the states in which we operate.
Grown Rogue has developed end user product marketing collateral and other educational information regarding Grown Rogue products as part of all sales with dispensaries that include strain type, testing results, information on the product and other necessary information to clearly articulate the product being provided. Each product is uniquely packaged while maintaining brand consistency across the product suite.
Grown Rogue works with dispensary owners to develop promotional opportunities for retail customers and bud tenders. Grown Rogue provides detailed tutorials to the staff and owners of the dispensaries around the product and how it is grown, processed, cured and packaged so that they are intimately familiar with the Grown Rogue process. Grown Rogue also invites dispensary owners and operators to Grown Rogue’s operating facilities so they can see first-hand the methods and processes used to create the product.
Pg **7** of **48**
Based upon information from MarketScape, which is part of the sales analytics tool utilized by LeafLink, which handles all of our sales and invoicing, we are the largest producer in Oregon and a top five indoor flower producer in Michigan.
BRANDING
Developing compelling branding that engages, inspires, and creates transparency and trust with consumers is one of the most important aspects of building a successful cannabis company. Cannabis product branding has been evolving from promising high-quality flower, to providing descriptions of the effect a consumer should expect from a particular product.
While other brands have shifted into the “one word” product description, Grown Rogue has leveraged consumer insights and product feedback to evolve the messaging to provide significantly more detail so consumers can make a more informed choice about which Grown Rogue products will optimally enhance their experience.
In order to grow the Grown Rogue community and spread knowledge of its products, Grown Rogue leverages social media and other digital platforms. Grown Rogue aspires to eliminate the “dark mystery” historically associated with cannabis by empowering consumers to learn about the plant and then “enhance experiences” as they desire. The transition from prohibition to legal cannabis has provided the cannabis community with an opportunity to welcome a large group of new members and it is vital that product education is completed in an authentic and informative manner to ensure that everyone’s first cannabis experience is not only positive but also as expected.
MARKETINGAND ADVERTISING
Grown Rogue’s marketing channels include a comprehensive, fully-responsive, interactive website (including mobile). The website has been search-engine optimized and includes calls to action that encourage consumers to become part of the Grown Rogue community by following the Company on social media.
Grown Rogue is focused on providing education to new and existing consumers through our website but even more hands on through our retail partners. We provide vendor days and budtender education days where we spend one on one time with the budtenders educating them about everything Grown Rogue.
We strategically leverage the narrative at retail through digital and physical retail assets to further educate consumers about Grown Rogue.
Grown Rogue has established a social media presence that includes Facebook, Twitter, Instagram, LinkedIn, TikTok and YouTube. Grown Rogue’s social identity is defined by delivering fresh content and keeping interaction with followers/fans prompt and positive. Grown Rogue attracts existing cannabis industry participants as well as people not familiar with the industry by creating a positive, inclusive environment where dialogue is encouraged. The goal is to change existing stereotypes and overcome the stigmas associated with the cannabis industry.
TRADEMARKSAND PATENTS
Grown Rogue actively seeks to protect its brand and intellectual property. Grown Rogue currently has one registered U.S. trademarks:
| 1. | Grown Rogue was filed on September 22, 2017, and registered on August 7, 2018 under Registration No. 5537240. |
|---|
Grown Rogue filed a patent for its nitrogen sealed glass containers on February 15, 2018, with the United States Patent and Trademark Office (“USPTO”). The nitrogen sealed glass containers preserve the freshness of the flower and essential terpenes to improve the “entourage effect.” The USPTO issued Grown Rogue United States Patent Number 10,358,282 on July 23, 2019. Several third parties have contacted us to request licensing information on this technology.
Pg **8** of **48**
We have introduced nitrogen sealed jars and pre-rolls in Michigan and plan on launching them as we enter additional new markets and may license the technology to third parties operating in markets in which Grown Rogue is not currently licensed.
SOCIALAND ENVIRONMENTAL POLICIES
Grown Rogue employs sustainable business models in our operations. We maintain the highest standards of environmental stewardship in cultivation. This includes sustainable water sources with optimization of reclamation and recapture from runoff and recycling of water input. We use only natural and sustainable products in all applications, including nutrients and integrated pest management. We maintain the highest level of sustainable cannabis practices through our focus on sustainable and natural cultivation methods. Grown Rogue hires and pays a living wage to its team members and is very involved in each of the communities where we operate.
PLANSFOR EXPANSION AND ECONOMIC OUTLOOK
Grown Rogue continues to focus on taking its learnings and experience from Oregon and Michigan into new markets across the United States. During the last two years, Grown Rogue has established a platform that excels at licensing, compliance, high-quality and low-cost production, understanding consumer purchasing preferences, and product innovation. This platform places Grown Rogue in a superior position to capitalize on new markets compared to our competitors. Oregon is arguably the most competitive cannabis market in the world, and we have excelled by implementing standard business practices that make the Company well suited for entering and building successful brand presence in newly-legalized cannabis markets.
The expansion into Airport (see “Description of the Business – Oregon”) and acquisition of Golden Harvests (see “Description of the Business – Michigan”) represent execution of management’s strategy of growth through high quality, low-cost flower production. In addition, we have added a profitable services segment (see “Description of the Business – Services),” which leverages our cultivation expertise to generate margin and increase our presence to two new states at low financial risk. As other growth opportunities arise under favorable financial terms, management can activate known and repeatable systems into new assets.
We believe that the future of the cannabis industry is in branded products and that the leading brands are being developed on the west coast, which is well known for high quality cannabis. Grown Rogue is focused on expanding our industry leading cultivation business focused on high quality and low cost products that delight our customers into new markets. Over the next twelve months, we are focused on continuing to grow market shares in the Oregon and Michigan markets, turning on the New Jersey project, constructing the Illinois project, continuing to add new products to our portfolio, and exploring and executing strategic opportunities in new states.
With the recent shift in political landscape, we have also begun analyzing the potential for federal de-regulation and the subsequent ability to export cannabis products across state lines. We believe Oregon will be a large export state. Being located in the Emerald Triangle provides a unique product differentiator due to the ability to produce high-quality and low-cost, sungrown flower due to the environmental conditions that occur naturally in Southern Oregon. Our strategy to take advantage of what is projected to be a multi-billion-dollar export business is developing, and we are excited to begin implementation of this business plan over the coming years, including the expansion into New Jersey.
On October 3, 2023, GR Unlimited executed a promissory note (the “New Jersey Retail Bridge Promissory Note”) and advanced $250,000 to an individual representing the principal amount of the note. Pursuant to the New Jersey Retail Bridge Promissory Note, interest on the outstanding principal borrowed accrues at a rate of 12% per annum provided that, if the extended maturity date of the note is triggered, interest shall accrue on the outstanding balance commencing on the maturity date and ending on the extended maturity date of the New Jersey Retail Bridge Promissory Note. On April 21, 2024, the New Jersey Retail Bridge Promissory Note was repaid and extinguished.
Pg **9** of **48**
On October 4, 2023, the Company announced that it signed a definitive agreement with an option to acquire 70% of ABCO Garden State, LLC (“ABCO”), pending regulatory approval from the New Jersey Cannabis Regulatory Commission (the “CRC”). ABCO was granted a conditional cultivation and manufacturing license by the CRC and will receive its annual cultivation license soon. GR Unlimited executed a secured draw down promissory note (the “ABCO Promissory Note” formerly “Iron Flag Promissory Note”) with Iron Flag, LLC (“Iron Flag”), to fund tenant improvements and for general working capital at the 50,000 square foot facility leased by ABCO for use in ABCO’s cannabis cultivation operations under construction and estimated to be completed in the fourth quarter of 2024. Pursuant to the ABCO Promissory Note, GR Unlimited shall make the maximum amount available in one or more advances in an aggregate amount not to exceed $4,000,000. Interest on the outstanding principal borrowed accrues at a rate of 12.5% per annum commencing with respect to each advance and accruing until the date the standing advances and all accrued interest is paid in full. On May 23, 2024, the Company executed its first option to acquire 44% of ABCO. As of the consolidated statements of financial position dated September 30, 2024, the Company has advanced the full $4M agreed to under the ABCO Promissory Note. An additional $2,054,782 has been funded, of which the Company has applied $1,257,142 as proceeds towards the payment of its first option to acquire the equity of ABCO. $797,640 remains to be paid that will be applicable towards the second option, which can be exercised on the second anniversary following the commencement of operations. Another $400,000 has been advanced under the ABCO Bridge Promissory Note and a further $2,500,000 has been advanced under the ABCO Drawdown Promissory Note.
On January 16, 2024, the Company signed a definitive agreement to invest in the development of an adult-use dispensary in West New York, New Jersey. As part of this agreement, GR Unlimited executed a secured convertible promissory note and advanced $500,000 to Nile of NJ LLC, (“Nile”) a New Jersey limited liability company. Pursuant to the secured convertible promissory note agreement, interest on the outstanding principal borrowed shall accrue at a rate of 10%. In addition to the $500,000 invested, GR Unlimited received investments of $650,000 into West NY which facilitates the full $1,150,000 convertible debt investment into Nile. As of September 30, 2024, West NY has advanced the full $1,150,000 to Nile, representing 34.5% on an as-converted basis.
On March 5, 2024, the Company announced it signed a definitive agreement to form Rogue EBC, a joint venture with EBC Ventures, to develop a cultivation and manufacturing facility in Illinois. The joint venture has entered into a definitive agreement to acquire 100% of Cannequality, which holds a craft growers license with the Illinois Department of Agriculture, in which the transaction is pending state approval. The Company owns 70% of Rogue EBC and has agreed to initially contribute up to US$4,000,000 to support the development of the facility. The joint venture agreement includes multiple purchase options, which ultimately gives Grown Rogue the ability to acquire 100% of the membership interests of the joint venture.
On April 25, 2024, the Company announced it completed the acquisition of the remaining minority interests in Canopy for total consideration of US$780,000 and subsequently owns 100% of the membership interests. At the same time, the Company, through Canopy, announced it completed the acquisition of an additional 20% of Golden Harvests for total consideration of US$2,000,000 plus true-up amounts, increasing the Company’s ownership to 80%.
COMMITMENTSAND CONTINGENCIES
On September 22, 2022, the United States Securities and Exchange Commission (the “Commission”) issued an Order Instituting Proceedings (“OIP”) pursuant to Section 12(j) of the Securities Exchange Act of 1934 (the “1934 Act”), against the Company alleging violations of the 1934 Act, as amended, and the rules promulgated thereunder, by failing to timely file periodic reports. Section 12(j) authorizes the Commission as it deems necessary or appropriate for the protection of investors to suspend for a period not exceeding 12 months, or to revoke, the registration of a security if the Commission finds, on the record after notice and opportunity for hearing, that the issuer of such security has failed to comply with any provision of the 1934 Act, as amended, or the rules promulgated thereunder. The Company has filed an answer to the OIP and is seeking a hearing in the matter. The Company is currently fully compliant with all of its filings, is vigorously defending itself in the matter, and is preparing to re-register its security if necessary.
Pg **10** of **48**
SELECTED FINANCIAL INFORMATION
The following selected financial data for each of the three most recent reporting periods^3^ are derived from the Financial Statements of the Company.
| Nine months ended September 30, 2024 () | Two months ended December 31, 2023 () | Year ended October 31, 2023 () | |||
|---|---|---|---|---|---|
| Total revenue | |||||
| Income from operations | |||||
| Net income (loss) | ) | ) | |||
| Net income (loss) per share, basic | ) | ) | |||
| Net income (loss) per share, diluted | ) | ||||
| Comprehensive income (loss) | ) | ) | |||
| Comprehensive income (loss) per share, basic | ) | ) | |||
| Comprehensive income (loss) per share, diluted | ) | ||||
| Total assets | |||||
| Total liabilities | |||||
| Cash dividends |
All values are in US Dollars.
RESULTS OF OPERATIONS
SELECTED FINANCIAL RESULTS
Effective December 31, 2023, the Company changed its financial year-end to December 31 from October 31. Comparative figures in preparing the Interim Financial Statements have been reclassified to conform to the current period presentation, and to reflect the results for the three and nine months ended October 31, 2023, in the unaudited condensed interim consolidated statements of comprehensive net income (loss), cash flows and changes in equity. All variances will reflect differences to some degree due to the different months included in the current period presentation versus the comparative period.
Three Months Ended September 30, 2024
Selected financial results of operations for the three months ended September 30, 2024, and the three months ended October 31, 2023, are summarized below:
| Three months ended September 30, 2024 () | Three months ended October 31, 2023 () | Variance () | Variance % | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7 | % | |||||||
| Cost of goods and services sold,<br> excluding fair value adjustments | ) | ) | ) | 17 | % | ||||
| Gross profit before fair value adjustments | ) | (1 | %) | ||||||
| Net income (loss) | ) | ) | (67 | %) |
All values are in US Dollars.
| ^3^ | The Company changed its year-end to December 31, which resulted in a two month reporting period for December 31, 2023 |
|---|
Pg **11** of **48**
Significant items contributing to the generation of net income for the three months ended September 30, 2024, and the three months ended October 31, 2023, are summarized in the table below:
| Three months ended September 30, 2024 () | Three months ended October 31, 2023 () | Variance | Variance % | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 7 | % | |||||||
| Cost of revenues, excluding fair value | ) | ) | ) | 17 | % | ||||
| Realized fair value amounts in inventory sold | ) | ) | ) | 11 | % | ||||
| Unrealized fair value gain on growth<br> of biological assets | ) | (21 | %) | ||||||
| Accretion expense | ) | ) | ) | 80 | % | ||||
| General and administrative expenses | ) | ) | ) | 27 | % | ||||
| Stock option expense | ) | ) | ) | 203 | % | ||||
| Interest expense | ) | ) | ) | 19 | % | ||||
| Amortization of property and equipment | ) | ) | ) | 32 | % | ||||
| Unrealized (gain) loss on derivative liability | ) | ) | (90 | %) | |||||
| Unrealized gain on warrants asset | ) | (11 | %) | ||||||
| Gain (loss) on disposal of property<br> and equipment | ) | (172 | %) |
All values are in US Dollars.
More detailed analysis of the components of results of operations are described in the following sections.
Nine Months Ended September 30, 2024
Selected financial results of operations for the nine months ended September 30, 2024, and the nine months ended October 31, 2023, are summarized below:
| Nine months ended September 30, 2024 () | Nine months ended October 31, 2023 () | Variance () | Variance % | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | % | |||||||
| Cost of goods and services sold,<br> excluding fair value adjustments | ) | ) | ) | 7 | % | ||||
| Gross profit before fair value adjustments | 20 | % | |||||||
| Net income (loss) | ) | ) | ) | 889 | % | ||||
| Cash flow from operations before NCWC | ) | (21 | %) |
All values are in US Dollars.
Pg **12** of **48**
Significant items contributing to the generation of net loss for the nine months ended September 30, 2024, and the nine months ended October 31, 2023, are summarized in the table below:
| Nine months ended September 30, 2024 () | Nine months ended<br> October 31, 2023 () | Variance | Variance % | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 14 | % | |||||||
| Cost of revenues, excluding fair value items | ) | ) | ) | 7 | % | ||||
| Realized fair value amounts in inventory sold | ) | ) | ) | 41 | % | ||||
| Unrealized fair value gain on growth<br> of biological assets | ) | (24 | %) | ||||||
| Accretion expense | ) | ) | ) | 78 | % | ||||
| General and administrative expenses | ) | ) | ) | 50 | % | ||||
| Stock option expense | ) | ) | ) | 31 | % | ||||
| Interest expense | ) | ) | - | % | |||||
| Amortization of property and equipment | ) | ) | ) | 57 | % | ||||
| Unrealized (gain) loss on derivative liability | ) | ) | ) | 194 | % | ||||
| Unrealized gain on warrants asset | 1,504 | % | |||||||
| Loss on disposal of property and equipment | ) | (156 | %) |
All values are in US Dollars.
More detailed analysis of the components of results of operations are described in the following sections.
Revenues – Three Months Ended September 30, 2024, and the Three Months Ended October 31, 2023
| **** | Three months ended September 30, 2024<br> () | Three months ended October 31, 2023 () | Variance () | Variance (%) | **** | |
|---|---|---|---|---|---|---|
| Revenue from Grown Rogue production | 3 | % | ||||
| Revenue from services | 60 | % | ||||
| Total revenue | 7 | % |
All values are in US Dollars.
Service revenues during the three months ended September 30, 2024, and the three months ended October 31, 2023, were derived from the Consulting Agreement (see Description of Business – Services).
Pg **13** of **48**
The following table summarizes revenues from Grown Rogue production for the three months ended September 30, 2024, and the three months ended October 31, 2023:
| **** | Three months ended September 30, 2024 () | Three months ended October 31, 2023 () | Variance () | **** | Variance (%) | **** | |
|---|---|---|---|---|---|---|---|
| Indoor | ) | -4 | % | ||||
| Outdoor | 38 | % | |||||
| Pre-rolls | 167 | % | |||||
| Trim & other | ) | (61 | %) | ||||
| Revenue from Grown Rogue production | 3 | % |
All values are in US Dollars.
Revenues during the three months ended September 30, 2024, were higher than the comparative three months ended October 31, 2023, due primarily to more pounds sold.
As detailed further below, we sold more pounds in the three months ended September 30, 2024, than the comparative three months ended October 31, 2023, at lower ASP.
The following tables summarize pounds sold and average selling prices:
| **** | Three months ended September 30, 2024 Pounds sold | Three months ended October 31, 2023 Pounds sold | Poundsvariance | Three months ended September 30, 2024 ASP () | Three months ended October 31,<br> 2023 ASP () | ASP variance | **** | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Indoor flower | 5,230 | 4,812 | 418 | (115 | ) | ||||||
| Outdoor flower | 2,393 | 1,602 | 791 | (24 | ) | ||||||
| Pre-rolls | 1,331 | 282 | 1,049 | (537 | ) | ||||||
| Total | 8,954 | 6,696 | 2,258 | (140 | ) |
All values are in US Dollars.
Pg **14** of **48**
Revenues – Nine Months Ended September 30, 2024, and the Nine Months Ended October 31, 2023
| Nine months ended September 30,<br> 2024 () | Nine months ended October 31,<br> 2023 () | Variance () | Variance (%) | |||
|---|---|---|---|---|---|---|
| Revenue from Grown Rogue production | 10 | % | ||||
| Revenue from services | 83 | % | ||||
| Total revenue | 14 | % |
All values are in US Dollars.
Service revenues during the nine months ended September 30, 2024, and the nine months ended October 31, 2023, were derived from the Consulting Agreement (see Description of Business – Services).
The following table summarizes revenues from Grown Rogue production for the nine months ended September 30, 2024, and the nine months ended October 31, 2023.
| Nine months ended September 30, 2024 () | Nine months ended October 31, 2023<br> () | Variance () | Variance (%) | ||||
|---|---|---|---|---|---|---|---|
| Indoor | 1 | % | |||||
| Outdoor | 8 | % | |||||
| Pre-rolls | 251 | % | |||||
| Trim & other | ) | (21 | %) | ||||
| Revenue from Grown Rogue production | 10 | % |
All values are in US Dollars.
Revenues during the nine months ended September 30, 2024, were higher than the comparative nine months ended October 31, 2023, due primarily to higher pounds sold.
As detailed further below, we sold more pounds in the nine months ended September 30, 2024, than the comparative nine months ended October 31, 2023, at lower ASP.
The following tables summarize pounds sold and average selling prices:
| **** | Nine months ended September 30, 2024 Pounds sold | Nine months ended October 31, 2023 Pounds sold | Pounds variance | Nine months ended September 30, 2024 ASP () | Nine months ended October 31, 2023 ASP () | ASP variance | **** | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Indoor flower | 15,682 | 15,398 | 284 | (11 | ) | ||||||
| Outdoor flower | 6,810 | 6,358 | 452 | 3 | |||||||
| Pre-rolls | 3,321 | 565 | 2,756 | (504 | ) | ||||||
| Total | 25,813 | 22,321 | 3,492 | (22 | ) |
All values are in US Dollars.
COSTS OF GOODS AND SERVICES SOLD
Three Months Ended September 30, 2024, and the Three Months Ended October 31, 2023
| **** | Three months ended September 30, 2024 () | Three months ended October 31, 2023 () | Change () | **** | Change (%) | **** | |
|---|---|---|---|---|---|---|---|
| Costs of goods sold | 18 | % | |||||
| Costs of service revenues | ) | (44 | %) | ||||
| Costs of goods sold, excl. fair value items | 17 | % |
All values are in US Dollars.
Cost of finished cannabis inventory sold during the three months ended September 30, 2024, increased by 17% over the comparative three months ended October 31, 2023, while revenues for the same periods increased by 8%.
Pg **15** of **48**
Nine Months Ended September 30, 2024, and the Nine Months Ended October 31, 2023
| Nine months ended September 30, 2024 () | Nine months ended October 31, 2023 () | Change () | Change (%) | ||||
|---|---|---|---|---|---|---|---|
| Costs of goods sold | 9 | % | |||||
| Costs of service revenues | ) | (33 | %) | ||||
| Costs of goods sold, excl. fair value items | 7 | % |
All values are in US Dollars.
Cost of finished cannabis inventory sold during the nine months ended September 30, 2024, increased by 7% over the comparative nine months ended October 31, 2023, while revenues for the same periods increased by 14%.
NET INCOME AND LOSS
Share-based Compensation
During the nine months ended September 30, 2024, we granted, or committed to grant, common shares and stock options as compensation to employees and service providers.
The common shares issuances and stock options (measured at fair value using the Black-Scholes pricing model) resulted in total expense recognition of $294,807 and $379,178, respectively, during the three and nine months ended September 30, 2024 (for the three and nine months ended October 31, 2023 - $97,672 and $290,491, respectively). The fair value of the options granted during the nine months ended September 30, 2024 was $2,411,071 as 6,755,000 stock options were granted.
General and Administrative Expenses
The general and administrative expenses for the three months and nine months ended September 30, 2024, and the three and nine months ended October 31, 2023, are as follows:
| Three months ended September 30, 2024 () | Three months ended<br> October 31,<br>2023 () | Nine months ended September 30, 2024 () | Nine months ended<br>October 31,<br>2023 () | |
|---|---|---|---|---|
| Office, banking, travel, and overheads | ||||
| Professional services | ||||
| Salaries and benefits | ||||
| General and administrative expenses |
All values are in US Dollars.
General and administrative costs for the three and nine months ended September 30, 2024, were higher than the three and nine months ended October 31, 2023, in support of the Company’s growth and increased sales volumes.
Pg **16** of **48**
Interest and Interest Accretion Expense
The interest and interest accretion expense for the three and nine months ended September 30, 2024, and the three and nine months ended October 31, 2023, are as follows:
| **** | Three months ended September 30, 2024 () | Three months ended October 31, 2023 () | Change<br>() | Change(%) | **** | |
|---|---|---|---|---|---|---|
| Interest and accretion expense | 70 | % |
All values are in US Dollars.
| Nine months ended September 30, 2024 () | Nine months ended October 31, 2023 () | Change<br>() | Change(%) | |||
|---|---|---|---|---|---|---|
| Interest and accretion expense | 59 | % |
All values are in US Dollars.
Interest and accretion expenses reflect the increase in accretion due to the convertible debentures issued on December 5, 2022, (the “December Convertible Debentures”); and the convertible debentures issued on July 13, 2023 (the “July Convertible Debentures”) and on August 17, 2023 (the “August Convertible Debentures”); in addition to new debt and business acquisition payables issued during the nine months ended September 2024.
Pg **17** of **48**
SEGMENT REPORTING
We operate in the states of Oregon and Michigan in the United States, and we recently began providing consulting and management services. The following table summarize performance by segment for the three and nine months ended September 30, 2024, and the three and nine months ended October 31, 2023.
| Segments | Oregon | Michigan | Other | Services | Total |
|---|---|---|---|---|---|
| Non-current assets other than financial instruments: | |||||
| As at September 30, 2024 | |||||
| As at December 31, 2023 | |||||
| Nine months ended September 30, 2024: | |||||
| Net revenue | |||||
| Gross profit | |||||
| Gross profit before fair value adjustments | |||||
| Nine months ended October 31, 2023: | |||||
| Net revenue | |||||
| Gross profit | |||||
| Gross profit before fair value adjustments | |||||
| Three months ended September 30, 2024: | |||||
| Net revenue | |||||
| Gross profit | |||||
| Gross profit before fair value adjustments | |||||
| Three months ended October 31, 2023: | |||||
| Net revenue | |||||
| Gross profit | |||||
| Gross profit before fair value adjustments |
All values are in US Dollars.
Pg **18** of **48**
Summary of Quarterly Results
The following table sets out selected quarterly results of the Company for the seven quarters ended on or before September 30, 2024. Also included are the two months ended December 31, 2023. The quarterly information contained herein is drawn from the consolidated condensed interim financial statements of the Company for each of the aforementioned seven quarters. The information contained herein for the three months ended September 30, 2024, is derived from the Interim Financial Statements of the Company. Revenues in any period are subject to market sales pricing, which historically has fluctuated significantly. Management has observed that pricing and sales volumes tend to be lower seasonally during winter months, in the Company’s first fiscal quarter, although we do not have high confidence that this will persist. Net income and loss include the impact of significant non-cash expenses, such as losses on the fair valuation of derivative liabilities, marketable securities, share-based payments, and interest accretion. Expenses contributing to net loss do not have significant seasonal trends, except for costs of sales, which follow trends in revenues.
| Calendar<br> Year 2024<br> Quarter End<br> June 30 | Calendar<br> Year 2024<br> Quarter End<br> Mar 31 | Two Months<br> Ended<br> Dec 31,<br> 2023 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue () | 6,992,714 | 7,718,129 | 6,654,474 | 3,638,087 | ||||||
| Net income (loss) () | (667,240 | ) | (7,573,822 | ) | (4,165,700 | ) | 672,427 | |||
| Net income (loss)/share, basic | (0.00 | ) | (0.04 | ) | (0.02 | ) | 0.00 | |||
| Net income (loss)/share, diluted | (0.00 | ) | (0.01 | ) | 0.01 | 0.00 |
All values are in US Dollars.
| Fiscal<br> Year 2023<br> Quarter End<br> Jul 31 | Fiscal<br> Year 2023<br> Quarter End<br> Apr 30 | Fiscal<br> Year 2023<br> Quarter End<br> Jan 31 | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue () | 6,522,291 | 6,295,717 | 6,004,637 | 4,530,540 | ||||
| Net income (loss) () | (2,012,324 | ) | 345,488 | 411,979 | 592,537 | |||
| Net income (loss)/share, basic | (0.00 | ) | 0.00 | 0.00 | 0.01 | |||
| Net income (loss)/share, diluted | (0.00 | ) | 0.00 | 0.00 | 0.01 |
All values are in US Dollars.
LIQUIDITY
Our ability to generate cash in the short term is based upon sales from production and financing proceeds, and in the long term is based upon sales from production, including production from investments in production increases, or from growth by business acquisitions, or a combination thereof. Investments to increase production or acquire business may require further financing. The Company generates operating cash flows from sales of cannabis products which generate margin that contribute to coverage of other operating costs. We have generated net income for four of the seven most recent quarters and expect to continue generating net income consistently. We have raised financing historically through debt and equity, which has been and will be invested in the business in order to improve production yields and increase total productive capacity, as well as cover operating costs, and to strategically expand the business. We raised proceeds of $5,667,418 from the exercise of warrants, stock options, and sale of membership units in a subsidiary during the nine months ended September 30, 2024 (for the nine months ended October 31, 2023 - $6,000,000 from issuance of convertible debentures).
Pg **19** of **48**
We are typically able to sell finished goods shortly after inventory reaches its final state, and sales are primarily made on cash-on-delivery terms, or with short net terms. Our ability to fund operations, to plan capital expenditures, and to plan acquisitions, depends on future operating performance and cash flows and the availability of capital by way of debt or equity investment in the Company, which are subject to prevailing economic conditions and financial, business, and other factors, some of which are beyond the Company’s control.
CASH FLOWS
The following table summarizes certain cash flow items for the nine months ended September 30, 2024, and the nine months ended October 31, 2023:
| Nine months ended September 30, 2024 () | Nine months ended October 31, 2023 () | |||
|---|---|---|---|---|
| Net income (loss) | ) | ) | ||
| Net cash provided by operating activities | ||||
| Net cash used in investing activities | ) | ) | ||
| Net cash provided by / (used in) financing activities | ||||
| Net increase (decrease) in cash and cash equivalents | ) | |||
| Effect of currency translation | ) | ) | ||
| Cash and cash equivalents, beginning | ||||
| Cash and cash equivalents, ending |
All values are in US Dollars.
Operating Activities
During the nine months ended September 30, 2024, cash provided by operating activities was $5,010,600 (nine months ended October 31, 2023 - $4,863,206). This number was derived by adding back non-cash items to net income, including the following significant adjustments:
| ● | $728,095 (nine months ended October 31, 2023 - $463,002) in amortization of property and equipment; |
|---|---|
| ● | $1,554,747 (nine months ended October 31, 2023 - $1,481,110) from depreciation expensed in costs of finished inventory sold; |
| --- | --- |
| ● | Deduction of $2,065,695 (nine months ended October 31, 2023 - deduction of $2,724,925) from the unrealized change in fair value of biological assets; |
| --- | --- |
| ● | $2,772,840 (nine months ended October 31, 2023 - $1,966,436) for changes in fair value in inventory sold; |
| --- | --- |
| ● | Deduction of $453,871 (nine months ended October 31, 2023 - $470,358) from deferred income taxes; |
| --- | --- |
| ● | $379,178 (nine months ended October 31, 2023 - $288,971) in share-based compensation and stock option vesting expense, including expense for option grants under our stock option plan implemented during 2020, as well as shares issued directly as compensation for employees, directors, and service providers; |
| --- | --- |
| ● | $1,531,551 (nine months ended October 31, 2023 - $862,624) in accretion of interest expense on debt and convertible debentures outstanding; |
| --- | --- |
| ● | $534,089 (nine months ended October 31, 2023 - $nil) from loss on equity method investment; |
| --- | --- |
| ● | Deduction of $7,823 (nine months ended October 31, 2023 - $13,881) from loss on disposal of property and equipment; |
| --- | --- |
| ● | $13,584,791 (nine months ended October 31, 2023 - $4,563,498) from the loss on fair value of derivative liability; |
| --- | --- |
| ● | Deduction of $2,071,411 (nine months ended October 31, 2023 - deduction of $129,113) from the unrealized gain on warrants asset. |
| --- | --- |
Pg **20** of **48**
Changes in non-cash working capital are summarized in the following table.
| Nine months ended September 30, 2024 () | Nine months ended October 31, 2023 () | |||
|---|---|---|---|---|
| Accounts receivable | ) | ) | ||
| Inventory and biological assets | ) | |||
| Prepaid expenses | ) | ) | ||
| Accounts payable and accrued liabilities | ||||
| Income tax payable | ||||
| Unearned revenue | ) | |||
| Total | ) |
All values are in US Dollars.
Changes in accounts receivable are due to the timing and collection of sales. Changes in inventory and biological assets reflect increases due to increased productive capacity, as well as the timing of harvests, the timing of the completion growth cycles, and the timing of sales of finished inventory. Changes in liabilities, including accounts payable and accrued liabilities, reflect the use of credit terms and cash flow management based upon ongoing liquidity management.
Investing Activities
During the nine months ended September 30, 2024, we added $4,350,213 (nine months ended October 31, 2023 - $1,420,404) to property and equipment, including non-cash right-of-use asset additions. We expended cash flows of $1,267,534 (nine months ended October 31, 2023 - $1,420,404) for property and equipment additions.
We expended $5,981,851 (nine months ended October 31, 2023 - $1,430,526) as cash advances and loans to other parties during the nine months ended September 30, 2024.
We also expended $1,980,000 as equity investment in ABCO State Garden LLC (nine months ended October 31, 2023 - $nil), of which $1,257,142 was converted to equity and $797,640 remains to be applied towards the second option which can be exercised two years from the start of ABCO’s operations.
We received $250,000 as repayment of the NJ Retail Promissory Note.
Financing Activities
Net cash flows provided from financing activities during the nine months ended September 30, 2024 were $3,344,072 (nine months ended October 31, 2023 – $3,357,523).
Significant financing activities for the nine months ended September 30, 2024, included the following:
| ● | Proceeds of $650,000 from sales of units of subsidiary; |
|---|---|
| ● | Proceeds of $4,657,460 from exercise of warrants; |
| --- | --- |
| ● | Proceeds of $357,778 from exercise of stock options; |
| --- | --- |
| ● | Payment of $126,914 of equity issuance costs; |
| --- | --- |
| ● | Repayments of $430,828 of convertible debentures; |
| --- | --- |
| ● | Repayments of $855,002 of lease principal; and |
| --- | --- |
| ● | Repayments of $910,602 of long-term debt. |
| --- | --- |
Financing activities during the comparable nine months ended October 31, 2023, included the following:
| ● | Proceeds of $6,000,000 from issuance of convertible debentures; |
|---|
Pg **21** of **48**
| ● | Repayments of $246,006 of convertible debentures; |
|---|---|
| ● | Repayments of $1,185,371 of lease principal; and |
| --- | --- |
| ● | Repayments of $1,211,100 of long-term debt. |
| --- | --- |
TRENDS AND EXPECTED FLUCTUATIONS IN LIQUIDITY
| September 30, 2024 () | December 31, 2023 () | Variance () | Variance<br> (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current assets | 22 | % | |||||||
| Current liabilities | ) | ) | ) | 40 | % | ||||
| Working capital | 15 | % |
All values are in US Dollars.
Working capital increased by $1,654,776 from December 31, 2023, to September 30, 2024, due primarily to the fact that the Company has advanced significant amounts due from ABCO which are classified as current assets. The current liabilities included to derive working capital excludes the current portion of convertible debt which has a maturity greater than one year but is classified as current liabilities based on the newly adopted amendment to IAS 1 – Presentation of Financial Statements effective January 1, 2024. The current liabilities also excludes the derivative liability balance related to convertible debentures.
We expect significant ongoing fluctuations in working capital over time, as we are in the early stages of growth. We have historically raised debt with principal due on maturity, and accordingly, we expect significant one-time payments as debt matures, as opposed to smooth cash outflows over time. We have historically been able to meet commitments, modify debt maturities, and raise new financing as required to respond to changes in our liquidity position, although there is no guarantee we will be able to do so in the future. We are exposed to market pricing for cannabis products, which materially impacts our liquidity and is out of our control. The market for cannabis products, including flower, which is our primary product, is relatively immature, having recently become legal to buy and sell in certain markets.
We have observed some indications of seasonality, and in addition, we have observed that market conditions can change rapidly without apparent explanations or analyzable causes. We cannot control whether we will be able to raise financing when required or sell cannabis products at profitable prices in the future; however, part of our strategy is to produce flower at sustainable gross margins over a growing productive base, which, holding other factors constant, is expected to result in improved net loss or net income, as well as net cash flows.
Commitments and Obligations
Set out below are undiscounted minimum future lease payments after September 30, 2024.
| Total future minimum lease payments () | ||
|---|---|---|
| Less than one year | ||
| Between one and five years | ||
| Total minimum lease payments | ||
| Less amount representing interest | ) | |
| Present value of minimum lease payments |
All values are in US Dollars.
Pg **22** of **48**
The Company has four lease contracts with extension options remaining after September 30, 2024, which were negotiated by management to provide flexibility in managing business needs. Set out below are the undiscounted potential rental payments related to periods following the date of exercise options that are not included in the lease term:
| Within<br> five years | More than<br> five years | |||
|---|---|---|---|---|
| Extension options available to be exercised | $ | 4,247,775 | $ | 13,491,032 |
The contractual maturities of the Company’s accounts payable and accrued liabilities, debt, leases, and business acquisition consideration payable occur over the next five years are as follows:
| Year 1 | Over 1 Year -<br>3 Years | Over 3 Years -<br>5 Years | |
|---|---|---|---|
| Accounts payable and accrued liabilities | |||
| Lease liabilities | |||
| Convertible debentures | |||
| Debt | |||
| Business acquisition consideration payable | |||
| Total |
All values are in US Dollars.
CAPITALRESOURCES
DEBT FINANCING
On January 12, 2024, debt with a principal amount of $1,285,000 was received, secured by deed of trust of $1,285,000. Interest is paid at the higher of 5% or the London Interbank Offered Rate (‘LIBOR”) for the first twelve months. For the thirteenth month to the twenty-fourth month, interest is paid at the higher of 6% or the LIBOR and for twenty-fifth month to the thirty-sixth month, interest is paid at the higher of 7% or the LIBOR. Interest is paid at the end of the month in arrears and is computed based on a 30 -day month and has a maturity date of December 1, 2027. The note is reported at amortized cost using an effective rate of approximately 7.2%. During the nine months ended September 30, 2024, the Company made principal and interest payments of $94,229.
On March 15, 2024, GR Unlimited guaranteed a note payable owed by ABCO Gardens State, LLC, with an original principal limit amount of $1,100,000. The note allows the Company to borrow any amount which is more than $150,000 but less than the loan limit of $1,100,000. All advances in aggregate should not exceed the loan limit of $1,100,000. Each advance will be subjected to a 1.55% origination fee payable to the lender at the time of the advance, which can be deducted from the advance. Interest is paid at 17.32% per annum and each advance has a maturity date of 3 years after the effective date of the advance. Interest only will be payable on the 15th of the next month following the effective date of the advance and continuing for six months. At any time after the Company has paid twelve months’ worth of interest, the Company may repay the note in full following written notice to the lender. The principal and interest payments for the note payable are to be made by GR Unlimited, in which the principal loan balance has been added to the ABCO Promissory Note (formerly Iron Flag Promissory Note) and is considered an advance issued by GR Unlimited to Iron Flag.
During the nine months ended September 30, 2024, the Company issued 23,270,249 common shares on the exercise of the same number of warrants, for total proceeds of $4,657,460 gross and incurred issuance costs of $126,914.
Pg **23** of **48**
During the nine months ended September 30, 2024, the Company issued 13,483,670 common shares in settlement of conversions of its convertible debt totaling $8,861,989.
On April 24, 2024, the Company acquired an additional 20% interest in Golden Harvests for aggregate consideration of $2,342,207 comprised of deferred cash payments of $2,000,0000 (the Initial Purchase Price or “IPP”) plus true-up amounts (the Additional Purchase Price or “APP”). The IPP is to be paid for in thirteen quarterly installments beginning on January 1, 2025. The Company may pay all or part of the cash portion of the business acquisition consideration payable after January 1, 2025. IPP remaining to be paid at the date of the Interim Financial Statements included cash payments of $2,000,000. The IPP was recorded at its fair value at the date of inception of $1,644,695.
The APP is calculated on a distribution equivalent basis whereby the seller receives a true-up payment pro-rata based on the proportion of remaining IPP balance at the time of the distribution payment made to the Company. If distribution equivalent amounts in any quarter are in excess of the minimum interest amounts, then no minimum interest amount is due. The distribution equivalent is reduced pro-rata in accordance with amounts paid down against sellers IPP
On April 24, 2024, the Company acquired the remaining 13% interest in Canopy for aggregate consideration of $780,000 comprised of upfront cash payments of $156,000 and deferred cash payments of $624,000. The deferred cash payments are to be paid in 48 equal installments with a 5.21% interest rate applied. Consideration remaining to be paid at the date of these Interim Financial Statements included cash payments of $620,478.
EQUITY FINANCING
During the nine months ended September 30, 2024, the Company issued 3,516,308 common shares in exchange for the exercise of stock options raising proceeds of $359,958. Contemporaneously, the fair value of the options exercised of $266,582 was transferred from contributed surplus to share capital.
TRENDS AND EXPECTED FLUCTUATIONS IN CAPITAL RESOURCES
We realized net cash flows provided by financing activities of approximately $3.3 million during the nine months ended September 30, 2024, (nine months ended October 31, 2023 – $3.4 million), resulting from proceeds of $0.65 million from sale of units in subsidiary, proceeds of $4.7 million from exercise of warrants and proceeds of $0.4 million from exercise of stock options (nine months ended October 31, 2023 - $6 million from convertible debentures), less debt, debenture, and lease principal repayments of $2.3 million (nine months ended October 31, 2023 - $2.6 million).
Financing activities have been critical to our ability to continue operating, and significant portions of our financing have historically been raised from key management personnel. However, we are able to raise such financing from third parties; this highlights the importance of management’s strategy of scaling operations. Our business strategy contemplates growing cash flows from operations, which may contribute to reinvestment and growth; however, further financing may be required or utilized based upon our future capital position and future business opportunities.
OFF-BALANCE SHEET ARRANGEMENTS
The Company does not have any off-balance sheet arrangements.
Pg **24** of **48**
TRANSACTIONS WITH RELATED PARTIES
TRANSACTIONS WITH KEY MANAGEMENT AND DIRECTORS
During the nine months ended September 30, 2024, the Company completed the following related party transactions:
Through its wholly owned subsidiary, GRU Properties, the Company leased a property located in Trail, Oregon (“Trail”) owned by the Company’s President and CEO (“CEO”). The lease was extended during the year ended October 31, 2021, with a term through December 31, 2025. Lease charges of $54,000 were incurred for nine months ended September 30, 2024 (nine months ended October 31, 2023 – $54,000). The lease liability for Trail at September 30, 2024, was $84,011 (December 31, 2023 - $129,401).
During the year ended October 31, 2021, the Company leased a property which is beneficially owned by the CEO and is located in Medford, Oregon (“Lars”) with a term through June 30, 2026. Lease charges for Lars of $147,518 were incurred for the nine months ended September 30, 2024 (nine months ended October 31, 2023 - $159,135). The lease liability for Lars at September 30, 2024, was $326,423 (December 31, 2023 - $445,708).
Leases liabilities payable to the CEO were $410,434 in aggregate at September 30, 2024 (December 31, 2023 - $575,109).
During the year ended October 31, 2023, the Company, through GR Unlimited, acquired 87% of the membership units of Canopy from the CEO. All payments necessary for GR Unlimited to exercise its option to acquire 87% of Canopy were equal to payments made by Canopy to purchase a controlling 60% interest of Golden Harvests for aggregate consideration of $1,007,719 comprised of 1,025,000 common shares of the Company with a fair value of $158,181 and cash payments of $849,536. Following GR Unlimited’s acquisition of 87% of the membership units of Canopy in January of 2023, Canopy became owned 87% by GR Unlimited; 7.5% by officers and directors; and 5.5% by the CEO.
During April 2024, the Company, through GR Unlimited, acquired the remaining 13% of the membership units in Canopy. As part of this transaction, the Company purchased the CEO’s 5.5% membership interest in Canopy. The consideration due to the CEO is comprised of an upfront cash payment of $66,000 and deferred cash payments of $264,000.
During the nine months ended September 30, 2024, the Company incurred expenses of $75,384 (nine months ended October 31, 2023 - $75,769) for salary paid to the spouse of the CEO, who is employed as our Community Relations manager. At September 30, 2024, accounts and accrued liabilities payable to this individual were $2,308 (December 31, 2023 - $3,846).
During the nine months ended September 30, 2024, the spouse of the CEO exercised 500,000 stock options into common share. The Company also issued 300,000 stock options during the nine months ended September 30, 2024.
Through its subsidiary, Golden Harvests, the Company leased Morton, owned by the Company’s GM, that is located in Michigan, with a lease term through January 2026. Lease charges of $162,000 were incurred during the nine months ended September 30, 2024 (nine months ended October 31, 2023 - $154,000). The lease liability of Morton at September 30, 2024, was $255,170 (December 31, 2023 - $350,668).
Through its subsidiary, Golden Harvests, the Company also leased Morton Annex located in Michigan, which is owned by the Company’s GM. The lease term was extended during the two months ended December 31, 2023, through November 2024. Lease charges of $250,000 were incurred during the nine months ended September 30, 2024 (nine months ended October 31, 2023 - $580,000). The lease liability of Morton Annex at September 30, 2024, was $nil (December 31, 2023 - $239,871).
Pg **25** of **48**
During April 2024, the Company, through Canopy, acquired an additional 20% of the membership units in Golden Harvests from the GM for aggregate consideration of $1,644,695, comprised of deferred cash payments of $2,000,0000 plus true-up amounts. Distributions totaling $360,000 was paid to the GM during the nine months ended September 30, 2024 and true-up amounts of $360,000 were paid to the GM.
Key management personnel consists of the President and CEO; the Senior Vice President (“SVP”); General Manager (“GM”); and the Chief Financial Officer (“CFO”) of the Company. The compensation to key management is presented in the following table:
| Three months ended September 30, 2024 | Three months ended October 31, 2023 | Nine months ended September 30, 2024 | Nine months ended October 31, 2023 | |
|---|---|---|---|---|
| Salaries and consulting fees | ||||
| Royalty fees paid to GM | ||||
| Stock option expense | ||||
| Total |
All values are in US Dollars.
| *** | SVP effective last day was December 31, 2023. |
|---|
Stock options granted to key management personnel and close family members of key management personnel include the following. During the nine months ended September 30, 2024, 1,400,000 options were granted to the CEO; 170,000 options granted to the CFO, and 300,000 options granted to the GM. During the nine months ended September 30, 2024, the CFO exercised 1,000,000 stock options into common shares. During the two months ended December 31, 2023, no options were granted to key management personnel.
During the nine months ended September 30, 2024, options of 250,000 were exercised into common shares by a Director. Options of 510,000 were also granted to Directors during the nine months ended September 30, 2024.
Accounts payable, accrued liabilities, and lease liabilities due to key management at September 30, 2024, totaled $3,122,109 (December 31, 2023 $1,230,808).
Pg **26** of **48**
DEBT BALANCES AND MOVEMENTS WITH KEY MANAGEMENT AND DIRECTORS
The following table sets out the movements and balances of debt with related parties during the nine months ended September 30, 2024 and the two months ended December 31, 2023. Borrowings from related parties were executed at times because we could identify very limited other sources of financing. The borrowing from the Chief Operating Officer (“COO”) was transacted to accelerate expansion of an indoor growing facility at a competitive rate of interest. The borrowings from other than the COO in the table below were transacted to accelerate construction and production in Michigan. The names of the related parties, by designation, are as follows: CEO – Obie Strickler; SVP – Adam August; Directors – Abhilash Patel; and GM – David Pleitner.
| CEO | SVP | Director | GM | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Balance – October 31, 2023 | ||||||||||
| Interest | ||||||||||
| Payments | ) | ) | ) | ) | ) | |||||
| Balance – December 31, 2023 | ||||||||||
| Borrowed | ||||||||||
| Interest | ||||||||||
| Payments | ) | ) | ) | ) | ||||||
| Balance – September 30, 2024 |
All values are in US Dollars.
Pursuant to the loan and related agreements transacted during the year ended October 31, 2020, the CEO, SVP, and a director obtained 5.5%; 1%; and 2.5% of GR Michigan, respectively; third parties obtained 4% as part of the agreements, such that GR Michigan has a 13% non-controlling interest. These parties, except the CEO, obtained the same interests in Canopy; the CEO obtained 92.5% of Canopy Management, of which 87% was acquired by the Company during the year ended October 31, 2023; all payments necessary for the Company to exercise its option to acquire 87% of Canopy were equal to payments made by Canopy to purchase a controlling 60% interest of Golden Harvests. Interest payments of $48,000 were made on the business acquisition consideration payable of $360,000 for the nine months ended September 30, 2024 ($10,400 for the two months ended December 31, 2023).
Pursuant to the Canopy purchase agreement executed on April 24, 2024, the Company, through GR Unlimited, acquired the remaining 13% of the membership units in Canopy. As part of this transaction, the Company purchased a 5.5% membership interest in Canopy from the CEO, comprised of an upfront cash payment of $66,000 and deferred cash payments of $264,000. Additionally, the Company purchased a 2.5% membership interest in Canopy from a Director, comprised of an upfront cash payment of $66,000 and deferred cash payments of $264,000. The deferred cash payments are to be paid in 48 equal installments with a 5.21% interest rate applied. Principal payments of $25,798 and interest payments of $4,726 were made on the business acquisition consideration payable ($264,000) due to the CEO for the nine months ended September 30, 2024 ($nil for the two months ended December 31, 2023). Principal payments of $11,726 and interest payments of $2,149 were made on the business acquisition consideration payable ($120,000) due to the Director for the nine months ended September 30, 2024 ($nil for the two months ended December 31, 2023).
During April 2024, the Company, through Canopy, acquired an additional 20% of the membership units in Golden Harvest from the GM for aggregate consideration of $1,644,695, comprised of deferred cash payments of $2,000,0000 plus true-up amounts, discounted at a market interest rate. Pursuant to the purchase agreement executed on April 24, 2024, the deferred cash payments are to be paid in thirteen quarterly installments beginning on January 1, 2025. True-up payments of $360,000 were made on the business acquisition consideration payable.
Pg **27** of **48**
OTHERSELECTED FINANCIAL INFORMATION
EBITDA AND ADJUSTED EBITDA (NON-IFRS MEASURES)
The Company’s “Adjusted EBITDA,” or “aEBITDA,” is a non-IFRS measure used by management that does not have any prescribed meaning by IFRS and that may not be comparable to similar measures presented by other companies. Adjusted EBITDA is intended to provide a proxy for our operating cash flow before changes in non-cash working capital (“CNCWC”), which was $4,071,330 for the nine months ended September 30, 2024 (for the nine months ended October 31, 2023 – $5,121,486). The Company defines “EBITDA” as the Company’s net income or loss for a period, as reported, before interest, taxes, depreciation and amortization, and is further adjusted to remove transaction costs, stock-based compensation expense, accretion expense, gain (loss) on derecognition of derivative liabilities, the effects of fair-value accounting for biological assets and inventory, as well as other non-cash items and items not representative of ongoing operational performance as reported in net income (loss). Adjusted EBITDA is defined as EBITDA adjusted for the impact of various significant or unusual transactions. The Company believes that this is a useful metric to evaluate its operating performance, as it allows analysts to compare us to our competitors and derive expectations of our future performance. Adjusted EBITDA increases comparability between comparative companies by adjusting for variability resulting from differences in capital structures, resource allocations and investments, the impact of fair value adjustments on biological assets and inventory and financial statements, which may be volatile and fluctuate significantly from period to period.
| Adjusted EBITDA Reconciliation | Nine months ended 30-Sep-24 2024 () | Nine months ended 31-Oct-23 2023 () | ||
|---|---|---|---|---|
| Net income (loss), as reported | ) | ) | ||
| Add back realized fair value amounts included in inventory sold | ||||
| Deduct unrealized fair value gain on growth of biological assets | ) | ) | ||
| Add back amortization of property and equipment included in cost of sales | ||||
| Add back interest and interest accretion expense, as reported | ) | ) | ||
| Add back amortization of property and equipment, as reported | ||||
| Add back share-based compensation | ||||
| Deduct unrealized gain/add back unrealized loss on derivative liability, as reported | ||||
| Add back (gain)loss on disposal of property plant and equipment | ) | |||
| Deduct unrealized gain on warrants asset, as reported | ) | ) | ||
| Add back income tax expense, as reported | ||||
| EBITDA | ||||
| Compliance costs*^1^* | ||||
| One time compensation payments | ||||
| Additional compliance costs associated with year end change | ||||
| Eliminated management fees due from Equity Method Investment | ||||
| Costs associated with acquisition of Golden Harvests*^2^* | ||||
| New production location startup costs*^3^* | ||||
| Non recurring legal and transaction costs | ||||
| Adjusted EBITDA |
All values are in US Dollars.
| ^1^ | Costs for professional services pertaining to prior periods as a result of efforts to bring the Company’s disclosures current with the Commission. The Company’s required disclosures were brought current, and over-the-counter trading resumed in the United States. |
|---|---|
| ^2^ | Costs associated with the Company’s acquisition of the Michigan assets. |
| ^3^ | During the nine months ended September 30, 2024, we incurred $587,539 in labor costs associated with the investment in New Jersey. |
Pg **28** of **48**
Segmented Adjusted EBITDA – Nine Months ended September 30, 2024
| Oregon | Michigan | Services | Corporate | Consolidated | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9,572,906 | 10,096,685 | 1,281,226 | 414,500 | 21,365,317 | ||||||||||
| Costs of revenue, excluding fair value adjustments | (5,639,139 | ) | (4,255,180 | ) | (206,670 | ) | - | (10,100,989 | ) | ||||||
| Gross profit (loss) before fair value adjustments | 3,933,767 | 5,841,505 | 1,074,556 | 414,500 | 11,264,328 | ||||||||||
| Net fair value (“FV”) adjustments | 18,736 | (725,881 | ) | - | - | (707,145 | ) | ||||||||
| Gross profit | 3,952,503 | 5,115,624 | 1,074,556 | 414,500 | 10,557,183 | ||||||||||
| Operating expenses: | |||||||||||||||
| General and administration | 2,038,098 | 2,290,981 | - | 3,089,459 | 7,418,538 | ||||||||||
| Depreciation and amortization | 86,979 | 524,068 | - | 117,048 | 728,095 | ||||||||||
| Share based compensation | - | - | - | 379,178 | 379,178 | ||||||||||
| Other income and expense: | |||||||||||||||
| Interest and accretion | (202,485 | ) | (61,627 | ) | - | (1,538,504 | ) | (1,802,616 | ) | ||||||
| Loss on disposal or property and equipment | 7,823 | - | - | - | 7,823 | ||||||||||
| Unrealized (loss) gain on derivative liability | - | - | - | (13,584,791 | ) | (13,584,791 | ) | ||||||||
| Unrealized (loss) gain on warrants asset | - | - | - | 2,071,411 | 2,071,411 | ||||||||||
| Other income and expense | 190 | - | - | 51,737 | 51,927 | ||||||||||
| Net income (loss) before tax | 1,632,954 | 2,238,948 | 1,074,556 | (16,171,332 | ) | (11,224,874 | ) | ||||||||
| Tax | 32 | 649,001 | - | 532,855 | 1,181,888 | ||||||||||
| Net income (loss) after tax | 1,632,922 | 1,589,947 | 1,074,556 | (16,704,187 | ) | (12,406,762 | ) | ||||||||
| Net FV adjustments | (18,736 | ) | 725,881 | - | - | 707,145 | |||||||||
| Amortization of property and equipment included in cost of sales | 1,009,540 | 545,207 | - | - | 1,554,747 | ||||||||||
| Amortization of property and equipment | 86,979 | 524,067 | - | 117,049 | 728,095 | ||||||||||
| Share-based compensation | - | - | - | 379,178 | 379,178 | ||||||||||
| Unrealized derivative liability | - | - | - | 13,584,791 | 13,584,791 | ||||||||||
| Loss on disposal of property plant and equipment | (7,823 | ) | - | - | - | (7,823 | ) | ||||||||
| Unrealized warrants asset | - | - | - | (2,071,411 | ) | (2,071,411 | ) | ||||||||
| Interest and accretion | 202,485 | 61,626 | - | 1,538,505 | 1,802,616 | ||||||||||
| Income tax | 32 | 649,001 | - | 532,855 | 1,181,888 | ||||||||||
| EBITDA before one-time adjustments | 2,905,399 | 4,095,729 | 1,074,556 | (2,623,220 | ) | 5,452,464 | |||||||||
| Add back to EBITDA: | |||||||||||||||
| One time compensation payments | - | - | - | 121,336 | 121,336 | ||||||||||
| Additional compliance costs | - | - | - | 79,091 | 79,091 | ||||||||||
| Eliminated management fees | - | - | - | 46,200 | 46,200 | ||||||||||
| Costs associated with acquisition of Golden Harvests | - | 603,000 | - | - | 603,000 | ||||||||||
| New production location startup costs | - | - | - | 587,539 | 587,539 | ||||||||||
| Non recurring legal and transaction costs | - | - | - | 187,342 | 187,342 | ||||||||||
| Adjusted EBITDA | 2,905,399 | 4,698,729 | 1,074,556 | (1,601,712 | ) | 7,076,972 |
OUTSTANDINGSHARE DATA
On June 24, 2024, the Company completed a reorganization of its share capital as approved by the shareholders of the Company at its annual and special meeting. Pursuant to the share reorganization, the Company amended its articles to redesignate its existing class of common shares without par value in the capital of the Company as Subordinate Voting Shares (“SV Shares”) and created a new class of unlisted Multiple Voting Shares (“MV Shares”). The SV Shares can be converted into MV Shares at a conversion ratio of 1,000:1, and the MV Shares carry 1,000 votes per share. All share amounts or per amounts in this document are expressed on an as converted basis as all shares converted are expected to be imminently reconverted to common shares.
As of the date of this MD&A, the Company had 222,276,113 subordinate voting shares outstanding, in which all MV Shares have been converted into SV Shares.
As of the date of this MD&A, the Company has no warrants outstanding, exercisable into common shares, except for those issued to Vireo Growth.
Pg **29** of **48**
As of the date of this MD&A, the Company has the following stock options outstanding and exercisable into common shares:
| Exercise price (CAD) | Options outstanding | Number exercisable | Remaining<br> Contractual Life<br> (years) | Expiry period | |||
|---|---|---|---|---|---|---|---|
| 200,000 | 200,000 | 0.01 | November 2024 | ||||
| 1,000,000 | 1,000,000 | 0.46 | April 2025 | ||||
| 1,150,000 | 1,150,000 | 0.53 | May 2025 | ||||
| 85,000 | 85,000 | 0.98 | November 2025 | ||||
| 300,000 | 300,000 | 1.43 | April 2026 | ||||
| 4,475,000 | 4,475,000 | 2.16 | January 2027 | ||||
| 400,000 | 116,666 | 2.84 | September 2027 | ||||
| 600,000 | 550,000 | 3.01 | November 2027 | ||||
| 5,455,000 | - | 2.80 | August 2027 | ||||
| 1,400,000 | - | 4.80 | August 2029 | ||||
| 15,065,000 | 7,876,666 | 2.40 |
All values are in US Dollars.
As of the date of this MD&A, the Company also has July Convertible Debentures outstanding with an aggregate principal balance of $4,050,000 and accrued interest of approximately $43,582. The debentures mature on July 13, 2026. Interest accrues at 9% per annum and is payable on the last business days of March, June, September, and December.
Shares issuable upon conversion of the July Convertible Debentures as of the date of this MD&A are presented in the table below:
| Debenture principal | Accrued interest | USD/CAD<br><br> <br>exchange rate* | Exercise price<br><br> <br>(CAD$) | Shares issuable if converted |
|---|---|---|---|---|
| $4,050,000 | $43,582 | 1.38825 | 0.24 | 23,426,719 |
| * | Most recent exchange rate as published by the Bank of Canada. | |||
| --- | --- |
Additionally, as of the date of this MD&A, the Company has no December Convertible Debentures or August Convertible Debentures outstanding.
Pg **30** of **48**
CRITICALACCOUNTING JUDGMENTS AND ESTIMATION UNCERTAINTIES
The preparation of the Interim Financial Statements in conformity with IFRS requires that the Company’s management make critical judgments, estimates and assumptions about future events that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting period. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. The most significant judgments include those related to the ability of the Company to continue as a going concern, the determination of when property and equipment are available for use, and impairment of its financial and non-financial assets. The most significant estimates and assumptions include those related to the valuation of biological assets, the collectability of accounts receivable, the useful lives of property and equipment, inputs used in accounting the determination of the discount rate used to estimate the fair value of the liability component of convertible debt instruments, the discount rates used to calculate present values of lease liabilities, the inputs used in the estimate of the fair value of equity based compensation, and the inputs used in the estimate of the fair value of equity instruments.
NEWLYADOPTED ACCOUNTING PRONOUNCEMENTS
Amendments to IAS 1 – Presentation of Financial Statements
The amendment to IAS 1 – Presentation of Financial Statements specifies that the classification of current versus non-current liabilities may change (e.g. convertible debt). Prior to this amendment, the classification of liabilities was considered current when there was no unconditional right to defer settlement for at least twelve months after the reporting date. Under the amendment to IAS 1, the IASB removed the requirement for a right to be unconditional and instead requires that a right to defer settlement must exist at the reporting date and have substance. The amendment is effective for annual periods beginning on or after January 1, 2024. The Company adopted the amendments to IAS 1 effective January 1, 2024, which impacts the classification of the Company’s Financial Statements by recording its convertible debt as a current liability in its consolidated statements of financial position dated September 30, 2024.
NEWACCOUNTING PRONOUNCEMENTS
IFRS 18 – Presentation and Disclosures
IFRS 18 – Presentation and Disclosures in Financial Statements will replace IAS 1 – Presentation of Financial Statements. The new standard aims at improving how entities communicate in their financial statements and will be effective for annual periods beginning on or after January 1, 2027. The standard is applied retrospectively, with specific transition provisions, and early adoption is permitted. The Company is evaluating the impact of this standard on the Company’s consolidated financial statements.
FINANCIALINSTRUMENTS AND OTHER RISK FACTORS
MARKET RISK
Market risk is the risk that the fair value or cash flows of a financial instrument will fluctuate due to changes in market prices. Market risk reflects interest rate risk, currency risk and other price risks.
Pg **31** of **48**
Interest Rate Risk
At September 30, 2024 and December 31, 2023, the Company’s exposure to interest rate risk relates to long term debt, convertible promissory notes, and finance lease obligations, but its interest rate risk is limited as the aforementioned financial instruments are fixed interest rate instruments.
Currency Risk
As at September 30, 2024, the Company had a portion of its accounts payable and accrued liabilities denominated in Canadian dollars which amounted to CAD$203,112 (CAD $155,679 at December 31, 2023). The Company also has derivative liabilities of $13,222,933 which are based on the underlying price of the Company’s stock in Canadian Dollars. The Company is exposed to the risk of fluctuation in the rate of exchange between the Canadian Dollar and the United States Dollar.
Other Price Risk
Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices, other than those arising from interest rate risk or foreign currency risk and a change in the price of cannabis. he Company is exposed to price risk related to its derivative liabilities and warrant assets which are based on the underlying value of the Company stock. The Company is not exposed to significant other price risk.
CREDIT RISK
Credit risk is the risk that one party to a financial instrument will cause a loss for the other party by failing to pay for its obligation.
Credit risk to the Company is derived from cash and trade accounts receivable. The Company places its cash in deposit with United States financial institutions. The Company has established a policy to mitigate the risk of loss related to granting customer credit by primarily selling on a cash-on-delivery basis.
Financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At September 30, 2024 and December 31, 2023, the Company had $4,841,717 and $6,054,579 in excess of the FDIC insured limit, respectively.
The carrying amount of cash and trade accounts receivable represents the Company’s maximum exposure to credit risk; the balances of these accounts are summarized in the following table:
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| Cash | ||
| Accounts Receivable | ||
| Notes Receivable | ||
| Total |
All values are in US Dollars.
The allowance for doubtful accounts at September 30, 2024, was $390,604 (December 31, 2023 - $373,393).
Pg **32** of **48**
LIQUIDITY RISK
Liquidity risk represents the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities. The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when they become due. At September 30, 2024, and December 31, 2023, the Company’s working capital accounts were as follows:
| September 30, 2024 | December 31, 2023 | |||
|---|---|---|---|---|
| Cash | ||||
| Current assets excluding cash | ||||
| Total current assets | ||||
| Current liabilities | ) | ) | ||
| Working capital |
All values are in US Dollars.
The current liabilities included to derive working capital excludes the current portion of convertible debt which has a maturity greater than one year but is classified as current liabilities based on the newly adopted amendment to IAS 1 effective January 1, 2024. Current liabilities also excludes non-cash derivative liabilities classified as current liabilities.
The Company Faces Risks Inherent in an Agricultural Business.
Cannabis is an agricultural product. There are risks inherent in the agricultural business, such as insects, plant diseases, forest fire and similar agricultural risks. Although some of the Company’s cannabis flower is grown indoors under climate-controlled conditions, with conditions monitored, there can be no assurance that natural elements will not have a material adverse effect on the production of the Company’s products.
Provision for income taxes
The Company’s Provision for income taxes is comprised of current and deferred taxes. Current taxes are recognized on taxable income (loss) for the fiscal period, as adjusted for unrealized tax benefits, changes in tax receivables (payables) that arose in a prior period and recovery of taxes paid in a prior period. Current taxes are measured using tax rates and laws enacted during the period within which the taxable income (loss) arose. Current taxes can also arise from dividends. Current tax assets and liabilities are offset only if the right of offset exists.
Deferred taxes are recognized with respect to temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax basis, with certain exceptions. Deferred taxes are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. If the Company determines, based on available evidence, that it is more likely than not that all or a portion of a deferred tax asset will not be realized, a valuation allowance is established to reduce the deferred tax asset by the amount expected to be unrealizable. Management reassesses the need for a valuation allowance at the end of each reporting period and takes into consideration, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability and the duration of statutory carryforwards.
Upon filing of its tax return for fiscal year ending October 31, 2023, the Company has adopted a new U.S. federal income tax position as of August 15, 2024, asserting that the restrictions of Section 280E of the Internal Revenue Code (“Section 280E”) do not apply to the Company’s cannabis operations. The decision to adopt this position is supported by legal interpretations that challenge the Company’s tax liability as determined pursuant to Section 280E. If the Company’s interpretation is upheld, the Company’s financial position could be significantly enhanced by the ability to deduct additional ordinary and necessary business expenses that are non-deductible under Section 280E.
Pg **33** of **48**
While the Company believes its position is supported by sound legal reasoning, the cannabis industry remains in a complex regulatory environment. The U.S. federal illegality of cannabis poses unique challenges and uncertainties, including the potential for differing interpretations and enforcement actions. The Company is prepared to vigorously defend its tax position if challenged and will continue to monitor legal developments in this matter closely; however, the Company cannot be certain that it will prevail on this issue with the Internal Revenue Service (“IRS”). As a precautionary measure, if the Company were not to prevail on this issue with the IRS, it has set aside reserves to mitigate the potential financial impact of such a determination, which is recognized within the Company’s income tax payable on its Condensed Interim Consolidated Balance Sheets (Unaudited) in the accompanying Interim Financial Statements.
The Company Is Likely To Be Audited By The IRS And The IRS Is Likely To Challenge The Non-Application of Section 280E To The Company’s U.S. Marijuana Operations.
The Company believes there is a great likelihood that the IRS will audit the income tax returns of cannabis-related businesses. Starting in the quarter ended June 30, 2024, the Company has taken the position that Section 280E does not apply to any of its business, including its U.S. operations engaged in the production and sale of “marijuana” under U.S. Federal Law. This is contrary to previous positions taken by the Company in its historical tax filings with respect to its U.S. marijuana operations. On June 28, 2024, the IRS confirmed that it continues to consider Section 280E to apply to businesses that engage in the U.S. marijuana business, even if such businesses are state-licensed. The IRS further indicated that it intends to challenge refund claims by taxpayers claiming that Section 280E does not apply to such operations. The Company has recorded a liability on its balance sheet for income taxes payable which has been prepared under the methodology assuming 280E does apply, as there is a risk that it may not prevail in a dispute with the IRS.
Pg **34** of **48**
FAIR VALUES
A number of the Company’s accounting policies and disclosures require the measurement of fair valued for both financial and nonfinancial assets and liabilities. The Company has an established framework, which includes team members who have overall responsibility for overseeing all significant fair value measurements, including Level 3 fair values. When measuring the fair value of an asset or liability, the Company uses observable market data as far as possible.
The Company regularly assesses significant unobservable inputs and valuation adjustments. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:
Level 1: unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly; or
Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).
The carrying values of the financial instruments at September 30, 2024, are summarized in the following table:
| Level in fair<br><br> <br>value hierarchy | Amortized Cost | FVTPL | |
|---|---|---|---|
| Financial Assets | |||
| Cash | Level 1 | ||
| Accounts receivable | Level 2 | ||
| Warrants asset | Level 2 | ||
| Financial Liabilities | |||
| Accounts payable and accrued liabilities | Level 2 | ||
| Debt | Level 2 | ||
| Convertible debentures | Level 2 | ||
| Business acquisition consideration payable | Level 2 | ||
| Derivative liability | Level 2 |
All values are in US Dollars.
During the nine months ended September 30, 2024, there were no transfers of amounts between levels.
Pg **35** of **48**
The carrying values of the financial instruments at December 31, 2023, are summarized in the following table:
| Level in fair value hierarchy | Amortized Cost | FVTPL | |
|---|---|---|---|
| Financial Assets | |||
| Cash | Level 1 | ||
| Accounts receivable | Level 2 | ||
| Warrants asset | Level 2 | ||
| Financial Liabilities | |||
| Accounts payable and accrued liabilities | Level 2 | ||
| Debt | Level 2 | ||
| Convertible debentures | Level 2 | ||
| Business acquisition consideration payable | Level 2 | ||
| Derivative liabilities | Level 2 |
All values are in US Dollars.
During the two months ended December 31, 2023, there were no transfers of amounts between levels.
See additional risk factors relating to the Company as described in section 17 of the Company’s Listing Statement dated November 15, 2018 which can be found under the Company’s profile on www.sedarplus.ca.
Pg **36** of **48**
SUBSEQUENTEVENTS
TERMINATION OF ADVISORY AGREEMENT WITH VIREO GROWTH INC.
On October 11, 2024, the Company announced the termination of the advisory agreement with Vireo Growth. As consideration for the early termination, Vireo Growth will forfeit and return for cancellation 4,500,000 of the 8,500,000 share purchase warrants in Grown Rogue International Inc. that are held by Vireo Growth at a CAD$0.225 strike price. Additionally, Vireo Growth will pay the Company US$800,000 in cash. Vireo has the option of deferring the cash payment by making 4 quarterly payments of US$250,000. Grown Rogue will also receive its full consulting fee for the work performed in Q3 2024 and retains its 10,000,000 warrants in Vireo Growth Inc. Subsequent to the unaudited interim consolidated statements of financial position dated September 30, 2024, the Company received a termination fee of $800,000 in cash in accordance with the Consulting Agreement on October 18, 2024.
ABCO CONVERTIBLE NOTE
On October 25, 2024, the Company executed a convertible promissory note with ABCO in the amount of $1,050,000. The note is convertible into equity of ABCO at a rate of 1% per $28,571.43 of principal borrowed upon certain future regulatory milestones. The note carries an interest rate of 15% and can be drawn down in increments of $10,000. As of November 13, 2024, the Company had advanced $700k on this promissory note.
ADVANCES TO NILE OF NJ LLC UNDER CONVERTIBLE PROMISSORY NOTE
On November 1, 2024, the Company through its subsidiary West New York advanced an additional $287,500 to Nile of NJ LLC under a convertible note in the amount of $287,500. West New York concurrently received equity subscriptions of $137,500 in support of this funding.
Pg **37** of **48**
REGULATORYDISCLOSURE
Grown Rogue derives a substantial portion of its revenues from the state-legal cannabis industry in the United States. Grown Rogue is indirectly involved (through subsidiaries) in the state-legal cannabis industry in the United States where respective state laws permit “adult-use”/“reactional” and/or medical cannabis cultivation, manufacture, distribution, sales, and possession. Currently, Grown Rogue’s subsidiaries directly participate in the cultivation, manufacture, possession, distribution, or sale of cannabis in Oregon’s adult-use market and in Michigan’s medical and adult-use market. Pending regulatory approval, Grown Rogue, through its subsidiaries, expects to participate in Illinois’s and New Jersey’s adult-use markets over the coming year.
Cannabis is classified as a Schedule I narcotic under the United States Controlled Substances Act (the “CSA” or “Federal CSA”), making it federally illegal in the United States. A Schedule I narcotic under the CSA is deemed to have a high potential for abuse, no accepted medical use, and a lack of accepted safety for the use of the drug under medical supervision. The United States Food and Drug Administration has not approved marijuana as a safe and effective drug for any indication.
Despite federal illegality, over the past decade 38 states have legalized cannabis for medical use within their borders, 24 states, two territories, and the District of Columbia have enacted measures to regulate cannabis for recreational use, and nine states have approved measures to allow for “low THC” medical use programs. As such, cannabis is largely regulated at the state level in the United States. Notwithstanding the permissive regulatory environment of cannabis at the state level, pursuant to the Supremacy Clause of the United States Constitution, United States federal laws are paramount and in case of conflict between federal and state law in the United States, the federal law shall apply. As a result of the conflict between state and federal law regarding cannabis, investments in cannabis businesses in the United States are subject to inconsistent legislation and regulation.
On the federal legislative side, a number of bills (some bi-partisan) have been introduced in Congress over the years in an attempt to address and perhaps reconcile the tension between state-legal cannabis programs and federal illegality, including the Strengthening the Tenth Amendment Through Entrusting States (STATES) Act, the Marijuana Opportunity Reinvestment and Expungement Act (MORE) Act, the Cannabis Administration and Opportunity (CAOA) Act, the Secure and Fair Enforcement (SAFE) Banking Act, the Preparing Regulators Effectively for a Post-Prohibition Adult-Use Regulated Environment (PREPARE) Act, and the Small Business Tax Equity (SBTE) Act. Congress has not passed any material marijuana reform legislation in decades.
There has, however, been activity with respect to cannabis from the administrative branch. In 2013, then United States Department of Justice Deputy Attorney General James M. Cole issued a memorandum (the “Cole Memorandum”) for all United States Attorneys providing updated guidance to federal prosecutors concerning marijuana enforcement under the CSA. The Cole Memorandum applied to all Department of Justice federal enforcement activity, including civil enforcement, criminal investigations, and prosecutions concerning marijuana in all states. However, the Cole Memorandum was rescinded by Attorney General Jeff Sessions on January 4, 2018. Notably, the Biden administration has tacitly reverted to the guidance provided in the Cole Memorandum. Although current Attorney General Merrick Garland has not officially reinstated the Cole Memorandum, he advised in written testimony in early 2021 that he did not “think it the best use of the Department’s limited resources to pursue prosecutions of those who are complying with the laws in states that have legalized and are effectively regulating marijuana.” The Department of the Treasury adopted recommendations based on the standards set forth in the Cole Memorandum in its guidance (the “FinCen Guidance”) provided in 2014. Despite the repeal of the Cole Memorandum, the Department of Treasury’s Financial Crimes Enforcement Network (“FinCEN”) has confirmed that the FinCEN Guidance remains in effect and the Department of Treasury indicated it will remain in place.
Pg **38** of **48**
On October 6, 2022, President Biden, among other things, asked the Secretary of Health and Human Services and the Attorney General to initiate the administrative process to review expeditiously how marijuana is scheduled under federal law. On or about August 29, 2023, Deputy Secretary of Health and Human Services (“HHS”) Rachel Levine transmitted a letter to the head of the Drug Enforcement Agency (“DEA”), Anne Milgram, recommending that cannabis and its derivatives be removed from Schedule I of the CSA. HHS’s recommendation is to reschedule cannabis to Schedule III. Schedule III substances are deemed to have medicinal value and have potential for abuse but less than substances in Schedules I or II, and abuse that may lead to moderate or low physical dependence or high psychological dependence. HHS’s recommendation remains pending and the Department of Justice (“DOJ”), specifically the DEA, is in the process of assessing it. If DOJ accepts the recommendation, it will then promulgate rules to effectuate the reschedule.
There is no guarantee that state laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned. Unless and until the United States amends the CSA with respect to marijuana, there is a risk that federal authorities may enforce current federal law. If the federal government begins to enforce federal law, or if existing applicable state laws are repealed or curtailed, Grown Rogue’s business, results of operations, financial condition, and prospects would be materially adversely affected. There thus remains a risk that federal authorities may enforce current federal law against companies such as Grown Rogue for violation of federal law or they may seek to bring an action or actions against Grown Rogue and/or its investors for violation of federal law or otherwise, including, but not limited to, a claim against investors for aiding and abetting another’s criminal activities.
In light of the uncertainty surrounding the treatment of United States cannabis-related activities, including the rescission of the Cole Memorandum, the Canadian Securities Administrators published a Staff Notice 51-352 (Revised) – Issuers with U.S. Marijuana-Related Activities (“Staff Notice 51-352”) on February 8, 2018 setting out certain disclosure expectations for issuers with United States cannabis-related activities. Staff Notice 51-352 includes additional disclosure expectations that apply to all issuers with United States cannabis-related activities, including those with direct and indirect involvement in the cultivation and distribution of cannabis, as well as issuers that provide goods and services to third parties involved in the United States cannabis industry.
In accordance with the Staff Notice 51-352*,* below is a table of concordance that is intended to assist readers in identifying the disclosure expectations outlined in Staff Notice 51-352.
In accordance with Staff Notice 51-352, this section provides a discussion of the federal and state-level U.S. regulatory regimes in the jurisdictions where Grown Rogue is currently directly involved through its subsidiaries or is planning to be directly involved in the future. Certain Grown Rogue subsidiaries are directly engaged in the cultivation, manufacture, possession, sale, or distribution of cannabis in the recreational cannabis marketplace in the State of Oregon and in the medical and recreational marketplaces in the State of Michigan. Pending regulatory approval, certain Grown Rogue subsidiaries expect to be directly engaged in the cultivation, manufacture, possession, sale, or distribution of cannabis in the recreational cannabis marketplace in New Jersey and Illinois. In accordance with Staff Notice 51-352, Grown Rogue will evaluate, monitor and reassess this disclosure, and any related risks, on an ongoing basis and the same will be supplemented and amended to investors in public filings, including in the event of government policy changes or the introduction of new or amended guidance, laws, or regulations regarding marijuana regulation. Any non-compliance, citations or notices of violation which may have an impact on Grown Rogue’s licenses, business activities, or operations will be promptly disclosed by Grown Rogue.
Pg **39** of **48**
| All Issuers with US Marijuana-Related Activities | Response |
|---|---|
| Describe the nature of the issuer’s involvement in the U.S. marijuana industry and include the disclosures indicates for at least one of the direct, indirect and ancillary industry involvement types. | See above under “Description of Business”.<br><br> <br><br><br> <br>See below under “U.S. Regulatory Matters” |
| Prominently state that marijuana is illegal under US federal law and that enforcement of relevant laws is a significant risk | See above |
| Discuss any statements and other available guidance made by federal authorities or prosecutors regarding the risk of enforcement action in any jurisdiction where the issuer conducts U.S. marijuana-related activities. | See below under “U.S. Regulatory Matters”<br><br> <br><br><br> <br>See the following risk factors included in the Company’s Listing Statement available on www.sedarplus.ca:<br><br> <br><br><br> <br>Section 17 – Risk Factors – Grown Rogue’s Business is Illegal under U.S. Federal Law<br><br> <br><br><br> <br>Section 17 – Risk Factors – Because marijuana is illegal under federal law, investing in cannabis business could be found to violate the Federal CSA |
| Outline related risks including, among others, the risk that third party service providers could suspend or withdraw services and the risk that regulatory bodies could impose certain restrictions on the issuer’s ability to operate in the U.S. | See the following risk factors included in the Company’s Listing Statement available on www.sedarplus.ca:<br><br> <br><br><br> <br>Section 17 – Risk Factors – Grown Rogue’s Business is Illegal under U.S. Federal Law<br><br> <br><br><br> <br>Section 17 – Risk Factors – Because marijuana is illegal under federal law, investing in cannabis business could be found to violate the Federal CSA<br><br> <br><br><br> <br>Section 17 – Risk Factors – Risks Relating to Other Laws and Regulations<br><br> <br><br><br> <br>Section 17 – Risk Factors – Current and Future Consumer Protection Regulatory Requirements<br><br> <br><br><br> <br>Section 17 – Risk Factors – Operational Risks<br><br> <br><br><br> <br>Section 17 – Risk Factors – Grown Rogue will not be able to deduct many normal business expenses<br><br> <br><br><br> <br>Section 17 – Risk Factors – External Factors<br><br> <br><br><br> <br>Section 17 – Risk Factors – Failure to Protect Intellectual Property<br><br> <br><br><br> <br>Section 17 – Risk Factors – Agricultural Operations<br><br> <br><br><br> <br>Section 17 – Risk Factors – Liability, Enforcement Complaints etc.<br><br> <br><br><br> <br>Section 17 – Risk Factors – Grown Rogue’s business is highly regulated and it may not be issued necessary licenses, permits, and cards<br><br> <br><br><br> <br>Section 17 – Risk Factors – Licenses<br><br> <br><br><br> <br>Section 17 – Risk Factors – Local Laws and Ordinances |
Pg **40** of **48**
| All Issuers with US Marijuana-Related Activities | Response |
|---|---|
| Section 17 – Risk Factors – Third party service providers to Grown Rogue may withdraw or suspend their service<br><br> <br><br><br> <br>Section 17 – Risk Factors – Grown Rogue may not be able to obtain or maintain a bank account<br><br> <br><br><br> <br>Section 17 – Risk Factors – Grown Rogue’s contracts may be unenforceable and property may be subject to seizure<br><br> <br><br><br> <br>Section 17 – Risk Factors – The protections of US bankruptcy law may be unavailable<br><br> <br><br><br> <br>Section 17 – Risk Factors – Grown Rogue may have a difficult time obtaining insurance which may expose Grown Rogue to additional risk and financial liabilities<br><br> <br><br><br> <br>Section 17 – Risk Factors – Grown Rogue’s websites are accessible in jurisdictions where medicinal or recreational use of marijuana is not permitted and, as a result Grown Rogue may be found to be violating the laws of those jurisdictions<br><br> <br><br><br> <br>Section 17 – Risk Factors – The marijuana industry faces significant opposition in the United States | |
| Given the illegality of marijuana under US federal law, discuss the issuer’s ability to access both public and private capital and indicate what financing options are/are not available in order to support continuing operations. | See above under “Description of Business”.<br><br> <br><br><br> <br>See the following risk factor included in the Company’s Listing Statement available on www.sedarplus.ca:<br><br> <br><br><br> <br>Section 17 – Risk Factors – Grown Rogue may not be able to obtain or maintain a bank account |
| Quantify the issuer’s balance sheet and operating statement exposure to U.S. marijuana-related activities. | 100% of Grown Rogue’s balance sheet and operating statements are exposed to U.S. marijuana-related activities. |
| Disclose if legal advice has not been obtained, either in the form of a legal opinion or otherwise, regarding (a) compliance with applicable state regulatory frameworks and (b) potential exposure and implications arising from U.S. federal law. | Grown Rogue has received legal advice from multiple attorneys regarding (a) compliance with applicable state regulatory frameworks and (b) potential exposure and implications arising from U.S. federal law. |
| Federal CSA Requirement – US Marijuana Issuers with direct involvement in cultivation or distribution | Response |
| Outline the regulations for U.S. states in which the issuer operates and confirm how the issuer complies with applicable licensing requirements and the regulatory framework enacted by the applicable U.S. state. | See below under “U.S. Regulatory Matters” |
Pg **41** of **48**
| Federal CSA Requirement – US Marijuana Issuers with direct involvement in cultivation or distribution | Response |
|---|---|
| Discuss the issuer’s program for monitoring compliance with U.S. state law on an ongoing basis, outline internal compliance procedures and provide a positive statement indicating that the issuer is in compliance with U.S. state law and the related licensing framework. Promptly disclose any non-compliance, citations or notices of violation which may have an impact on the issuer’s license, business activities or operations. | See below under “U.S. Regulatory Matters”<br><br> <br><br><br> <br>See the following risk factors included in the Company’s Listing Statement available on www.sedarplus.ca:<br><br> <br><br><br> <br>Section 17 – Risk Factors – Grown Rogue’s Business is Illegal under U.S. Federal Law<br><br> <br><br><br> <br>Section 17 – Risk Factors – Risks Relating to Other Laws and Regulations<br><br> <br><br><br> <br>Section 17 – Risk Factors – Grown Rogue’s business is highly regulated and it may not be issued necessary licenses, permits, and cards<br><br> <br><br><br> <br>Section 17 – Risk Factors – Licenses<br><br> <br><br><br> <br>Section 17 – Risk Factors – Liability, Enforcement Complaints etc. |
| U.S. Marijuana Issuers with indirect involvement in cultivation or distribution | Response |
| Outline the regulations for U.S. states in which the issuer’s investee(s) operate. | N/A |
| Provide reasonable assurance, through either positive or negative statements, that the investee’s business is in compliance with applicable licensing requirements and the regulatory framework enacted by the applicable U.S. state. Promptly disclose any non-compliance, citations or notices of violation, of which the issuer is aware, that may have an impact on the investee’s licence, business activities or operations. | N/A |
| U.S. Marijuana Issuers with material ancillary involvement | Response |
| Provide reasonable assurance,<br>through either positive or negative statements, that the applicable customer’s or investee’s business is in compliance with<br>applicable licensing requirements and the regulatory framework enacted by the applicable U.S. state. | N/A |
U.S. REGULATORY MATTERS
Grown Rogue (through its subsidiaries) has direct involvement in the cultivation, manufacture, possession, sale, and distribution of marijuana in the United States. Grown Rogue and its subsidiaries are primarily involved in the U.S. marijuana industry as a seed to retail company with operations currently in Oregon and Michigan (both of which have legalized medical and recreational marijuana). Grown Rogue, through its subsidiaries, produces recreational marijuana and distributes it to dispensaries throughout Oregon and Michigan.
Pg **42** of **48**
Grown Rogue incorporates its discussion above in the “Regulatory Disclosure” section regarding the status of cannabis in the United States and the interplay between federal and state laws. As discussed therein, active enforcement of the current federal law on cannabis may directly and adversely affect revenues and profits of Grown Rogue. The risk of strict enforcement of the Federal CSA remains uncertain.
U.S. FEDERAL LAWS APPLICABLE TO BANKING
Because producing, manufacturing, processing, possessing, distributing, selling, and using marijuana is a crime under the CSA, most U.S. banks and other financial institutions are unwilling to provide banking services to marijuana-related businesses due to concerns about criminal liability under the CSA as well as concerns related to federal money laundering rules under the U.S. Bank Secrecy Act. Canadian banks are also hesitant to work with cannabis companies, due to the uncertain legal and regulatory framework of the industry. Banks and other financial institutions could be prosecuted and possibly convicted of money laundering for providing services to cannabis businesses.
Under U.S. federal law, banks or other financial institutions that provide a cannabis business with a checking account, debit or credit card, small business loan, or any other service could be found guilty of money laundering or conspiracy. In both Canada and the United States transactions by cannabis businesses involving banks and other financial institutions are both difficult and unpredictable under the current legal and regulatory landscape. Though guidelines issued in past years allow financial institutions to provide bank accounts to certain cannabis businesses, relatively few U.S. banks have taken advantage of those guidelines, and many U. S. cannabis businesses still operate on an all-cash basis.
OREGON STATE REGULATION
The Oregon Medical Marijuana Program (“OMMP”) is a state registry program within the Public Health Division, Oregon Health Authority (“OHA”). The role of the OHA is to administer the Oregon Medical Marijuana Act. The OMMP allows individuals with a medical history of one or more qualifying illnesses and a doctor’s written statement to apply for registration with the OMMP. Qualified applicants are issued a registry identification card that entitles them to legally possess and cultivate cannabis, subject to certain limitations.
On November 4, 2014, Oregon voters passed Measure 91, known as the Control, Regulation, and Taxation of Marijuana and Industrial Hemp Act (the “Act”), effectively ending the state’s prohibition of recreational marijuana and legalizing the possession, use, and cultivation of marijuana within legal limits by adults 21 years and older. The Act did not amend or affect the Oregon Medical Marijuana Act and the OMMP. The Act empowered the Oregon Liquor Control Commission (“OLCC”) with regulating sales of recreational marijuana in Oregon. It is possible that the voters could potentially repeal the law that permits both the medical and recreational marijuana industry to operate under state law.
Under current Oregon law, possession, and home cultivation by adults at least 21 years old is allowed within legal limits. Public sales of marijuana and marijuana products may be done only through OLCC-licensed retailers. Medical marijuana patients and adults at least 21 years of age may purchase marijuana and marijuana products at OLCC-licensed retailers. Medical marijuana patients are not charged sales tax for their purchases when they present their registry identification card. OLCC-licensed retailers (and their associated applicants and licensees) are required to obtain a certificate of tax compliance to show compliance with Oregon tax laws at the time of license issuance and at each annual license renewal. The OLCC has the authority to require all OLCC license types to demonstrate compliance with Oregon tax laws, but it has not yet done so.
Pg **43** of **48**
The OLCC issues five basic types of recreational marijuana licenses: (a) producer, (b) processor, (c) wholesaler, (d) retailer, and (e) testing laboratory. Each license type must be renewed annually and in a timely manner (i.e., on or before the license expiration date). Oregon currently has a moratorium on the issuance of new OLCC licenses (with the exception of testing laboratories). This moratorium sunsets on December 31, 2024, and will be replaced with a per capita limit on the issuance of new OLCC licenses. Under the new license limit, the OLCC may not accept new applications for: (a) producer or retail licenses unless there is not more than one active license per 7,500 residents in the state who are 21 years of age or older; and (b) processor and wholesale licenses unless there is not more than one active license per 12,500 residents in the state who are 21 years of age or older. Applications for renewals, changes of location, changes of ownership, or changes in the size of a mature canopy are exempt from both the moratorium and the license limit. The OLCC may disqualify applicants for a number of reasons, including for lacking a good moral character, for lacking sufficient financial resources or responsibility, for relevant past convictions, and for using marijuana, alcohol, or drugs “to excess.”
Grown Rogue has a comprehensive compliance program, which tracks all aspects of operations through the METRC program (an online software tool mandated by the State of Oregon that tracks seed to retail purchases), as well as compliance with all state and federal employment and other safety regulations.
Grown Rogue is periodically advised by various outside attorneys about the requirements for compliance with Oregon law.
Grown Rogue is in compliance with Oregon state law and its related licensing framework.
MICHIGAN STATE REGULATION
In November 2008, Michigan residents approved the Michigan Medical Marihuana Act (the “MMMA”) to provide a legal framework for a safe and effective medical marijuana program. In September 2016, the Michigan Senate passed the Medical Marihuana Facilities Licensing Act (the “MMFLA”) and the Marihuana Tracking Act (the “MTA”). On November 6, 2018, Michigan voters approved the Michigan Regulation and Taxation of Marihuana Act, which makes marijuana legal under state and local law for adults 21 years of age or older and controls the commercial production and distribution of marijuana under a system that licenses, regulates, and taxes the businesses involved.
The Michigan Department of Licensing and Regulatory Affairs (“LARA”) is the main regulatory authority for the licensing of marijuana businesses, and it currently administrates five types of “state operating licenses” for marijuana businesses: (a) a “grower” license, (b) a “processor” license, (c) a “secure transporter” license, (d) a “provisioning center” license and (e) a “safety compliance facility” license. There are no stated limits on the number of licenses that can be made available on a state level; however, LARA has discretion over the approval of applications and municipalities can pass additional restrictions including zoning and licensing requirements.
Grown Rogue has a comprehensive compliance program, which tracks all aspects of operations through the METRC program (an online software tool mandated through the State of Michigan that tracks seed to retail purchases), as well as compliance with all state and federal employment and other safety regulations.
Grown Rogue is periodically advised by various outside attorneys about the requirements for compliance with Michigan law. Grown Rogue is in compliance with Michigan state law and its related licensing framework.
MICHIGAN LICENSE CLASSES AND MUNICIPAL AUTHORITY
State operating licenses for marijuana businesses have a 1 year term and are annually renewable if certain conditions are met: (a) the renewal application is submitted prior to the date the license expires, or within sixty (60) days of expiration if all other conditions are met and a late fee is paid, (b) the licensee pays the regulatory assessment fee set by LARA and (c) the licensee continues to meet the requirements to be a licensee under the Michigan Cannabis Regulations.
Pg **44** of **48**
Each renewal application is reviewed by LARA, and provided that the requisite renewal fees are paid, the renewal application is timely submitted prior to the expiration date, and there are no material violations noted against the applicable licenses, a licensee would expect to receive the applicable renewed license in the ordinary course of business.
There are no stated limits on the number of licenses that can be made available on a state level; however, regulatory authorities have discretion over the approval of applications and municipalities can pass additional restrictions.
Licensees are heavily regulated with on-going requirements related to operations, security, storage, transportation, inventorying, personnel, and more. As in other states where cannabis is legal, Michigan regulators can deny or revoke licenses and renewals for multiple reasons. Additionally, license holders must ensure that no cannabis is sold, delivered, or distributed by a producer from or to a location outside of Michigan.
Pursuant to the requirements of the MTA, LARA utilizes METRC as the state’s third-party solution for marijuana and marijuana product tracking. METRC is Michigan’s statewide seed-to-sale marijuana tracking system that uses serialized tags attached to every plant — and labels attached to wholesale packages — to track marijuana inventory. METRC allows us to track our inventory, permissible sales and seed-to-sale information. METRC also gives regulators access to our product supply chain from seed-to-sale.
NEW JERSEY STATE REGULATION
New Jersey enacted the Compassionate Use Medical Marijuana Act (“CUMMA”) on January 18, 2010. CUMMA allows patients with qualifying medical conditions to access cannabis through a program regulated by the New Jersey Department of Health (“NJDOH”), which authorized six alternative treatment centers (“ATCs”) to operate as vertically integrated cultivators and dispensaries. In 2019, the NJDOH held a “Request for Application” process for 24 additional ATCs, with some ATCs limited to cultivation, some limited to retail dispensaries, and some vertically integrated.
Following voter approval of an adult-use cannabis ballot measure amending the New Jersey Constitution to permit the use of cannabis for adults 21 years of age and older, on February 22, 2021, New Jersey enacted the Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act (“CREAMMA”), which legalized the adult use of marijuana and established the New Jersey Cannabis Regulatory Commission (“CRC”) as the regulatory body for both the medical and recreational cannabis within the state.
Under CREAMMA, ATCs can apply to serve the recreational cannabis market as “Expanded ATCs.” In addition, New Jersey established six (6) new classes of licenses for recreational use: Class 1 Cannabis Cultivator, authorized to grow recreational cannabis; Class 2 Cannabis Manufacturer, permitted to manufacture cannabis products; Class 3 Cannabis Wholesaler, licensed to store, sell, and transfer cannabis items among cultivators, wholesalers, and retailers; Class 4 Cannabis Distributor, authorized to transport cannabis items in bulk within the state; Class 5 Cannabis Retailer, allowed to purchase cannabis from licensed sources and sell to consumers in retail settings; and Class 6 Cannabis Delivery, tasked with transporting purchases from retailers to consumers. Additionally, New Jersey offers microbusiness licenses targeting smaller, local enterprises. These licenses are restricted to operations with no more than 10 employees, with at least 51% of them required to reside in the local or neighboring municipalities. Notably, there are no statutory caps on the number of licenses the CRC may issue. However, the CRC has discretion over the approval of applications and municipalities can pass additional restrictions including zoning and licensing requirements.
Recreational cannabis businesses in New Jersey are permitted to integrate vertically by holding licenses across several classes—cultivator, manufacturer, retailer, and delivery service, or as both a wholesaler and a distributor. However, businesses are restricted to holding only one license per class.
Pg **45** of **48**
As part of the adult use licensing process, applicants are permitted to apply for “conditional” or “annual” licenses. Conditional licenses serve as an entry point for industry newcomers, providing them up to 120 days (with a potential 45-day extension) to site their proposed operations. To qualify for a conditional license, applicants must meet specific residency and financial requirements. Successful conditional license holders may transition to annual licenses, which transition is required for the business to be approved by the CRC to begin operations. Additionally, the CRC implemented a program that prioritizes review of applications from Diversely Owned, Social Equity, and Impact Zone qualifying applicants. Microbusinesses are also prioritized, with opportunities for expansion.
Recently, the CRC approved new regulations for cannabis consumption lounges, which are set to be implemented following approvals from the New Jersey Office of Administrative Law and local municipalities. These lounges, required to be attached to existing dispensaries and prohibited from selling food or alcohol, aim to offer a secure, regulated environment for medical and recreational cannabis users to consume their own products.
To safeguard fair business practices and maintain competitive market conditions, New Jersey imposes specific prohibitions on Financial Source Agreements (FSA) and Management Services Agreements (MSA).
The CRCA utilizes METRC as the state’s third-party solution for marijuana and marijuana product tracking from seed to sale.
ILLINOIS STATE REGULATIONS
In August 2013, Illinois became the 20^th^ state to authorize a program for the cultivation and dispensing of cannabis for medical purposes for qualified medical patients—the Compassionate Use of Medical Cannabis Program. In June 2019, Illinois passed the Cannabis Regulation and Tax Act (“CRTA”), which legalized cannabis for recreational use and created one of the largest adult use markets in the country. The law went into effect on June 25, 2019, and adult use sales of cannabis began in the state on January 1, 2020. Under the CRTA, existing medical cannabis license holders were allowed to apply for Early Approval Adult Use Dispensing Organization (“EAAUDO”) licenses to be able to sell adult use product at existing medical cannabis dispensaries. Existing medical operators also received the privilege of opening a secondary adult use only retail dispensary for every medical cannabis dispensary location already existing in the operator’s portfolio. All EAAUDO license holders were also required to commit to Illinois’s groundbreaking Social Equity program either through a financial contribution, grant agreement, donation, incubation program, or sponsorship program.
The CRTA also authorized the issuance of an additional 75 Adult Use Dispensing Organization (“AUDO”) licenses, 40 craft grower licenses as well as infuser and transporter licenses in 2020. Generally speaking, these licenses were to be awarded via a competitive application process. The CRTA provided a significant advantage to applicants that qualified as a “Social Equity Applicant” under the CRTA. In addition, the CRTA authorized issuance up to 110 additional AUDO licenses and 60 craft grower licenses by December 21, 2021. However, due the COVID-19 pandemic, litigation relating to the application process, and the passage of H.B. 1443, which amended the CRTA, the issuance of new cannabis licenses in Illinois was delayed until July 2021. By June 2022, the Illinois Department of Agriculture (“IDOA”) has issued approximately 87 craft grower licenses in several tranches, along with infuser and transporter licenses. Note that those applicants who did not win a craft grow license have since sued IDOA alleging a host of issues and arguments relating to the application and scoring process. All such cases were consolidated for administrative purposes and are still pending (In re Cannabis Craft Grow Litigation, Case No.: 22 CH 06071).
Pg **46** of **48**
On September 3, 2021, the Illinois Department of Financial and Professional Regulation (“IDFPR”) announced that 185 Conditional AUDO licenses have been awarded through three license lotteries that took place on July 29, 2021, August 5, 2021, and August 19, 2021 respectively. These Conditional AUDO licenses were ultimately issued to the respective winners in July 2022. The CRTA was subsequently amended in the Spring of 2023 and Conditional AUDO license holders are now required to site and operationalize their dispensaries within 720 days of license receipt.
The state of Illinois currently uses BioTrackTHC as its computerized track-and-trace system for seed-to-sale reporting. However, Illinois announced that it will be switching to Metrc as the state’s track-and-trace system and that switch is expected to be implemented in or around the beginning of 2024. Individual licensees, whether directly or through third-party integration systems, are required to push data to the state to meet all reporting requirements.
Illinois allows for five types of cannabis businesses within the state: (1) cultivation centers; (2) craft growers; (3) infusers; and (4) transporters, which are regulated by the IDOA. Fifth are dispensaries, which are regulated by the IDFPR. Vertical integration is permissible through the acquisition of the various license types, but there are restrictions on certain license ownership. Pursuant to the CRTA, an individual may not be a “Principal Officer” in: (1) more than 10 adult use dispensaries, (2) more than three craft growers, and (3) a craft grower and cultivation center simultaneously. Principal Officer includes a cannabis business establishment applicant or licensed cannabis business establishment’s board member, owner with more than 1% interest of the total cannabis business establishment or more than 5% interest of the total cannabis business establishment of a publicly traded company, president, vice president, secretary, treasurer, partner, officer, member, manager member, or person with a profit sharing, financial interest, or revenue sharing arrangement.
All cultivation, infusing, and transporter establishments must register with the IDOA. All dispensaries must register with the IDFPR. If applications contain all required information, establishments are issued a marijuana establishment registration certificate. Registration certificates are valid for a period of one year and are subject to annual renewals after required fees are paid and the business remains in good standing. Pursuant to Illinois law, registration renewal applications must be received 45 days prior to expiration and may be denied if the license has a history of non-compliance and penalties.
The cultivation and craft grower licenses permit a licensee to acquire, possess, cultivate, manufacture and process cannabis into edible products and cannabis-infused products. Cultivators and craft growers can transfer, have tested, supply or sell cannabis and cannabis products and related supplies to licensed dispensaries, craft growers, and infusers. Craft growers can cultivate a flowering stage canopy of up to 14,000 sq. ft. Infusing licenses permit a licensee to acquire and possess distillate from a licensed cultivator or craft grower and to manufacture edible and cannabis-infused products. Infusers can transfer, have tested, supply or sell cannabis and cannabis products to dispensaries. The transporter license permits a licensee to transport cannabis and cannabis products to and from licensed entities.
The retail dispensary license permits us to purchase cannabis and manufactured cannabis products from licensed cultivation centers, craft growers, and infusing organizations and to sell such products to adult consumers (21 years old or older).
There are significant risks associated with the business of the Company, as described above and in Section 17 – Risk Factors of the Company’s Listing Statement as filed on www.sedarplus.ca. Readers are strongly encouraged to carefully read all of the risk factors contained in Section 17 – Risk Factors of the Company’s Listing Statement.
Pg **47** of **48**
INTERNALCONTROL OVER FINANCIAL REPORTING AND DISCLOSURE CONTROLS
Management, including the President and CEO and the CFO, is responsible for designing, establishing, and maintaining a system of ICFR to provide reasonable assurance that all information prepared by the Company for external purposes is reliable and timely. Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Financial Statements for external purposes in accordance with IFRS.
The Company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately reflect the transactions of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the Company’s Financial Statements. Due to its inherent limitations, internal control over financial reporting and disclosure may not prevent or detect all misstatements.
As the Company is a Venture Issuer (as defined under under NI 52-109), the Company and Management are not required to include representations relating to the evaluation, design, establishment and/or maintenance of DC&P and/or Internal Controls over Financial Reporting, as defined in NI 52 -109, nor has it completed such an evaluation. Inherent limitations on the ability of the certifying officers to design and implement on a cost-effective basis DC&P and ICFR for the issuer may result in additional risks of quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation. The CEO and CFO have evaluated whether there were changes to the ICFR during the nine months ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, the ICFR. As a result, no such significant changes were identified through their evaluation.
There have been no material changes in the Company’s internal control over financial reporting during the nine months ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.
Pg **48** of **48**
Exhibit5
FORM 52-109FV2
CERTIFICATION OF INTERIM FILINGS
VENTURE ISSUER BASIC CERTIFICATE
I, J. Obie Strickler, President and Chief Executive Officer of Grown Rogue International Inc., certify the following:
| 1. | Review: I have reviewed the interim financial report and interim MD&A<br>(together, the “interim filings”) of Grown Rogue International Inc. (the “issuer”) for the interim period<br>ended September 30, 2024. |
|---|---|
| 2. | No misrepresentations: Based on my knowledge, having exercised reasonable<br>diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be<br>stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to<br>the period covered by the interim filings. |
| --- | --- |
| 3. | Fair presentation: Based on my knowledge, having exercised reasonable<br>diligence, the interim financial report together with the other financial information included in the interim filings fairly present in<br>all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods<br>presented in the interim filings. |
| --- | --- |
Date: November 14, 2024.
| (signed) “J. Obie Strickler” | ||
|---|---|---|
| Name: | J. Obie Strickler | |
| Title: | President and Chief Executive Officer | |
| NOTE TO READER | ||
| --- | --- | --- |
| In contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of | ||
| i) | controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and | |
| ii) | a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP. | |
| The issuer’s certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate. Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation. |
Exhibit6
FORM 52-109FV2
CERTIFICATION OF INTERIM FILINGS
VENTURE ISSUER BASIC CERTIFICATE
I, Ryan Kee, Chief Financial Officer and Corporate Secretary of Grown Rogue International Inc., certify the following:
| 1. | Review: I have reviewed the interim financial report and interim MD&A<br>(together, the “interim filings”) of Grown Rogue International Inc. (the “issuer”) for the interim period<br>ended September 30, 2024. |
|---|---|
| 2. | No misrepresentations: Based on my knowledge, having exercised reasonable<br>diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be<br>stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to<br>the period covered by the interim filings. |
| --- | --- |
| 3. | Fair presentation: Based on my knowledge, having exercised reasonable<br>diligence, the interim financial report together with the other financial information included in the interim filings fairly present in<br>all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods<br>presented in the interim filings. |
| --- | --- |
Date: November 14, 2024.
| (signed) “Ryan Kee” | ||
|---|---|---|
| Name: | Ryan Kee | |
| Title: | Chief<br> Financial Officer and Corporate Secretary | |
| NOTE TO READER | ||
| --- | --- | --- |
| In contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of | ||
| i) | controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and | |
| ii) | a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP. | |
| The issuer’s certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate. Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation. |
Exhibit 7
Grown Rogue Reports Third Quarter 2024 Results
| ● | Third quarter revenue of $7.0M compared to $6.5M in the three months ended October 31, 2023, an increase of 7% |
|---|---|
| ● | Operating Cash Flow (OCF), before changes in working capital (WC), of $1.2M compared to $1.5M in the three months ended October 31, 2023, a decrease of 24%, related largely to an increased ramp of SG&A spending to support the provisioning of New Jersey and one-time compensation payments |
| --- | --- |
| ● | Free Cash Flow^1^ (FCF) of ($1.2M), after accounting for $2.2M in cash advances to fund construction in the New Jersey cultivation facility |
| --- | --- |
| ● | Announced commencement of phase I operations in New Jersey, which includes ~8,000 square feet of flowering canopy that will produce 500-600 pounds of whole flower per month with sales anticipated in Q4 2024 |
| --- | --- |
| ● | Subsequent to quarter-end, announced the termination of an advisory agreement with Vireo Growth Inc. |
| --- | --- |
Medford, Oregon, November 14, 2024 – Grown Rogue International Inc. (“Grown Rogue” or the “Company”) (CSE: GRIN) (OTC: GRUSF), a craft cannabis company born from the amazing terroir of Oregon’s Rogue Valley, is pleased to report its third quarter 2024 results for the three months ended September 30, 2024. The comparison period for 2023 is the three months ended October 31, 2023, due to the fiscal year-end change from October 31 to December 31. All financial information is provided in U.S. dollars unless otherwise indicated.
Third Quarter 2024 Financial Summary ($USD Millions)
| Third Quarter 2024 Summary | Q3 2024 | Q4 2023* | +/- % | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $ | 7.0 | $ | 6.5 | +7 | % | |||
| aEBITDA | $ | 2.1 | $ | 2.1 | +0 | % | |||
| aEBITDA % | 30.0 | % | 32.1 | % | -210 bps | ||||
| OCF (Before Changes in WC) | $ | 1.2 | ^1^ | $ | 1.5 | -24 | % | ||
| OCF % | 16.5 | % | 23.3 | % | -680 bps | ||||
| * | Comparable 2023 data is August-October due to the fiscal year end change | ||||||||
| --- | --- | ||||||||
| ^1^ | Includes $0.6M in increased ramp of SG&A related to New Jersey and one-time compensation payments | ||||||||
| --- | --- |
Management Commentary
“This was another exciting quarter for Grown Rogue with solid financial metrics showing the continued execution by our team in competitive markets against a backdrop of modest price compression. We continue to see strong indoor production yields of craft-quality flower, retail buyer and consumer loyalty, and great initial reception and sell through with our branded pre-
rolls, including our newest brand Yeti. We have experienced some pricing pressure in 2024 in both Oregon and Michigan but are seeing stabilization headed into year-end. We are quite experienced at this point with pricing fluctuation, and we continue to combat this with our relentless focus on quality and yield; boosted recently by a modest investment in new technologies that have shown very encouraging early results in yield and quality. We strongly believe that high-quality, low-cost cannabis cultivation, that delights consumers, is a protectable moat when done at the proper scale,” said Obie Strickler, CEO of Grown Rogue.
“We had a decline in our operating cash flow before changes in working capital, which was largely attributable to the ramp of spending in advance of launching New Jersey. I am super excited to announce we completed our first harvest in New Jersey with the anticipated first drops of product in December. We remain excited for this investment to flip to meaningful cash flow generation based upon market conditions, and believe with solid execution in New Jersey, we are well positioned to support future expansion opportunities that present excellent cash-on-cash returns. We maintain a strong balance sheet with minimal debt and sufficient cash to fund our near-term plans," continued Mr. Strickler.
“Our primary growth drivers entering 2025 continue to be our expansion efforts in New Jersey and Illinois. Phase II of construction is underway and is expected to be complete in the first half of 2025 with the first harvest occurring in the summer. Upon completion of Phase II, we will be producing approximately 1,100 pounds of whole flower per month. Illinois design and engineering is nearly complete, and the team is currently evaluating contractor bids for the construction work. We are targeting completion of Phase I in the second half of 2025 and will give more precise timing as we finalize the construction plans. We remain very intentional about new market expansion and are confident that we will find one or two new opportunities that meet our strict criteria over the coming year. We are continuing to evaluate growth capital options that strengthen our balance sheet to support expansion.
I want to personally thank all of our customers, the entire Grown Rogue team, and our supportive shareholders for each doing their part to help Grown Rogue achieve our goal of becoming the first nationally recognized craft cannabis company in the U.S,” said Obie Strickler.
Oregon Market Highlights ($USD Millions)
| Oregon | Q3 2024 | Q4 2023* | +/- % | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.9 | 2.9 | -1 | % | |||||
| aEBITDA | 0.6 | 0.9 | -33 | % | |||||
| aEBITDA Margin % | 20.8 | % | 30.8 | % | -1000 bps | ||||
| * | 2023 data is August-October | ||||||||
| --- | --- |
Michigan Market Highlights ($USD Millions)
| Michigan | Q3 2024 | Q4 2023* | +/- % | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.4 | 3.2 | +7 | % | |||||
| aEBITDA | 1.7 | 1.3 | +33 | % | |||||
| aEBITDA Margin % | 50.4 | % | 40.8 | % | +960 bps | ||||
| * | 2023 data is August-October | ||||||||
| --- | --- |
Michigan operations are through Golden Harvests, LLC.
2
Financial Statements and aEBITDA reconciliation
| Consolidated Statements of Financial Position | September 30, 2024 | December 31, 2023 | ||
|---|---|---|---|---|
| ASSETS | ||||
| Current assets | ||||
| Cash and cash equivalents | ||||
| Accounts receivable (Note 17) | ||||
| Biological assets (Note 3) | ||||
| Inventory (Note 4) | ||||
| Prepaid expenses and other assets | ||||
| Current portion of notes receivable (Note 6.3) | ||||
| Total current assets | ||||
| Property and equipment (Note 8) | ||||
| Notes receivable (Note 6.3) | ||||
| Warrants asset (Note 13) | ||||
| Intangible assets and goodwill (Note 9) | ||||
| Deferred tax assets (Note 19) | ||||
| Other investments (Note 6.2) | ||||
| TOTAL ASSETS | ||||
| LIABILITIES | ||||
| Current liabilities | ||||
| Accounts payable and accrued liabilities | ||||
| Current portion of lease liabilities (Note 7) | ||||
| Current portion of long-term debt (Note 10) | ||||
| Current portion of business acquisition consideration payable (Note 5) | ||||
| Derivative liability^1^ (Note 11) | ||||
| Income tax payable | ||||
| Convertible debentures^2^ (Note 11) | ||||
| Total current liabilities | ||||
| Lease liabilities (Note 7) | ||||
| Long-term debt (Note 10) | ||||
| Convertible debentures (Note 11) | ||||
| Business acquisition consideration payable (Note 5) | ||||
| TOTAL LIABILITIES | ||||
| EQUITY | ||||
| Share capital (Note 12) | ||||
| Contributed surplus (Notes 13 and 14) | ||||
| Accumulated other comprehensive loss | ) | ) | ||
| Accumulated deficit | ) | ) | ||
| Equity attributable to shareholders | ||||
| Non-controlling interests (Note 22) | ||||
| TOTAL EQUITY | ||||
| TOTAL LIABILITIES AND EQUITY |
All values are in US Dollars.
| ^1^ | Represents derivative liability associated with the fair valuation of the outstanding convertible debentures and is a non-cash liability, settleable in equity upon conversion |
|---|---|
| ^2^ | Face value of outstanding convertible debentures as of September 30, 2024 is $4,050,000 |
| --- | --- |
3
| Consolidated Statements of Comprehensive Income (Loss) | Three months ended<br>September 30, 2024 | Three months ended<br>October 31, 2023 | ||
|---|---|---|---|---|
| Revenue | ||||
| Product sales | ||||
| Service revenue | ||||
| Total revenue | ||||
| Cost of goods sold | ||||
| Cost of finished cannabis inventory sold | ) | ) | ||
| Costs of service revenue | ) | ) | ||
| Gross profit, excluding fair value items | ||||
| Realized fair value loss amounts in inventory sold | ) | ) | ||
| Unrealized fair value gain on growth of biological assets | ||||
| Gross profit | ||||
| Expenses | ||||
| Amortization of property and equipment (Note 8) | ||||
| General and administrative (Note 18) | ||||
| Share option expense | ||||
| Total expenses | ||||
| Income from operations | ||||
| Other income and (expense) | ||||
| Interest expense | ) | ) | ||
| Accretion expense | ) | ) | ||
| Other (expense) income | ) | |||
| Unrealized loss on derivative liability | ) | ) | ||
| Unrealized gain on warrants asset | ||||
| Gain (loss) on disposal of property and equipment | ) | |||
| Total expense, net | ) | ) | ||
| Loss from operations before taxes | ) | ) | ||
| Income tax (Note 19) | ) | |||
| Net loss | ) | ) | ||
| Other comprehensive income (loss) (items that may be subsequently reclassified to profit & loss) | ||||
| Currency translation gain (loss) | ) | |||
| Total comprehensive loss | ) | ) | ||
| Gain (loss) per share attributable to owners of the parent – basic | ) | ) | ||
| Weighted average shares outstanding – basic | ||||
| Gain per share attributable to owners of the parent<br> – diluted | ) | ) | ||
| Weighted average shares outstanding – diluted | ||||
| Net income (loss) for the period attributable to: | ||||
| Non-controlling interest | ||||
| Shareholders | ) | ) | ||
| Net loss | ) | ) | ||
| Comprehensive income (loss) for the period attributable to: | ||||
| Non-controlling interest | ||||
| Shareholders | ) | ) | ||
| Total comprehensive loss | ) | ) |
All values are in US Dollars.
4
| Consolidated Statements of Cash Flows | Nine months ended September 30, 2024 | Nine months ended October 31, 2023 | ||
|---|---|---|---|---|
| Operating activities | ||||
| Net loss | ) | ) | ||
| Adjustments for non-cash items in net income (loss): | ||||
| Amortization of property and equipment | ||||
| Amortization of property and equipment included in costs of inventory sold | ||||
| Unrealized fair value gain amounts on growth of biological assets | ) | ) | ||
| Realized fair value loss amounts in inventory sold | ||||
| Deferred income taxes | ) | ) | ||
| Share option expense | ||||
| Accretion expense | ||||
| Loss on equity method investment | ||||
| Loss on disposal of property and equipment | ) | |||
| Unrealized loss on fair value of derivative liability | ||||
| Unrealized gain on warrants asset | ) | ) | ||
| Currency translation loss | ) | ) | ||
| Loss on acquisition of non-controlling interest paid in shares | ||||
| Changes in non-cash working capital (Note 15) | ) | |||
| Net cash provided by operating activities | ||||
| Investing activities | ||||
| Purchase of property and equipment and intangibles | ) | ) | ||
| Cash advances and loans made to other parties | ) | ) | ||
| Repayment of NJ Retail promissory note | ||||
| Acquisition of Canopy Management, LLC and Golden Harvests, LLC | ) | |||
| Equity investment in ABCO Garden State LLC | ) | |||
| Net cash used in investing activities | ) | ) | ||
| Financing activities | ||||
| Proceeds from convertible debentures | ||||
| Proceeds from warrants exercises | ||||
| Proceeds from options exercises | ||||
| Proceeds from sale of membership units of subsidiary | ||||
| Payment of equity and debt issuance costs | ) | |||
| Repayment of long-term debt | ) | ) | ||
| Repayment of convertible debentures | ) | ) | ||
| Payments of lease principal | ) | ) | ||
| Net cash provided by financing activities | ||||
| Change in cash and cash equivalents | ) | |||
| Cash and cash equivalents, beginning | ||||
| Cash and cash equivalents, ending |
All values are in US Dollars.
5
| Segmented aEBITDA | 9 months ended September 30, 2024 | **** | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **** | Oregon | **** | Michigan | **** | Services | **** | Corporate | **** | Consolidated | **** | |||||
| Revenue | 9,572,906 | 10,096,685 | 1,281,226 | 414,500 | 21,365,317 | ||||||||||
| Costs of revenue, excluding fair value adjustments | (5,639,139 | ) | (4,255,180 | ) | (206,670 | ) | - | (10,100,989 | ) | ||||||
| Gross profit (loss) before fair value adjustments | 3,933,767 | 5,841,505 | 1,074,556 | 414,500 | 11,264,328 | ||||||||||
| Net fair value adjustments | 18,736 | (725,881 | ) | - | (707,145 | ) | |||||||||
| Gross profit | 3,952,503 | 5,115,624 | 1,074,556 | 414,500 | 10,557,183 | ||||||||||
| Operating expenses: | |||||||||||||||
| General and administration | 2,038,098 | 2,290,981 | - | 3,089,459 | 7,418,538 | ||||||||||
| Depreciation and amortization | 86,979 | 524,068 | - | 117,048 | 728,095 | ||||||||||
| Share based compensation | - | - | - | 379,178 | 379,178 | ||||||||||
| Other income and expense: | |||||||||||||||
| Interest and accretion | (202,485 | ) | (61,627 | ) | - | (1,538,504 | ) | (1,802,616 | ) | ||||||
| Loss on disposal or property and equipment | 7,823 | - | - | - | 7,823 | ||||||||||
| Unrealized (loss) gain on derivative liability | - | - | - | (13,584,791 | ) | (13,584,791 | ) | ||||||||
| Unrealized (loss) gain on warrants asset | - | - | - | 2,071,411 | 2,071,411 | ||||||||||
| Other income and expense | 190 | - | - | 51,737 | 51,927 | ||||||||||
| Net income (loss) before tax | 1,632,954 | 2,238,948 | 1,074,556 | (16,171,332 | ) | (11,224,874 | ) | ||||||||
| Tax | 32 | 649,001 | - | 532,855 | 1,181,888 | ||||||||||
| Net income after tax | 1,632,922 | 1,589,947 | 1,074,556 | (16,704,187 | ) | (12,406,762 | ) |
6
| EBITDA | Oregon | Michigan | Services | Corporate | Consolidated | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net FV adjs | (18,736 | ) | 725,881 | 707,145 | |||||||||||
| Depreciation in COGS | 1,009,540 | 545,207 | 1,554,747 | ||||||||||||
| Depreciation expense | 86,979 | 524,067 | 117,049 | 728,095 | |||||||||||
| Share comp | - | - | - | 379,178 | 379,178 | ||||||||||
| Unrealized derivative | - | - | - | 13,584,791 | 13,584,791 | ||||||||||
| Loss on disposal of property plant and equipment | (7,823 | ) | - | - | (7,823 | ) | |||||||||
| Unrealized warrants asset | - | - | - | (2,071,411 | ) | (2,071,411 | ) | ||||||||
| Interest and accretion | 202,485 | 61,626 | - | 1,538,505 | 1,802,616 | ||||||||||
| Income tax | 32 | 649,001 | - | 532,855 | 1,181,888 | ||||||||||
| EBITDA before one-time adjs | 2,905,399 | 4,095,729 | 1,074,556 | (2,623,220 | ) | 5,452,464 | |||||||||
| Add back to EBITDA: | |||||||||||||||
| One time compensation payments | 121,336 | 121,336 | |||||||||||||
| Additional compliance costs | 79,091 | 79,091 | |||||||||||||
| Eliminated management fees | 46,200 | 46,200 | |||||||||||||
| Costs associated with acquisition of Golden Harvests | 603,000 | 603,000 | |||||||||||||
| New production location startup costs | 587,539 | 587,539 | |||||||||||||
| Non recurring legal and transaction<br> costs | 187,342 | 187,342 | |||||||||||||
| aEBITDA | 2,905,399 | 4,698,729 | 1,074,556 | (1,848,339 | ) | 7,076,972 | |||||||||
| Adjusted EBITDA margin % | 30.4 | % | 46.5 | % | 83.9 | % | 33.1 | % |
NOTES:
| 1. | The Company’s “Free cash flow” metric is defined by cash flow from operations minus capital expenditures and expansion related advances |
|---|---|
| 2. | The Company’s “aEBITDA,” or “Adjusted EBITDA,” is a non-IFRS measure used by management that does not have any prescribed meaning by IFRS and that may not be comparable to similar measures presented by other companies. The Company defines “EBITDA” as the Company’s net income or loss for a period, as reported, before interest, taxes, depreciation and amortization, and is further adjusted to remove transaction costs, stock-based compensation expense, accretion expense, gain (loss) on derecognition of derivative liabilities, the effects of fair-value accounting for biological assets and inventory, as well as other non-cash items and items not representative of operational performance as reported in net income (loss). Adjusted EBITDA is defined as EBITDA adjusted for the impact of various significant or unusual transactions. The Company believes that this is a useful metric to evaluate its operating performance. |
| --- | --- |
NON-IFRS FINANCIAL MEASURES
EBITDA and aEBITDA are non-IFRS measures and do not have standardized definitions under IFRS. The Company has also provided unaudited pro-forma financial information, which assumes that closed and pending mergers and acquisitions in 2021 are included in the Company’s financial results as of the beginning of the quarterly and annual periods in 2021. The Company has provided the non-IFRS financial measures, which are not calculated or presented in accordance with IFRS, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. These supplemental non-IFRS financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-IFRS financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein. Accordingly, the following information provides reconciliations of the supplemental non-IFRS financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with IFRS.
7
About Grown Rogue
Grown Rogue International Inc. (CSE: GRIN | OTC: GRUSF) is a craft cannabis company operating in Oregon, Michigan, New Jersey and Illinois, focused on delighting customers with premium flower and flower-derived products at fair prices. The Company’s roots are in Southern Oregon, where it has proven its capabilities in the highly competitive and discerning Oregon market. The Company’s passion for quality product and value, combined with a disciplined approach to growth, prioritizes profitability and return on capital without sacrificing quality. The Company’s strategy is to pursue capital efficient methods to expand into new markets, bringing craft-quality product at fair prices to more consumers. The Company also continues to make modest investments to improve outdoor craft cultivation capabilities in preparation for eventual interstate commerce. For more information, visit www.grownrogue.com.
FORWARD-LOOKING STATEMENTS
This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward‐ looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding the future direction of the Company (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii) plans for expansion of the Company and securing applicable regulatory approvals, and (iv) expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward‐looking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws; compliance with extensive government regulation and related costs, and other risks described in the Company’s public disclosure documents filed on Sedar.
8
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.
The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational cannabis marketplace in the United States through its indirect operating subsidiaries. Local state laws where its subsidiaries operate permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business are disclosed in the Company’s Listing Statement filed on its issuer profile on SEDAR+ at www.sedarplus.ca. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
For further information on Grown Rogue, please visit www.grownrogue.com or contact:
Obie Strickler
Chief Executive Officer [email protected]
Jakob Iotte
Vice President of Investor Relations
[email protected] (458) 226-2662
9